<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">66014</article-id><article-id pub-id-type="doi">10.7554/eLife.66014</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-145512"><name><surname>Wilmes</surname><given-names>Stephan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4112-710X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-220473"><name><surname>Jeffrey</surname><given-names>Polly-Anne</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6476-0402</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-145511"><name><surname>Martinez-Fabregas</surname><given-names>Jonathan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5809-065X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-146398"><name><surname>Hafer</surname><given-names>Maximillian</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0853-2637</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167876"><name><surname>Fyfe</surname><given-names>Paul K</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3541-2294</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-145515"><name><surname>Pohler</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-220474"><name><surname>Gaggero</surname><given-names>Silvia</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233269"><name><surname>López-García</surname><given-names>Martín</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3833-8595</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-148159"><name><surname>Lythe</surname><given-names>Grant</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7966-5571</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-232892"><name><surname>Taylor</surname><given-names>Charles</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233270"><name><surname>Guerrier</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-220475"><name><surname>Launay</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-220476"><name><surname>Mitra</surname><given-names>Suman</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225775"><name><surname>Piehler</surname><given-names>Jacob</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2143-2270</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-220478"><name><surname>Molina-París</surname><given-names>Carmen</given-names></name><email>C.MolinaParis@leeds.ac.uk</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-72867"><name><surname>Moraga</surname><given-names>Ignacio</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9909-0701</contrib-id><email>imoragagonzalez@dundee.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee</institution><addr-line><named-content content-type="city">Dundee</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution>Department of Applied Mathematics, School of Mathematics, University of Leeds</institution><addr-line><named-content content-type="city">Leeds</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution>Department of Biology and Centre of Cellular Nanoanalytics, University of Osnabrück</institution><addr-line><named-content content-type="city">Osnabrück</named-content></addr-line><country>Germany</country></aff><aff id="aff4"><label>4</label><institution>Université de Lille, INSERM UMR1277 CNRS UMR9020–CANTHER and Institut pour la Recherche sur le Cancer de Lille (IRCL)</institution><addr-line><named-content content-type="city">Lille</named-content></addr-line><country>France</country></aff><aff id="aff5"><label>5</label><institution>Department of Statistics, School of Mathematics, University of Leeds</institution><addr-line><named-content content-type="city">Leeds</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff6"><label>6</label><institution>Univ. Lille, Univ. LilleInserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation</institution><addr-line><named-content content-type="city">Lille</named-content></addr-line><country>France</country></aff><aff id="aff7"><label>7</label><institution>T-6 Theoretical Division, Los Alamos National Laboratory</institution><addr-line><named-content content-type="city">Los Alamos</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>van der Meer</surname><given-names>Jos WM</given-names></name><role>Senior Editor</role><aff><institution>Radboud University Medical Centre</institution><country>Netherlands</country></aff></contrib><contrib contrib-type="editor"><name><surname>Graw</surname><given-names>Frederik</given-names></name><role>Reviewing Editor</role><aff><institution>Heidelberg University</institution><country>Germany</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>19</day><month>04</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e66014</elocation-id><history><date date-type="received" iso-8601-date="2020-12-22"><day>22</day><month>12</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-04-18"><day>18</day><month>04</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Wilmes et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Wilmes et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-66014-v2.pdf"/><abstract><p>Cytokines elicit pleiotropic and non-redundant activities despite strong overlap in their usage of receptors, JAKs and STATs molecules. We use IL-6 and IL-27 to ask how two cytokines activating the same signaling pathway have different biological roles. We found that IL-27 induces more sustained STAT1 phosphorylation than IL-6, with the two cytokines inducing comparable levels of STAT3 phosphorylation. Mathematical and statistical modeling of IL-6 and IL-27 signaling identified STAT3 binding to GP130, and STAT1 binding to IL-27Rα, as the main dynamical processes contributing to sustained pSTAT1 levels by IL-27. Mutation of Tyr613 on IL-27Rα decreased IL-27-induced STAT1 phosphorylation by 80% but had limited effect on STAT3 phosphorgylation. Strong receptor/STAT coupling by IL-27 initiated a unique gene expression program, which required sustained STAT1 phosphorylation and IRF1 expression and was enriched in classical Interferon Stimulated Genes. Interestingly, the STAT/receptor coupling exhibited by IL-6/IL-27 was altered in patients with systemic lupus erythematosus (SLE). IL-6/IL-27 induced a more potent STAT1 activation in SLE patients than in healthy controls, which correlated with higher STAT1 expression in these patients. Partial inhibition of JAK activation by sub-saturating doses of Tofacitinib specifically lowered the levels of STAT1 activation by IL-6. Our data show that receptor and STATs concentrations critically contribute to shape cytokine responses and generate functional pleiotropy in health and disease.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cytokines</kwd><kwd>SLE</kwd><kwd>STATs</kwd><kwd>IL6</kwd><kwd>IL27</kwd><kwd>signaling</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010661</institution-id><institution>Horizon 2020 Framework Programme</institution></institution-wrap></funding-source><award-id>714680</award-id><principal-award-recipient><name><surname>Wilmes</surname><given-names>Stephan</given-names></name><name><surname>Martinez-Fabregas</surname><given-names>Jonathan</given-names></name><name><surname>Fyfe</surname><given-names>Paul K</given-names></name><name><surname>Moraga</surname><given-names>Ignacio</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>202323/Z/16/Z</award-id><principal-award-recipient><name><surname>Pohler</surname><given-names>Elizabeth</given-names></name><name><surname>Moraga</surname><given-names>Ignacio</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000266</institution-id><institution>EPSRC</institution></institution-wrap></funding-source><award-id>1969354</award-id><principal-award-recipient><name><surname>Jeffrey</surname><given-names>Polly-Anne</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000777</institution-id><institution>University of Leeds</institution></institution-wrap></funding-source><award-id>764698</award-id><principal-award-recipient><name><surname>Lythe</surname><given-names>Grant</given-names></name><name><surname>Molina-París</surname><given-names>Carmen</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>ERC-206-STG</award-id><principal-award-recipient><name><surname>Martinez-Fabregas</surname><given-names>Jonathan</given-names></name><name><surname>Fyfe</surname><given-names>Paul K</given-names></name><name><surname>Pohler</surname><given-names>Elizabeth</given-names></name><name><surname>Moraga</surname><given-names>Ignacio</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003043</institution-id><institution>EMBO</institution></institution-wrap></funding-source><award-id>454–2017</award-id><principal-award-recipient><name><surname>Wilmes</surname><given-names>Stephan</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004875</institution-id><institution>DFG</institution></institution-wrap></funding-source><award-id>SFB 944, P8/Z</award-id><principal-award-recipient><name><surname>Piehler</surname><given-names>Jacob</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>K22HL125593</award-id><principal-award-recipient><name><surname>Piehler</surname><given-names>Jacob</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>IL-27 exerts differential activation of STAT1 and STAT3 via IL-27Ra and GP130, respectively, leading to a kinetic decoupling of its gene expression program, which contributes to tune its immuno-modulatory activities.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>IL-27 and IL-6 both have intricate functions regulating inflammatory responses (<xref ref-type="bibr" rid="bib59">O'Shea and Plenge, 2012</xref>). IL-27 is a hetero-dimeric cytokine comprised of p28 and EBI3 subunits (<xref ref-type="bibr" rid="bib64">Pflanz et al., 2002</xref>). IL-27 exerts its activities by binding GP130 and IL-27Rα receptor subunits in the surface of responsive cells, triggering the activation of the JAK1/STAT1/STAT3 signaling pathway. IL-27 elicits both pro- and anti-inflammatory responses, although the later activity seems to be the dominant one (<xref ref-type="bibr" rid="bib100">Yoshida and Hunter, 2015</xref>). IL-27 stimulation inhibits RORγt expression, thereby suppressing Th-17 commitment and limiting subsequent production of pro-inflammatory IL-17 (<xref ref-type="bibr" rid="bib82">Stumhofer et al., 2006</xref>; <xref ref-type="bibr" rid="bib16">Diveu et al., 2009</xref>). Moreover, IL-27 induces a strong production of anti-inflammatory IL-10 on (Tbet<sup>+</sup> and FoxP3<sup>-</sup>) Tr-1 cells (<xref ref-type="bibr" rid="bib20">Fitzgerald et al., 2007</xref>; <xref ref-type="bibr" rid="bib83">Stumhofer et al., 2007</xref>; <xref ref-type="bibr" rid="bib66">Pot et al., 2011</xref>) further contributing to limit the inflammatory response. IL-6 engages a hexameric receptor complex comprised each of two copies of IL-6Rα, GP130 and IL-6 (<xref ref-type="bibr" rid="bib5">Boulanger et al., 2003</xref>), triggering the activation, as IL-27 does, of the JAK1/STAT1/STAT3 signaling pathway. However, opposite to IL-27, IL-6 is known as a paradigm pro-inflammatory cytokine (<xref ref-type="bibr" rid="bib72">Rose-John, 2018</xref>; <xref ref-type="bibr" rid="bib33">Hunter and Jones, 2015</xref>). IL-6 inhibits lineage differentiation to Treg cells (<xref ref-type="bibr" rid="bib43">Korn et al., 2008</xref>) while promoting that of Th-17 cells (<xref ref-type="bibr" rid="bib41">Kimura and Kishimoto, 2010</xref>; <xref ref-type="bibr" rid="bib36">Jones et al., 2010</xref>), thus supporting its pro-inflammatory role. How IL-27 and IL-6 elicit opposite immunomodulatory activities despite activating almost identical signaling pathways is currently not completely understood.</p><p>The relative and absolute STAT activation levels seem to have a diverse set of roles, which lead to a strong signaling and functional plasticity by cytokines. Although IL-6 robustly activates STAT3, it is capable to mount a considerable STAT1 response as well (<xref ref-type="bibr" rid="bib71">Rolvering et al., 2017</xref>). Moreover, in the absence of STAT3, IL-6 induces a strong STAT1 response comparable to IFNγ – a prototypic STAT1 activating cytokine (<xref ref-type="bibr" rid="bib11">Costa-Pereira et al., 2002</xref>). Likewise, the absence of STAT1 potentiates the STAT3 response for IL-27, which normally elicits a strong STAT1 response, rendering it to mount an IL-6-like response (<xref ref-type="bibr" rid="bib71">Rolvering et al., 2017</xref>). This suggests a competition of STAT1/3 for phospho-tyrosine motifs at the cytoplasmic domain of cytokine receptors regulated by their different binding rate constants (on and off rates). Indeed, different STAT1 or STAT3 binding affinities have been assessed in vitro for the phospho-tyrosines on GP130 (<xref ref-type="bibr" rid="bib93">Wiederkehr-Adam et al., 2003</xref>). Furthermore, negative feedback mechanisms, controlled by SOCSs and phosphatases, have been described as critical players influencing STAT1 and STAT3 phosphorylation kinetics and thereby shaping their signal integration for GP130-utilizing cytokines (<xref ref-type="bibr" rid="bib77">Schmitz et al., 2000</xref>; <xref ref-type="bibr" rid="bib98">Yasukawa et al., 2003</xref>; <xref ref-type="bibr" rid="bib14">Croker et al., 2003</xref>; <xref ref-type="bibr" rid="bib6">Brender et al., 2007</xref>). Yet, how all these molecular components are integrated by a given cell to produce the desired response is still an open question. Among the IL-6/IL-12 cytokine family, IL-27 exhibits a unique STAT activation pattern. The majority of GP130-engaging cytokines activate preferentially STAT3, with activation of STAT1 an accessory or balancing component in the signaling pathway (<xref ref-type="bibr" rid="bib8">Camporeale, 2012</xref>; <xref ref-type="bibr" rid="bib68">Regis et al., 2008</xref>). IL-27, however, triggers STAT1 and STAT3 activation with high potency (<xref ref-type="bibr" rid="bib50">Lucas et al., 2003</xref>). Indeed, different studies have shown that IL-27 responses rely on either STAT1 (<xref ref-type="bibr" rid="bib37">Kamiya et al., 2004</xref>; <xref ref-type="bibr" rid="bib86">Takeda et al., 2003</xref>; <xref ref-type="bibr" rid="bib57">Neufert et al., 2007</xref>) or STAT3 activation (<xref ref-type="bibr" rid="bib83">Stumhofer et al., 2007</xref>; <xref ref-type="bibr" rid="bib62">Owaki et al., 2008</xref>). Moreover, recent transcriptomics studies showed that in the absence of STAT3, IL-6 and IL-27 lost more than 75% of target gene induction. Yet, STAT1 was the main factor driving the specificity of the IL-27 versus the IL-6 response, highlighting a critical interplay of STAT1 and STAT3 engagement (<xref ref-type="bibr" rid="bib27">Hirahara et al., 2015</xref>).</p><p>While the biological responses induced by IL-27 and IL-6 have been extensively studied (<xref ref-type="bibr" rid="bib100">Yoshida and Hunter, 2015</xref>; <xref ref-type="bibr" rid="bib33">Hunter and Jones, 2015</xref>), the very initial steps of signal activation and kinetic integration by these two cytokines have not been comprehensively analysed. Since the different biological outcomes elicited by IL-27 and IL-6 are most likely encoded in the early events of cytokine stimulation, here we specifically aimed to identify the molecular determinants underlying functional selectivity by IL-27 in human T-cells. We asked how a defined cytokine stimulus is propagated in time over multiple layers of signaling to produce the desired response. To this end, we probed IL-27 and IL-6 signaling at different scales, ranging from cell surface receptor assembly and early STAT1/3 effector activation to an unbiased and quantitative multi-omics approach: phospho-proteomics after early cytokine stimulation, kinetics of transcriptomic changes and alteration of the T-cell proteome upon prolonged cytokine exposure.</p><p>IL-6 and IL-27 induced similar levels of assembly of their respective receptor complexes, which resulted in comparable phosphorylation of STAT3 by the two cytokines. IL-27, on the other hand, triggered a more sustained STAT1 phosphorylation. To decipher the molecular events which determine sustained STAT1 phosphorylation by IL-27, we mathematically model the STAT1 and STAT3 signaling kinetics induced by each of these cytokines. We identified differential binding of STAT1 and STAT3 to IL-27Rα and GP130, respectively, as the main factors contributing to a sustained STAT1 activation by IL-27. At the transcriptional level, IL-27 triggered the expression of a unique gene program, which strictly required the cooperative action between sustained pSTAT1 and IRF1 expression to drive the induction of an interferon-like gene signature that profoundly shaped the T-cell proteome. Interestingly, our mathematical models of IL-6 and IL-27 signaling predicted that changes in receptor and STAT expression could fundamentally change the magnitude and timescale of the IL-6 and IL-27 responses. We found high levels of STAT1 expression in SLE patients when compared to healthy donors, which correlated with biased STAT1 responses induced by IL-6 and IL-27 in these patients. Strikingly, we could specifically inhibit STAT1 activation by IL-6 using suboptimal doses of the JAK inhibitor Tofacitinib. This could provide a new strategy to specifically target individual STATs engaged by cytokines.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>IL-27 induces a more sustained STAT1 activation than HypIL-6 in human Th-1 cells</title><p>IL-6 and IL-27 are critical immunomodulatory cytokines. Although IL-6 engages a hexameric surface receptor comprised of two molecules of IL-6Rα and two molecules of GP130 to trigger the activation of STAT1 and STAT3 transcription factors (<xref ref-type="fig" rid="fig1">Figure 1a</xref>), IL-27 binds GP130 and IL-27Rα to trigger activation of the same STATs molecules (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). Despite sharing a common receptor subunit, GP130, and activating similar signaling pathways, these two cytokines exhibit non-redundant immunomodulatory activities, with IL-6 eliciting a potent pro-inflammatory response and IL-27 acting more as an anti-inflammatory cytokine. Here, we set to investigate the molecular rules that determine the functional specificity elicited by IL-6 and IL-27 using human Th-1 cells as a model experimental system. Due to the challenging recombinant expression of the human IL-27, we have recombinantly produced a murine single-chain variant of IL-27 (p28 and EBI3) which cross-reacts with the human receptors and triggers potent signaling, comparable to the signaling output produced by commercial human IL-27 (<xref ref-type="bibr" rid="bib61">Oniki et al., 2006</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a</xref>). In addition, we have used a linker-connected single-chain fusion protein of IL-6Rα and IL-6 termed HyperIL-6 (HypIL-6) (<xref ref-type="bibr" rid="bib19">Fischer et al., 1997</xref>) to diminish IL-6 signaling variability due to changes in IL-6Rα expression during T cell activation (<xref ref-type="bibr" rid="bib60">Oberg et al., 2006</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Cytokine receptor activation by IL-27 and (Hyp)IL-6: (<bold>a</bold>) Cartoon model of stepwise assembly of the IL-27 and HypIL-6-induced receptor complex and subsequent activation of STAT1 and STAT3.</title><p>(<bold>b</bold>) Dose-dependent phosphorylation of STAT1 and STAT3 as a response to IL-27 and HypIL-6 stimulation in TH-1 cells, normalized to maximal IL-27 stimulation. Data was obtained from three biological replicates with each two technical replicates, showing mean ±std dev. (<bold>c</bold>) Phosphorylation kinetics of STAT1 and STAT3 followed after stimulation with saturating concentrations of IL-27 (2 nM) and HypIL-6 (20 nM) or unstimulated TH-1 cells, normalized to maximal IL-27 stimulation. Data was obtained from five biological replicates with each two technical replicates, showing mean ±std dev. (<bold>d</bold>) Top: Phosphorylation kinetics of STAT1 and STAT3 followed after stimulation with HypIL-6 (20 nM) or left unstimulated, comparing wt RPE1 and RPE1 GP130KO reconstituted with high levels of mXFPm-GP130 (=10 x [GP130]). Data was normalized to maximal stimulation levels of each treatment. Left: cell surface GP130 levels comparing RPE1 GP130KO, wt RPE1 and RPE1 GP130KO stably expressing mXFPm-GP130 measured by flow cytometry. Data was obtained from one biological replicate with each two technical replicates, showing mean ±std dev. Bottom right: cell surface levels of GP130 measured by flow cytometry for indicated cell lines. (<bold>e</bold>) Cartoon model of cell surface labeling of mXFP-tagged receptors by dye-conjugated anti-GFP nanobodies (NB) and identification of receptor dimers by single molecule dual-color co-localization. (<bold>f</bold>) Raw data of dual-color single-molecule TIRF imaging of mXFPe-IL-27Rα<sup>NB-RHO11</sup> and GP130<sup>NB-DY649</sup> after stimulation with IL-27. Particles from the insets (IL-27Ra: red and GP130: blue) were followed by single molecule tracking (150 frames ~ 4.8 s) and trajectories &gt; 10 steps (320 ms) are displayed. Receptor heterodimerization was detected by co-localization/co-tracking analysis. (<bold>g</bold>) Relative number of co-trajectories observed for heterodimerization of IL-27Rα and GP130 as well as homodimerization of GP130 for unstimulated cells or after indicated cytokine stimulation. Each data point represents the analysis from one cell with a minimum of 23 cells measured for each condition. Two-tailed Student’s T-test: *p&lt;0.05, **p≤0.01,***p≤0.001; n.s., not significant. (<bold>h</bold>) Stoichiometry of the IL-27–induced receptor complex revealed by bleaching analysis. Left: Intensity traces of mXFPe-IL-27Rα<sup>NB-RHO11</sup> and GP130<sup>NB-DY649</sup> were followed until fluorophore bleaching. Middle: Merged imaging raw data for selected timepoints. Right: overlay of the trajectories for IL-27Rα (red) and GP130 (blue).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Characterization of IL-27 and HypIL-6 signaling in T-cell subsets followed by high-throughput flow-cytometry.</title><p>(<bold>a</bold>) Comparison of dose-dependent phosphorylation (STAT1/3) of purchased IL-27 and mIL-27sc in activated CD4 + cells, normalized to maximal MFI levels. The EC<sub>50</sub> for purchased IL-27 for pSTAT1 was ~70 pM, for pSTAT3 was ~80 pM. The EC<sub>50</sub> for mIL-27sc for pSTAT1 was ~20 pM, for pSTAT3 was ~30 pM. Data was obtained from one (purchased) or two (mIL-27sc) biological replicates with each two technical replicates, showing mean ± std dev. (<bold>b</bold>) Schematic workflow of T-cell isolation, TH1 differentiation, fluorescence barcoding and gating strategy for high-throughput flow cytometry. (<bold>c</bold>) Phosphorylation kinetics of STAT1 and STAT3 followed after stimulation with IL-27 (10 nM) and HypIL-6 (20 nM) or unstimulated TH1 cells. Data (from <xref ref-type="fig" rid="fig1">Figure 1c</xref>) was normalized to maximal MFI levels for each cytokine. Data was obtained from five biological replicates with each two technical replicates, showing mean ± std dev. (<bold>d</bold>) Phosphorylation kinetics of activated PBMCs (CD4+, CD8+) of STAT1 and STAT3 followed after stimulation with IL-27 (2 nM) and HypIL-6 (20 nM) or unstimulated cells. Data was normalized to maximal IL-27 stimulation. Data was obtained from two biological replicates with each two technical replicates, showing mean ± std dev.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Functional characterization of RPE1 IL-27Rα.</title><p>(<bold>a</bold>) Dose-response experiments for pSTAT1 and pSTAT3 comparing RPE1 GP130 KO cells (left), wt RPE1 (middle) and RPE1 mXFPe-IL27Rα (right) after stimulation with IL-27 or HypIL-6, normalized to maximal HypIL-6 stimulation. Data was obtained from one representative experiment with each two technical replicates, showing mean ± std dev. Green boxes connect dose-response experiments of RPE1 IL-27Rα with corresponding kinetics experiments performed with this cell line (→b). (<bold>b</bold>) STAT1 (left) and STAT3 (right) phosphorylation kinetics of RPE1 IL-27Rα after stimulation with IL-27 (2 nM) or HypIL-6 (10 nM) normalized to maximal IL-27 stimulation. Data was obtained from three experiments with each two technical replicates, showing mean ± std dev.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Ligand-induced receptor assembly - stoichiometry and diffusion properties.</title><p>(<bold>a</bold>) Ligand-induced receptor dimerization: Top panel: Dual-color co-tracking of IL-27Rα and GP130 in the absence (top) and presence (bottom) of IL-27 (20 nM). Trajectories (150 frames,~4.8 s) of individual mXFPe-IL-27Rα<sup>NB-RHO11</sup> (red) and GP130<sup>NB-DY649</sup> (blue) and co-trajectories (magenta) are shown for a representative cell. Bottom panel: Dual-color co-tracking of GP130 in the absence (top) and presence (bottom) of HypIL-6 (20 nM). Trajectories (150 frames,~4.8 s) of individual mXFPe-IL-27Rα<sup>NB-RHO11</sup> (red) and GP130<sup>NB-DY649</sup> (blue) and co-trajectories (magenta) are shown for a representative cell. (<bold>b</bold>) Top: Cartoon model of cell surface labeling of mXFP-tagged GP130 by dye-conjugated anti-GFP nanobodies (NB) and formation of single-color homodimers (left) or dual-color homodimers (right). Below: Examples for intensity traces of single-color dual-step bleaching (left) or dual-color single-step bleaching (right). Insets show raw data for selected timepoints and corresponding trajectories. (<bold>c</bold>) Top: comparison of diffusion coefficients (D) for mXFPe-IL-27Rα<sup>NB-RHO11</sup> (red) and mXFPmGP130<sup>NB-DY649</sup> (blue) in presence and absence of IL-27 stimulation (20 nM), as well as co-trajectories after IL-27 stimulation (magenta). Bottom: comparison of diffusion coefficients for mXFPm-GP130<sup>NB-RHO11</sup> (red) in presence and absence of HypIL-6 stimulation (20 nM), as well as co-trajectories after HypIL-6 stimulation (magenta). Each data point represents the analysis from one cell with a minimum of 23 cells measured for each condition. Two-tailed Student’s T-test: *p&lt;0.05, **p≤0.01,***p≤0.001; n.s., not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig1-figsupp3-v2.tif"/></fig></fig-group><p>CD4 +T cells from human buffy coat samples were isolated by magnetic activated cell sorting (MACS) and grew under Th-1-polarizing conditions. Th-1 cells were then used to study in vitro signaling by IL-27 and IL-6 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b</xref>). We took advantage of a barcoding methodology allowing high-throughput multiparameter flow cytometry to perform detailed dose/response and kinetics studies induced by HypIL-6 and IL-27 in Th-1 cells (<xref ref-type="bibr" rid="bib45">Krutzik et al., 2011</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b</xref>). Dose-response experiments with IL-27 and HypIL-6 on Th-1 cells showed concentration-dependent phosphorylation of STAT1 and STAT3. Phosphorylation of STAT1/3 was more sensitive to activation by IL-27 with an EC<sub>50</sub> of ~20 pM compared to ~400 pM for HypIL-6 (<xref ref-type="fig" rid="fig1">Figure 1b</xref>). Despite this difference in sensitivity, both cytokines yielded the same activation amplitude for pSTAT3. For pSTAT1, however, we observed a significantly reduced maximal amplitude for HypIL-6 relative to IL-27 (<xref ref-type="fig" rid="fig1">Figure 1b</xref>). We next performed kinetic studies to assess whether the poor STAT1 activation by HypIL-6 was a result from different activation kinetics. For STAT3, we saw the peak of phosphorylation after ~15–30 min, followed by a gradual decline. Both cytokines exhibited an almost identical sustained pSTAT3 profile, with ~20% of activation still seen after 3 hr of continuous stimulation. Interestingly, IL-27 did not only activate STAT1 with higher amplitude but also more sustained than HypIL-6 (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). This could be better appreciated when pSTAT1 levels were normalized to maximal MFI for each cytokine, with IL-27 inducing clearly a more sustain phosphorylation of STAT1 than HypIL-6 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1c</xref>). The same phenotype was observed in other T-cell subsets of activated PBMCs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1d</xref>). As cell surface GP130 levels are significantly reduced upon T-cell activation (<xref ref-type="bibr" rid="bib4">Betz and Müller, 1998</xref>), we next investigated whether the transient STAT1 activation profile induced by HypIL-6 resulted from limited availability of GP130. For that we generated a RPE1 cell clone stably expressing 10 times higher levels of GP130 in its surface (<xref ref-type="fig" rid="fig1">Figure 1d</xref>, right panel). Stimulation of this RPE1 clone with HypIL-6 resulted in a more sustained activation of STAT3, with very little effect on STAT1 activation kinetics when compared to RPE1 wild-type cells, suggesting that GP130 receptor density does not contribute to the transient STAT1 activation kinetics elicited by HypIL-6 (<xref ref-type="fig" rid="fig1">Figure 1d</xref>).</p></sec><sec id="s2-2"><title>Ligand-induced cell-surface receptor assembly by IL-27 and HypIL-6</title><p>We next investigated whether IL-27 and HypIL-6 elicited differential cell surface receptor engagement that could explain their distinct signaling output. For that, we measured the dynamics of receptor assembly in the plasma membrane of live cells by simultaneous dual-color total internal reflection fluorescence (TIRF) imaging. RPE1 cells were chosen as a model experimental system since they do not express endogenous IL-27Rα (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2a</xref>). We generated an RPE1 clone, stably expressing IL-27Rα which responds to IL-27 and HypIL-6 stimulation. Importantly, this reconstituted experimental system mimicked the pSTAT1/3 activation kinetics of T-cells (Supp. Fig. 2b), albeit exhibiting similar pSTAT1 amplitudes for IL-27 and HypIL-6, most likely because of the high endogenous levels of GP130 in RPE1 cells. We used previously described RPE1 GP130 KO cells (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>; <xref ref-type="bibr" rid="bib51">Martinez-Fabregas et al., 2019</xref>) to transfect and express tagged variants of IL-27Rα and GP130, to allow quantitative site-specific fluorescence cell surface labeling by dye-conjugated nanobodies (NBs) (<xref ref-type="fig" rid="fig1">Figure 1e</xref>) as recently described in <xref ref-type="bibr" rid="bib24">Gorby et al., 2020</xref>. For both IL-27Rα and GP130, we found a random distribution and unhindered lateral diffusion of individual receptor monomers (<xref ref-type="fig" rid="fig1">Figure 1f</xref>). Single-molecule co-localization combined with co-tracking analysis was then used to identify correlated motion of IL-27Rα and GP130 which was taken as a readout for receptor heterodimer formation (<xref ref-type="bibr" rid="bib73">Ruprecht et al., 2010</xref>; <xref ref-type="fig" rid="fig1">Figure 1f</xref>, <xref ref-type="video" rid="video1">Video 1</xref>). In the resting state, we did not observe pre-assembly of IL-27Rα and GP130. However, after stimulation with IL-27 we found substantial heterodimerization (<xref ref-type="fig" rid="fig1">Figure 1f and g</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3a</xref>, <xref ref-type="video" rid="video1">Video 1</xref> and <xref ref-type="video" rid="video2">2</xref>). At elevated laser intensities, bleaching analysis of individual complexes confirmed a one-to-one (1:1) complex stoichiometry of IL-27Rα and GP130, whereas single-molecule Förster resonance energy transfer (FRET) further corroborated close molecular proximity of the two receptor chains (<xref ref-type="fig" rid="fig1">Figure 1h</xref>). We also observed association and dissociation events of receptor heterodimers, pointing to a dynamic equilibrium between monomers and dimers as proposed for other heterodimeric cytokine receptor systems (<xref ref-type="bibr" rid="bib54">Moraga et al., 2015a</xref>; <xref ref-type="bibr" rid="bib94">Wilmes et al., 2015</xref>; <xref ref-type="video" rid="video3">Video 3</xref>).</p><media id="video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-66014-video1.mp4"><label>Video 1.</label><caption><title>Single-molecule co-tracking as a readout for dimerization of cytokine receptors.</title><p>Cell surface labeling of mXFPe-IL-27Rα by eNB<sup>RHO11</sup> (left, top) and mXFPm-GP130 by mNB<sup>DY649</sup> (left, bottom) after stimulation with IL-27 (20 nM). In the overlay of the zoomed section of both spectral channels (mXFPe-IL-27Rα<sup>RHO11</sup>: Red, mXFPm-GP130<sup>DY649</sup>: Blue), yellow lines indicate co-locomotion of IL-27Rα and GP130 (≥10 steps). Acquisition frame rate: 30 Hz, Playback: real time.</p></caption></media><media id="video2" mime-subtype="mp4" mimetype="video" xlink:href="elife-66014-video2.mp4"><label>Video 2.</label><caption><title>Dynamics of IL-27-induced receptor assembly.</title><p>Formation of a single-molecule heterodimer of mXFPe-IL-27Rα<sup>RHO11</sup> (Red) and mXFPm-GP130<sup>DY649</sup> (Blue) in presence of IL-27. Yellow lines indicate co-locomotion of IL-27Rα and GP130 (≥10 steps). Acquisition frame rate: 30 Hz, Playback: real time with break at time of receptor dimerization.</p></caption></media><media id="video3" mime-subtype="mp4" mimetype="video" xlink:href="elife-66014-video3.mp4"><label>Video 3.</label><caption><title>Ligand-induced heterodimerization of IL-27Rα and GP130.</title><p>Overlay of the two spectral channels (mXFPe-IL-27Rα<sup>RHO11</sup>: Red, mXFPm-GP130<sup>DY649</sup>: Blue) in absence (left) or presence (right) of IL-27 (20 nM). Yellow lines indicate co-locomotion of IL-27Rα and GP130 (≥10 steps). Acquisition frame rate: 30 Hz, Playback: real time.</p></caption></media><media id="video4" mime-subtype="mp4" mimetype="video" xlink:href="elife-66014-video4.mp4"><label>Video 4.</label><caption><title>Ligand-induced homodimerization of GP130.</title><p>Overlay of the two spectral channels (mXFPm-GP130<sup>RHO11</sup>: Red, mXFPm-GP130<sup>DY649</sup>: Blue) in absence (left) or presence (right) of HypIL-6 (20 nM). Yellow lines indicate co-locomotion of IL-27Rα and GP130 (≥10 steps). Acquisition frame rate: 30 Hz, Playback: real time.</p></caption></media><p>To measure homodimerization of GP130 by HypIL-6, we stochastically labeled GP130 with equal concentrations of the same NB species conjugated to either of the two dyes (<xref ref-type="bibr" rid="bib95">Wilmes et al., 2020</xref>). We saw strong homodimerization of GP130 after stimulation with HypIL-6 (<xref ref-type="fig" rid="fig1">Figure 1g</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3a</xref>, <xref ref-type="video" rid="video4">Video 4</xref>). Homodimerization was confirmed either by single-color dual-step bleaching or dual-color single-step bleaching as shown for other homodimeric cytokine receptors (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3b</xref>; <xref ref-type="bibr" rid="bib65">Pflanz et al., 2004</xref>). For both cytokine receptor systems, we saw a cytokine-induced reduction of the diffusion mobility, which has been ascribed to increased friction of receptor dimers diffusing in the plasma membrane. However, we note that HypIL-6 stimulation impaired diffusion of GP130 more strongly than IL-27 did, possibly indicating faster receptor internalization (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3c</xref>). Based on the dimerization data, we were able to calculate the two-dimensional equilibrium dissociation constants (<inline-formula><mml:math id="inf1"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>D</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>) assuming mass action kinetics for a dynamic monomer-dimer equilibrium: for IL-27-induced heterodimerization of IL-27Rα and GP130, we calculated a two-dimensional constant, denoted by <inline-formula><mml:math id="inf2"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>D</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo></mml:math></inline-formula> of approximately 0.81 μm<sup>−2</sup>. In activated T-cells with high levels and a significant excess of IL-27Rα over GP130, this <inline-formula><mml:math id="inf3"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>D</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> ensures strong receptor assembly by IL-27 (<xref ref-type="bibr" rid="bib15">Diegelmann et al., 2012</xref>). <inline-formula><mml:math id="inf4"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>D</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> for GP130 homodimerization by HypIL-6 was approximately 0.21 μm<sup>−2</sup>. This higher affinity is most likely due to the two high-affinity binding sites engaged in the hexameric receptor complex (<xref ref-type="bibr" rid="bib5">Boulanger et al., 2003</xref>). However, in T-cells the expression of GP130 can be particularly low, thus, probably limiting HypIL-6-induced signaling. Taken together, these experiments marked ligand-induced receptor assembly as the initial step triggering downstream signaling for both IL-27 and HypIL-6, with no obvious differences in their receptor activation mechanism which could support the observed more sustained STAT1 activation elicited by IL-27.</p></sec><sec id="s2-3"><title>Mathematical and statistical analysis of HypIL-6 and IL-27-induced STAT kinetic responses</title><p>To gain further insight into the molecular rules and kinetics that define IL-27 sustained STAT1 phosphorylation, we developed two mathematical models of the initial steps of HypIL-6 and IL-27 receptor-mediated signaling, respectively. A diagram which describes the molecular reactions in each model is shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a</xref>, and the complete model reaction scheme is given in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1b–h</xref>. The mathematical model for each cytokine considers the following events: (i) cytokine association and dissociation to a receptor chain (<xref ref-type="fig" rid="fig2">Figure 2a</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1b and c</xref>, top panel), (ii) cytokine-induced dimer association and dissociation (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1b and c</xref>, bottom panel), (iii) STAT1 (or STAT3) binding and unbinding to dimer (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1d and e</xref>), (iv) STAT1 (or STAT3) phosphorylation when bound to dimer (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1d and e</xref>), (v) internalization/degradation of complexes (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1f and g</xref>), and (vi) dephosphorylation of free STAT1 (or STAT3) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1h</xref>). Details of model assumptions, model parameters and parameter inference have been provided in the Materials and methods under the sections Mathematical models and Bayesian inference. The ordinary differential equations for each mathematical model are given in Supplementary Information 1, where we have assumed mass action kinetics.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Mathematical modeling results in RPE1 and Th-1 cells.</title><p>(<bold>a</bold>) Simplified cartoon model of IL-27/HypIL-6 signal propagation layers and coverage of the mathematical modeling approach. (<bold>b</bold>) Model selection results showing the relative probabilities of each hypothesis, for different values of the distance threshold, <inline-formula><mml:math id="inf5"><mml:msup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>*</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula>, in RPE1 cells. (<bold>c</bold>) Pointwise median and 95% credible intervals of the predictions from the mathematical model, calibrated with the experimental data, using the posterior distributions for the parameters from the ABC-SMC. For the experimental data, phosphorylation kinetics of pSTAT1 and pSTAT3 were followed in RPE1 IL-27Rα after stimulation with saturating concentrations of IL-27 (2 nM) and HypIL-6 (10 nM). (<bold>d</bold>) Kernel density estimates of the posterior distributions for the parameters <inline-formula><mml:math id="inf6"><mml:mi>p</mml:mi><mml:mi/><mml:mo>∈</mml:mo><mml:mo>{</mml:mo><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mi>q</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mfenced><mml:mo>,</mml:mo><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mfenced><mml:mo>,</mml:mo><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mfenced><mml:mo>,</mml:mo><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mfenced><mml:mo>}</mml:mo></mml:math></inline-formula> in the mathematical models where <inline-formula><mml:math id="inf7"><mml:mi>j</mml:mi><mml:mi/><mml:mo>∈</mml:mo><mml:mo>{</mml:mo><mml:mn>6,27</mml:mn><mml:mo>}</mml:mo></mml:math></inline-formula> and <inline-formula><mml:math id="inf8"><mml:mi>i</mml:mi><mml:mi/><mml:mo>∈</mml:mo><mml:mo>{</mml:mo><mml:mn>1,3</mml:mn><mml:mo>}</mml:mo></mml:math></inline-formula>. A '+' in the parameter notation indicates that this is a forward rate constant (binding) and a '–' in the notation indicates that this is a reverse rate constant (dissociation). In the first row, a '6' in the notation indicates that this is a reaction rate in the HypIL-6 system and a '27' indicates that this is a reaction rate in the IL-27 system.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Schematic model of involved reactions and parameters for IL-27 and HypIL-6 receptor activation.</title><p>(<bold>a</bold>) Diagram of the reactions for the HypIL-6 and IL-27 mathematical models. From left to right in a single model panel: cytokines can bind to monomeric receptors, dimerization of receptor monomers can occur and STAT molecules can bind to the dimers, where they can then phosphorylate and dissociate. Each panel is one such example of the model, in general STAT molecules can bind to either receptor in the dimer until two STATs are bound to a given single dimer. The reverse reactions are also included in the models but have not been included in the diagramme to simplify it. Finally, in each model (HypIL-6 or IL-27), any molecular species involving a receptor molecule of either type can be internalized/degraded. (<bold>b</bold>) Reactions involving ligand binding and dimerization in the HypIL-6 model. (<bold>c</bold>) Reactions involving ligand binding and dimerization in the IL-27 model. (<bold>d</bold>) Reactions involving the STAT molecules <inline-formula><mml:math id="inf9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>j</mml:mi><mml:mo>∈</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> in the HypIL-6 model. (<bold>e</bold>) Reactions involving the STAT molecules <inline-formula><mml:math id="inf10"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>j</mml:mi><mml:mo>∈</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> in the IL-27 model. (<bold>f</bold>) Reactions involving receptor internalization/degradation in the HypIL-6 model. Here <inline-formula><mml:math id="inf11"><mml:mi>H</mml:mi><mml:mn>1</mml:mn><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf12"><mml:mi>H</mml:mi><mml:mn>2</mml:mn><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>p</mml:mi><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>p</mml:mi><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:math></inline-formula>. (<bold>g</bold>) Reactions involving receptor internalization/degradation in the IL-27 model. Here <inline-formula><mml:math id="inf13"><mml:mi>H</mml:mi><mml:mn>1</mml:mn><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf14"><mml:mi>H</mml:mi><mml:mn>2</mml:mn><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>p</mml:mi><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>p</mml:mi><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:math></inline-formula>. (<bold>h</bold>) Dephosphorylation of <inline-formula><mml:math id="inf15"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>j</mml:mi><mml:mo>∈</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> in the cytoplasm. This reaction occurs in both models.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig2-figsupp1-v2.tif"/></fig></fig-group><p>We first wanted to explore if there existed a potential feedback mechanism in the mechanisms of receptor complexes internalization/degradation over time. Negative feedback mechanisms have been reported for cytokine receptor signaling, while positive feedback loops are unlikely to happen at the timescale of the given experiments (3 hr). To this end, and for each cytokine model, we considered two hypotheses: hypothesis one assumes that receptor complexes (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1f and g</xref>) are internalized with rate proportional to the concentration of the species in which they are contained (e.g. different dimer types), and hypothesis 2, that receptor complexes are internalized with rate proportional to the product of the concentration of the species in which they are contained and the sum of the concentrations of free cytoplasmic phosphorylated STAT1 and STAT3. Hypothesis 2 is consistent with a negative feedback mechanism in which pSTAT molecules translocate to the nucleus, where they increase the translation of negative feedback proteins such as SOCS3. In order not to increase the complexity of the mathematical models with additional variables and parameters, we chose to include the feedback mechanism in hypothesis two implicitly, rather than by considering new equations for species such as SOCS3. Details of the two model hypotheses are described in the Materials and methods (Mathematical models).</p><p>We first carried out a structural identifiability analysis (<xref ref-type="bibr" rid="bib9">Castro and de Boer, 2020</xref>) for the IL-27 and HypIL-6 mathematical models under both hypotheses, to determine which of the model parameters could be independently inferred. We found that all model parameters and initial concentrations were structurally identifiable, given the data and the known experimental initial concentrations. We made use of the RPE1 experimental data set to carry out Bayesian model selection for the two different hypotheses. We found that hypothesis 1 could explain the data better than hypothesis 2, with a probability of 99%. This result can be seen in <xref ref-type="fig" rid="fig2">Figure 2b</xref>, in which we plot, for different values of the distance threshold, <inline-formula><mml:math id="inf16"><mml:mi mathvariant="normal">δ</mml:mi></mml:math></inline-formula>, between the mathematical model output and the data (see Mathematical models and Bayesian inference in Materials and methods, for details), the relative probability of each hypothesis, where hypothesis 1 is denoted <inline-formula><mml:math id="inf17"><mml:msub><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and hypothesis 2 is denoted <inline-formula><mml:math id="inf18"><mml:msub><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>. It can be observed that for smaller values of the distance threshold, which indicate data and mathematical model results are closer, the relative probability of hypothesis 1 is higher than that of hypothesis 2.</p><p>We then made use of this result to explore the mathematical models for both cytokines under hypothesis 1, in particular we performed parameter calibration. To this end (and as described in Materials and methods under Mathematical models and Bayesian inference), we carried out Bayesian inference (ABC-SMC <xref ref-type="bibr" rid="bib88">Toni et al., 2009</xref>) together with the mathematical models (hypothesis 1) and the experimental data sets to quantify the reaction rates (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>) and initial molecular concentrations (see Table 2 and Table 3). The Bayesian parameter calibration of the two models of cytokine signaling allows one to quantify the observed kinetics of pSTAT1/3 phosphorylation induced by HypIL-6 and IL-27 in RPE1 and Th-1 cells (<xref ref-type="fig" rid="fig2">Figure 2c</xref>). Substantial differences in STAT association rates to and dissociation rates from the dimeric complexes were inferred to critically contribute to defining pSTAT1/3 kinetics. <xref ref-type="fig" rid="fig2">Figure 2d</xref> shows the kernel density estimates (KDEs) for the posterior distributions of the rate constants and initial concentrations in the models. <inline-formula><mml:math id="inf19"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> denotes the rate at which STATi binds to GP130 and <inline-formula><mml:math id="inf20"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> denotes the rate at which STATi binds to IL-27Rα, for <inline-formula><mml:math id="inf21"><mml:mi>i</mml:mi><mml:mo>∈</mml:mo><mml:mi/><mml:mfenced close="}" open="{" separators="|"><mml:mrow><mml:mn>1,3</mml:mn></mml:mrow></mml:mfenced></mml:math></inline-formula>. Our results indicate that STAT1 and STAT3 exhibit different binding preferences toward IL-27Rα and GP130. While STAT1 exhibits stronger binding to IL-27Rα than GP130 (<inline-formula><mml:math id="inf22"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup><mml:mo>&gt;</mml:mo><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>), STAT3 exhibits stronger binding to GP130 than IL-27Rα, (<inline-formula><mml:math id="inf23"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mn>3</mml:mn><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup><mml:mo>&gt;</mml:mo><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mn>3</mml:mn><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>) in agreement with previous observations (<italic>17</italic>). To further quantify these differences in the posterior distributions for the STAT binding rates, <xref ref-type="table" rid="table1">Table 1</xref> provides summary statistics for each of these rates. For example, from the table we see that there is a difference of at least one order of magnitude between the means and medians of the pairs of STAT/receptor binding parameters (<inline-formula><mml:math id="inf24"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> compared with <inline-formula><mml:math id="inf25"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> for <inline-formula><mml:math id="inf26"><mml:mi>i</mml:mi><mml:mi/><mml:mo>∈</mml:mo><mml:mo>{</mml:mo><mml:mn>1,3</mml:mn><mml:mo>}</mml:mo></mml:math></inline-formula>). Finally, we note that, although there exist some significant correlations between posterior distributions for pairs of parameters in the analysis, for all four pairs of STAT/receptor interaction parameters (second row of <xref ref-type="fig" rid="fig2">Figure 2d</xref>), the absolute value of the correlation coefficient is less than 0.25, and thus, the posterior distributions are representative of the rates they correspond to.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Summary statistics of the posterior distributions for the STAT/receptor binding and dissociation rates.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Parameter</th><th valign="top">Mean</th><th valign="top">Median</th></tr></thead><tbody><tr><td><inline-formula><mml:math id="inf27"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf28"><mml:mn>1.1</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf29"><mml:mn>2.2</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td></tr><tr><td><inline-formula><mml:math id="inf30"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf31"><mml:mn>4.2</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf32"><mml:mn>1.8</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td></tr><tr><td><inline-formula><mml:math id="inf33"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf34"><mml:mn>1.2</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf35"><mml:mn>3.4</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td></tr><tr><td><inline-formula><mml:math id="inf36"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf37"><mml:mn>1.2</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf38"><mml:mn>7.2</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td></tr><tr><td><inline-formula><mml:math id="inf39"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf40"><mml:mn>1.1</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf41"><mml:mn>3.7</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td></tr><tr><td><inline-formula><mml:math id="inf42"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf43"><mml:mn>1.4</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf44"><mml:mn>8.0</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td></tr><tr><td><inline-formula><mml:math id="inf45"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf46"><mml:mn>6.8</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf47"><mml:mn>7.5</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td></tr><tr><td><inline-formula><mml:math id="inf48"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf49"><mml:mn>1.2</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf50"><mml:mn>4.3</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula></td></tr></tbody></table></table-wrap></sec><sec id="s2-4"><title>IL-27Rα cytoplasmic domain is required for sustained pSTAT1 kinetics</title><p>The Bayesian inference carried out with the experimental data and the mathematical models clearly indicated statistically significant differences in the binding rates of STAT1/STAT3 to GP130 and IL-27Rα, to account for the different phosphorylation kinetics exhibited by HypIL-6 and IL-27. Thus, we next investigated whether the more sustained STAT1 activation by IL-27 resulted from its specific engagement of IL-27Rα. For that, we used RPE1 cells, which do not express IL-27Rα (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2a</xref>), to systematically dissect the contribution of the IL-27Rα cytoplasmic domain to the differential pSTAT activation by IL-27. IL-27Rα’s intracellular domain is very short and only encodes two Tyr susceptible to be phosphorylated in response to IL-27 stimulation, that is, Tyr543 and Ty613 (<xref ref-type="fig" rid="fig3">Figure 3a</xref>). We mutated these two Tyr to Phe to analyse their contribution to IL-27 induced signaling. We stably expressed WT IL-27Rα as well as different IL-27Rα Tyr mutants in RPE1 cells with comparable cell surface expression levels (<xref ref-type="fig" rid="fig3">Figure 3b</xref>). As the endogenous GP130 expression levels remain unaltered, all generated clones exhibited very comparable responses to HypIL-6 (<xref ref-type="fig" rid="fig3">Figure 3b</xref>, bottom panels). IL-27 triggered comparable levels of STAT1 and STAT3 activation in RPE1 cells reconstituted with IL-27Rα WT and IL-27Rα Y543F mutant, suggesting that this Tyr residue does not contribute to signaling by this cytokine (<xref ref-type="fig" rid="fig3">Figure 3b</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1a</xref>). In RPE1 cells reconstituted with the IL-27Rα Y613F or Y543F-Y613F mutants, IL-27 stimulation resulted in 80% of the STAT3 activation, but only 20% of the STAT1 activation levels induced by this cytokine relative to IL-27Rα WT (<xref ref-type="fig" rid="fig3">Figure 3b</xref>; <xref ref-type="bibr" rid="bib67">Pradhan et al., 2010</xref>). These observations suggest a tight coupling of STAT phosphorylation to one of the receptor chains; namely, IL-27Rα with pSTAT1 and GP130 with pSTAT3, respectively. We next tested how the cytoplasmic domains of GP130 and IL-27Rα shape the pSTAT kinetic profiles. Thus, we generated a stable RPE1 clone expressing a chimeric construct comprised of the extracellular and transmembrane domain of IL-27Rα but the cytoplasmic domain of GP130 (<xref ref-type="fig" rid="fig3">Figure 3c</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1b</xref>). Again, as both cell lines express unaltered endogenous GP130 levels, they exhibited comparable responses to HyIL-6 (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). Strikingly, this domain-swap resulted in a transient pSTAT1 kinetic response by IL-27 comparable to HypIL-6 stimulation. STAT3 activation on the other hand remained unaltered suggesting that the cytoplasmic domain of IL-27Rα is essential for a sustained pSTAT1 response but not for pSTAT3.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>IL-27Rα cytoplasmic domain is required for sustained pSTAT1 kinetics.</title><p>(<bold>a</bold>) Representation of the cytoplasmic domain of IL-27Rα with its highlighted tyrosine residues Y543 and Y613. (<bold>b</bold>) STAT1 and STAT3 phosphorylation kinetics of RPE1 clones stably expressing wt and mutant IL-27Rα after stimulation with IL-27 (10 nM, top panels) or after stimulation with HypIL-6 (20 nM, bottom panels), normalized to maximal levels of wt IL-27Rα stimulated with IL-27 (top) or HypIL-6 (bottom). Data was obtained from three experiments with each two technical replicates, showing mean ± std dev. Bottom right: cell surface levels variants measured by flow cytometry for indicated IL-27Rα cell lines. (<bold>c</bold>) Cytoplasmic domain of IL-27Rα is required for sustained pSTAT1 activation. Left: Cartoon representation of receptor complexes. Right: STAT1 and STAT3 phosphorylation kinetics of RPE1 clones stably expressing wt IL-27Rα and IL-27Rα-GP130 chimera after stimulation with IL-27 (10 nM, top panels) or after stimulation with HypIL-6 (20 nM, bottom panels). Data was normalized to maximal levels for each cytokine and cell line. Data was obtained from two experiments with each two technical replicates, showing mean ±std dev. (<bold>d</bold>) Phosphatases do not account for differential pSTAT1/3 activity induced by IL-27 and HypIL-6. Left: Schematic representation of workflow using JAK inhibitor Tofacitinib. Right: MFI ratio of Tofacitinib-treated and non-treated RPE1 mXFPe-IL-27Rα cells for pSTAT1 and pSTAT3 after stimulation with IL-27 (10 nM) and HypIL-6 (20 nM). Data was obtained from two experiments with each two technical replicates, showing mean ± std dev.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Characterization of IL-27Rα mutants and probing phosphatase activity by Tofacitinib-mediated inhibition of JAK/STAT signaling.</title><p>(<bold>a</bold>) Dose-response experiments for pSTAT1 (left) and pSTAT3 (right) in RPE1 cells stably expressing wt IL-27Rα or tyrosine-mutants after stimulation with IL-27, normalized to maximal stimulation of wt IL-27Rα. Data was obtained from one representative experiment with each two technical replicates, showing mean ± std dev. (<bold>b</bold>) Dose-response experiments for pSTAT1 (left) and pSTAT3 (right) in RPE1 cells stably expressing wt IL-27Rα or IL-27Ra-GP130 chimera after stimulation with IL-27. Data normalized to maximal stimulation of wt IL-27Rα. Data was obtained from one representative experiment with each two technical replicates, showing mean ± std dev. (<bold>c</bold>) STAT1 (left) and STAT3 (right) phosphorylation kinetics in RPE1 IL-27Rα cells stimulated with with IL-27 (2 nM) or HypIL-6 (10 nM) with and without JAK inhibition by Tofacitinib. Data was normalized to maximal IL-27 stimulation. Data was obtained from two experiments with each two technical replicates, showing mean ± std dev. (<bold>d</bold>) STAT1 (left) and STAT3 (right) phosphorylation kinetics in Th-1 cells stimulated with with IL-27 (10 nM) or HypIL-6 (20 nM) with and without JAK inhibition by Tofacitinib. Data was normalized to to maximal IL-27 stimulation. Data was obtained from two biological replicates with each two technical replicates, showing mean ± std dev. (<bold>e</bold>) MFI ratio of Tofacitinib-treated and non-treated Th-1 cells for pSTAT1 (left) and pSTAT3 (right) after stimulation with IL-27 (10 nM) and HypIL-6 (20 nM). Data was obtained from two biological replicates with each two technical replicates, showing mean ±std dev.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Effects of Cycloheximide-mediated inhibition of protein neosynthesis on IL-27 and HypIL-6 signaling.</title><p>(<bold>a</bold>) STAT1 (left) and STAT3 (right) phosphorylation kinetics in RPE1 IL-27Rα cells stimulated with IL-27 or HypIL-6 with and without pretreatment with cycloheximide (CHX). Data was normalized to maximal IL-27 stimulation. Data was obtained from two experiments with each two technical replicates, showing mean ± std dev. (<bold>b</bold>) STAT1 (left) and STAT3 (right) phosphorylation kinetics in TH1 cells stimulated with IL-27 or HypIL-6 with and without pre-treatment with cycloheximide (CHX). Data was normalized to to maximal IL-27 stimulation. Data was obtained from two biological replicates with each two technical replicates, showing mean ± std dev.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig3-figsupp2-v2.tif"/></fig></fig-group><p>Two plausible scenarios could explain the observed pSTAT1/3 activation differential by HypIL-6 and IL-27: (i) IL-27Rα-JAK2 complex phosphorylates STAT1 faster than GP130-JAK1 complex or (ii) pSTAT1 is more quickly dephosphorylated in the IL-6/GP130 receptor homodimer. In the latter case, pSTAT deactivation by constitutively expressed phosphatases could be an additional factor of regulation. Indeed, SHP-2 has been described to bind to GP130 and shape IL-6 responses (<xref ref-type="bibr" rid="bib40">Kim et al., 1998</xref>). However, our Bayesian inference results (together with the mathematical models and the experimental data) identified the STAT/receptor association rates as the only rates that could account for the greater and more sustained activation of STAT1 by IL-27. We note (as described in the Materials and methods) that the phosphorylation rate, denoted by q, of STAT1 and STAT3 when bound to a dimer (homo- or hetero-) has been assumed to be independent of the STAT type and the receptor chain. Moreover, the model also included dephosphorylation of free pSTAT molecules, and predicted that the rates at which these reactions occur (<inline-formula><mml:math id="inf51"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf52"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>) had rather similar posterior distributions, hence arguing against the potential role of phosphatases to specifically target STAT1 upon HypIL-6 stimulation. To distinguish between the two plausible scenarios, we next determined the rates of pSTAT1/3 dephosphorylation by blocking JAK activity upon cytokine stimulation making use of the JAK inhibitor Tofacitinib in RPE1 cells. Tofacitinib was added 15 min after stimulation with either cytokine and pSTAT1 and pSTAT3 levels were measured at the indicated times. JAK inhibition markedly shortened the pSTAT1/3 activation profiles induced by both cytokines (<xref ref-type="fig" rid="fig3">Figure 3d</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1c</xref>). The relative dephosphorylation rates could then be determined by the signal intensity ratio of +/- Tofacitinib. Even though pSTAT1 levels were more affected by JAK inhibition than those of pSTAT3, the observed relative changes were nearly identical for IL-27 and HypIL-6. These findings were also confirmed for Th-1 cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1d and e</xref>) and indicate, that selective phosphatase activity cannot serve as an explanation for the pSTAT1/3 differential by HypIL-6 and IL-27, in agreement with our mathematical modeling predictions. Similarly, we tested whether neosynthesis of feedback inhibitors such as SOCS3 (<xref ref-type="bibr" rid="bib14">Croker et al., 2003</xref>) would selectively impair signaling by HypIL-6 but not by IL-27. To this end we pre-treated cells with Cycloheximide (CHX) and followed the pSTAT1/3 kinetics induced by the two cytokines (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2a and b</xref>). CHX treatment resulted in more sustained pSTAT3 activity for both cytokines. To our surprise, STAT1 phosphorylation by IL-27 was even more sustained while pSTAT1 levels induced by IL-6 remained unaffected. These observations exclude that feedback inhibitors selectively impair STAT1 activation kinetics by HypIL-6 and thus do not account for the faster STAT1 dephosphorylation kinetics observed under HypIL-6 stimulation. Overall, our data from the chimera and mutant experiments, which were not used in the Bayesian parameter calibration, provide additional support: they validate the mathematical models of HypIL-6 and IL-27 signaling and point to the differential association/dissociation of STAT1 and STAT3 to IL-27Rα and GP130, respectively, as the main factor defining STAT phosphorylation kinetics in response to HypIL-6 and IL-27 stimulation.</p></sec><sec id="s2-5"><title>Unique and overlapping effects of IL-27 and HypIL-6 on the Th-1 phosphoproteome</title><p>Thus far, we have investigated the differential activation of STAT1/STAT3 induced by HypIL-6 and IL-27. Next, we asked whether IL-27 and IL-6 induced the activation of additional and specific intracellular signaling programs that could contribute to their unique biological profiles. To this end, we investigated the IL-27 and HypIL-6 activated signalosome using quantitative mass-spectrometry-based phospho-proteomics. MACS-isolated CD4+ were polarized into Th-1 cells and expanded in vitro for stable isotope labeling by amino acids in cell culture (SILAC). Cells were then stimulated for 15 min with saturating concentrations of IL-27 (10 nM), HypIL-6 (20 nM) or left untreated. Samples were enriched for phosphopeptides (Ti-IMAC), subjected to mass spectrometry and raw files analysed by MaxQuant software (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). In total we could quantify ~6400 phosphopeptides from 2600 proteins, identified across all conditions (unstimulated, IL-27, HypIL-6) for at least two out of three tested donors. For IL-27 and HypIL-6 we detected similar numbers of significantly upregulated (87 vs. 78) and downregulated (155 vs. 140) phosphorylation events (<xref ref-type="fig" rid="fig4">Figure 4a</xref>) and systematically categorized them in context with their cellular location and ascribed biological functions (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1b and c</xref>; <xref ref-type="bibr" rid="bib32">Huang et al., 2009b</xref>). The two cytokines shared approximately half of the upregulated and one third of the downregulated phospho-peptides (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2a</xref>) but also exhibited differential target phosphorylation (<xref ref-type="fig" rid="fig4">Figure 4b</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2b</xref>). As expected, we found multiple members of the STAT protein family among the top phosphorylation hits by the two cytokines, validating our study (<xref ref-type="fig" rid="fig4">Figure 4b and c</xref>). In line with our previous observations, we detected the same relative amplitudes for tyrosine phosphorylated STAT3 and STAT1. In addition to tyrosine-phosphorylation, we detected robust serine-phosphorylation on S727 for STAT1 and STAT3 (<xref ref-type="fig" rid="fig4">Figure 4c</xref>). While pS-STAT1 activity correlated with pY-STAT1 with IL-27 being more potent than HypIL-6, this was not the case for STAT3. Despite an identical pY-STAT3 phosphorylation profile, HypIL-6 induced a ~50% higher pS-STAT3 relative to IL-27 (<xref ref-type="fig" rid="fig4">Figure 4c</xref>). These results were corroborated, following the phosphorylation kinetics of pS-STAT1 and pS-STAT3 by flow-cytometry (<xref ref-type="fig" rid="fig4">Figure 4d</xref>). Interestingly, while IL-27 and IL-6 have been described to also activate other signaling pathways, such as MAPK, p38, and AKT (<xref ref-type="bibr" rid="bib15">Diegelmann et al., 2012</xref>), we did not observe this in our phospho-target screening.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Unique and overlapping effects of IL-27 and HypIL-6 on the phosphoproteome of Th-1 cells.</title><p>(<bold>a</bold>) Volcano plot of the phospho-sites regulated (p value ≤ 0.05, fold change ≥+1.5 or≤−1.5) by IL-27 (left) and HypIL-6 (right). Cells were stimulated for 15 min at saturating concentrations (IL-27: 10 nM, HypIL-6: 20 nM). Data was obtained from three biological replicates. (<bold>b</bold>) Heatmap representation (examples) of shared and differentially up- (left) and downregulated (right) phospho-sites after IL-27 and HypIL-6 stimulation. Data represents the mean (log<sub>2</sub>) fold change of three biological replicates. (<bold>c</bold>) Tyrosine and Serine phosphorylation of selected STAT proteins after stimulation with IL-27 (red) and HypIL-6 (blue). Two-tailed Student’s T-test: *p&lt;0.05, **p≤0.01,***p≤0.001; n.s., not significant. (<bold>d</bold>) pS727-STAT1 and pS727-STAT3 phosphorylation kinetics in Th-1 cells after stimulation with IL-27 or HypIL-6, normalized to maximal IL-27 stimulation. Data was obtained from three biological replicates with each two technical replicates, showing mean ±std dev. (<bold>e</bold>) GO analysis ‘biological processes’ of the phospho-sites regulated by IL-27 (red) and HypIL-6 (blue) represented as bubble-plots. (<bold>f</bold>) Phosphorylation of target proteins associated with STAT3/CDK transcription initiation complex after stimulation with IL-27 (blue) and HypIL-6 (red) and schematic representation of transcription regulation of RNA polymerase II with identified phospho-sites (red flags). Two-tailed Student’s T-test: *p&lt;0.05, **p≤0.01,***p≤0.001; n.s., not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Workflow for phospho-proteomics and cellular localization of identified phosphorylation targets.</title><p>(<bold>a</bold>) Workflow for quantitative SILAC phospho-proteomic analysis of TH-1 cells stimulated (15 min) with IL-27 (10 nM), HypIL-6 (20 nM) or left untreated. (<bold>b</bold>) Schematic representation of the main GO terms regulated by IL-27 as inferred from our phospho-proteomics studies. Red represents downregulated phospho-sites and blue represents upregulated p-sites upon IL-27 stimulation of human primary Th-1 cells. (<bold>c</bold>) Schematic representation of the main GO terms regulated by HyIL6 as inferred from our phospho-proteomics studies. Red represents downregulated phospho-sites and blue upregulated p-sites upon HyIL6 stimulation of human primary Th-1 cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Phospho-proteomics - shared and unique targets and gene ontology analysis.</title><p>(<bold>a</bold>) Venn diagrams comparing the numbers of unique upregulated (left) and downregulated (right) phospho-sites by IL-27 (blue) and HypIL-6 (red) as well as the number of shared phospho-sites. (<bold>b</bold>) List of most strongly altered phosphosites (downregulated: green; upregulated: red) in response to IL-27 (left) or HypIL-6 (right). (<bold>c</bold>) GO analysis ‘cellular location’ and ‘UP keywords’ of the phospho-sites regulated by IL-27 (red) and HypIL-6 (blue) represented as bubble-plots. (<bold>d</bold>) Phosphorylation of target proteins related to Treg functions and schematic representation of their activity on T-cells. Two-tailed Student’s T-test: *p&lt;0.05, **p≤0.01,***p≤0.001; n.s., not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig4-figsupp2-v2.tif"/></fig></fig-group><p>Given the overlapping phospho-proteomic changes, gene ontology (GO) analysis associated several sets of phosphopeptides with biological processes that were mostly shared between both cytokines (<xref ref-type="fig" rid="fig4">Figure 4e</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2c</xref>). A large set of phospho-peptides was linked to transcription initiation (including JAK/STAT signaling) or mRNA modification (<xref ref-type="fig" rid="fig4">Figure 4e</xref>). Interestingly, IL-27 stimulation was associated to negative regulation of RNA polymerase II, whereas a positive regulation was detected for HypIL-6. A closer look into the functional regulation of RNA-pol II activity by the two cytokines revealed that multiple proteins involved in this process were differentially regulated by HypIL-6 and IL-27 (<xref ref-type="fig" rid="fig4">Figure 4f</xref>). While positive regulators of RNA-pol II transcription, such as Negative Elongation Factor A (NELFA), PPM1G, RCHY1 and POL2RA, were much more phosphorylated in response to HypIL-6 than IL-27, negative regulators of RNA-pol II transcription, such as LARP7, were much more engaged by IL-27 treatment than by HypIL-6 (<xref ref-type="fig" rid="fig4">Figure 4f</xref>). Interestingly, in a previous study we linked RNA-pol II regulation with the levels of STAT3 S727phosphorylation induced by HypIL-6 via recruitment of CDK8 to STAT3-dependent genes (<xref ref-type="bibr" rid="bib2">Bancerek et al., 2013</xref>). Our phospho-proteomic analysis thus, suggests that IL-27 and HypIL-6 recruit different transcriptional complexes that ultimately could contribute to provide gene expression specificity by the two cytokines. Additionally, we identified several interesting IL-27-specific phosphorylation targets. One example was Ubiquitin Protein Ligase E3 Component N-Recognin 5 (UBR5). Phosphorylated UBR5 leads to ubiquitination and subsequent degradation of Rorγc (<xref ref-type="bibr" rid="bib75">Rutz et al., 2015</xref>), the key transcription factor required for Th-17 lineage commitment, thus limiting Th-17 differentiation (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2d</xref>). A second example is PAK2, which phosphorylates and stabilizes FoxP3 leading to higher levels of T<sub>Reg</sub> cells (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2d</xref>; <xref ref-type="bibr" rid="bib58">O'Hagan et al., 2017</xref>). Moreover, IL-27 stimulation led to a very strong phosphorylation of BCL2-associated agonist of cell death (BAD), a critical regulator of T-cell survival and a well-known substrate of the PAK2 kinase (<xref ref-type="bibr" rid="bib99">Ye and Field, 2012</xref>). Overall, our data show a large overlap between the IL-6 and IL-27 signaling program, with a strong focus on JAK/STAT signaling. However, IL-27 engages additional signaling intermediaries that could contribute to its unique immuno-modulatory activities. Further studies will be required to assess how these IL-27 specific signaling pockets contribute to shape IL-27 responses.</p></sec><sec id="s2-6"><title>Kinetic decoupling of gene induction programs depends on sustained STAT1 activation and IRF1 expression by IL-27</title><p>Next, we investigated how the different kinetics of STAT activation induced by HypIL-6 and IL-27 ultimately modulated gene expression by these two cytokines. To this end, we performed RNA-seq analysis of Th-1 cells stimulated with HypIL-6 or IL-27 for 1 hr, 6 hr and 24 hr to obtain a dynamic perspective of gene regulation. We identified ~12500 shared genes that could be quantified for all three donors and throughout all tested experimental conditions. In a first step, we compared how similar the gene programs induced by HypIL-6 and IL-27 were. Principal component analysis (PCA) was run for a subset of genes, found to be significantly up- (total ~250) or downregulated (total ~950) by either of the experimental conditions (p value≤0.05, fold change ≥+2 or ≤−2). At one hour of stimulation HypIL-6 and IL-27 induced very similar gene programs, with the two cytokines clustering together in the PCA analysis regardless of whether we focused on the subsets of upregulated or downregulated genes (<xref ref-type="fig" rid="fig5">Figure 5a</xref>). However, the similarities between the two cytokines changed dramatically in the course of continuous stimulation. While the two cytokines induced the downregulation of comparable gene programs at 6 hr and 24 hr stimulation, as denoted by the close clustering in the PCA analysis (<xref ref-type="fig" rid="fig5">Figure 5a</xref>, right panel) and the fraction of shared genes (~40%, <xref ref-type="fig" rid="fig5">Figure 5b</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1a–c</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2a</xref>), this was not observed for upregulated genes. Although the two cytokines induced comparable gene upregulation programs after 1 hr of stimulation (~80% shared genes), this trend almost completely disappeared at later stimulation times (<xref ref-type="fig" rid="fig5">Figure 5a and b</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2b</xref>). This is well-reflected by the absolute numbers of up- or downregulated genes observed for IL-27 and HypIL-6 (<xref ref-type="fig" rid="fig5">Figure 5c</xref>). Stimulation with both cytokines yielded a similar trend of gene downregulation (<xref ref-type="fig" rid="fig5">Figure 5c</xref>, right panel). However, while HypIL-6 stimulation resulted in a spike of gene upregulation at 1 hr that quickly disappeared at later stimulation times, IL-27 stimulation was capable to increase the number of upregulated genes beyond 6 hr of stimulation and maintains it even after 24 hr (<xref ref-type="fig" rid="fig5">Figure 5c</xref>, left panel). This ‘kinetic decoupling’ of gene induction seems to have a striking functional relevance. Gene set enrichment analysis (GSEA) (<xref ref-type="bibr" rid="bib49">Liao et al., 2019</xref>) identified several reactome pathways to be enriched for IL-27 over the course of stimulation – most of them linked with Interferon signaling and immune responses (<xref ref-type="fig" rid="fig5">Figure 5d</xref>). In contrast, for HypIL-6 stimulation no pathway enrichment was detected. Most importantly, the vast majority of IL-27-induced genes that were associated to these pathways belonged to genes upregulated by IL-27 treatment and that have been previously linked to STAT1 activation (<xref ref-type="bibr" rid="bib76">Satoh and Tabunoki, 2013</xref>; <xref ref-type="bibr" rid="bib74">Rusinova et al., 2013</xref>; <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2c</xref>). Although HypIL-6 treatment resulted in the induction of some of these genes, their expression was very transient in time, in agreement with the short STAT1 activation kinetic profile exhibited by HypIL-6 (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2b and c</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Kinetic decoupling of gene induction programs depends on sustained STAT1 activation by IL-27.</title><p>(<bold>a</bold>) Principal component analysis for genes found to be significantly upregulated (left) or downregulated (right) for at least one of the tested conditions (time and cytokine). Data was obtained from three biological replicates. (<bold>b</bold>) Kinetics of gene induction shared between IL-27 and HypIL-6 (relative to IL-27) for upregulated genes (red) or downregulated genes (green). (<bold>c</bold>) Kinetics of gene numbers induced after IL-27 and HypIL-6 stimulation for upregulated genes (left) and downregulated genes (right). (<bold>d</bold>) GSEA reactome analysis of selected pathways with significantly altered gene induction in response to IL-27 or HypIL-6 stimulation. Data represents the mean (log<sub>2</sub>) fold change of three biological replicates. (<bold>e</bold>) Cluster analysis comparing the gene induction kinetics after IL-27 or HypIL-6 stimulation. Gene induction heatmaps for example genes as well as induction kinetics (mean) are shown for highlighted gene clusters. Data represents the mean (log<sub>2</sub>) fold change of three biological replicates.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>IL-27 and HypIL-6 stimulated gene induction profiles represented as volcano plots.</title><p>(<bold>a</bold>) Kinetics of gene induction in Th-1 cells induced by IL-27 represented as volcano plots. Genes significantly up- or downregulated are highlighted in red (p value ≤ 0.05, fold change ≥+2 or ≤−2). Data was obtained from three biological replicates. (<bold>b</bold>) Kinetics of gene induction in Th-1 cells induced by HypIL-6 represented as volcano plots. Genes significantly up- or downregulated are highlighted in red (p value ≤ 0.05, fold change ≥+2 or ≤−2). Data was obtained from three biological replicates. (<bold>c</bold>) Kinetics of gene induction in Th-1 cells induced by HypIL-6 represented as volcano plots. Genes identified to be significantly up- or downregulated by IL-27 are highlighted in red (p value ≤ 0.05, fold change ≥+2 or ≤−2). Data was obtained from three biological replicates.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Kinetic decoupling of gene induction programs - shared and unique genes and GSEA pathway analysis.</title><p>(<bold>a</bold>) Gene induction kinetics represented as pie-charts, separated for upregulated genes (top panel) and downregulated genes (bottom panel). (<bold>b</bold>) Kinetics of ISG induction (examples) as heatmap representation comparing IL-27 with HypIL-6 (top) and GSEA reactome pathway enrichment ‘IFN signaling’ for genes induced by IL-27 after 6 hr (bottom). Data represents the mean (log<sub>2</sub>) fold change of three biological replicates. (<bold>c</bold>) Heatmaps of the top 30 up- and downregulated genes by IL-27 compared to HypIL-6 for 1 hr, 6 hr, and 24 hr. Data represents the mean (log<sub>2</sub>) fold change of three biological replicates.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>IL-27-induced upregulation of IRF1 amplifies induction of STAT1-dependent genes.</title><p>(<bold>a</bold>) Kinetics of IRF1 protein expression as a response to continuous IL-27 and HypIL-6 stimulation in Th-1 cells. Data was obtained from three biological replicates with each two technical replicates, showing mean ± std dev. Dotted line indicates baseline level. (<bold>b</bold>) Kinetics of IRF1 protein expression and siRNA-mediated IRF1 knockdown in RPE1 IL-27Rα cells stimulated with IL-27 (2 nM). Data was obtained from one representative experiment with each two technical replicates, normalized to maximal IRF1 induction (6 hr), showing mean ± std dev. (<bold>c</bold>) Kinetics of STAT1 (left) and STAT3 (right) phosphorylation after siRNA-mediated IRF1 knockdown in RPE1 IL-27Rα cells stimulated with IL-27 (2 nM). Data was obtained from one representative experiment with each two technical replicates, showing mean ± std dev. (<bold>d</bold>) Kinetics of gene induction (STAT1, GBP5, OAS1, SOCS3) followed by RT qPCR in RPE1 IL-27Rα cells stimulated with IL-27 (2 nM) with and without siRNA-mediated knockdown of IRF1. Data was obtained from four experiments with each two technical replicates, showing mean ± std dev. Two-tailed Student’s T-test: *p&lt;0.05, **p≤0.01,***p≤0.001; n.s., not significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig5-figsupp3-v2.tif"/></fig></fig-group><p>Next, we performed cluster analysis to find further similarities and discrepancies between the gene expression programs engaged by HypIL-6 and IL-27 (<xref ref-type="fig" rid="fig5">Figure 5e</xref>). Since genes downregulated by IL-27 and HypIL-6 showed overall good similarity throughout the whole kinetic series, we mainly focused on differences in upregulated gene induction. We identified three functionally relevant gene clusters. The first gene cluster corresponds to genes that are transiently and equally induced by HypIL-6 and IL-27. These genes peak after one hour and return to basal levels after 6 hr and 24 hr of stimulation (<xref ref-type="fig" rid="fig5">Figure 5e</xref>). Interestingly, this cluster contains classical IL-6-induced and STAT3-dependent genes, such as members of the NFκB and Jun/Fos transcriptional complex (<xref ref-type="bibr" rid="bib84">Suh et al., 2008</xref>), as well as the feedback inhibitor Suppressor Of Cytokine Signaling 3 (<italic>SOCS3</italic>) (<xref ref-type="bibr" rid="bib91">Villarino et al., 2006</xref>) and T-cell early activation marker CD69. (<xref ref-type="fig" rid="fig5">Figure 5e</xref>). A second cluster of genes corresponded to genes that were persistently activated by IL-27 but only transiently by HypIL-6 (<xref ref-type="fig" rid="fig5">Figure 5e</xref>). Among these genes we found classical STAT1-dependent genes, such as <italic>SOCS1</italic>, Programmed Cell Death Ligand 1 (<italic>PDL1</italic> = <italic>CD274</italic>) (<xref ref-type="bibr" rid="bib26">Hirahara et al., 2012</xref>) and members of the interferon-induced protein with tetratricopeptide repeats (IFIT) family. The third cluster of genes corresponded to genes exhibiting strong and sustained activation by IL-27 after 6 hr and 24 hr stimulation but no activation by HypIL-6 at all. This ‘2nd wave’ of gene induction by IL-27 was almost exclusively comprised of classical Interferon Stimulated Genes (ISGs) (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2c</xref>), such as <italic>STAT1 and 2</italic>, Guanylate Binding Protein 1 (<italic>GBP1</italic>), <italic>GBP2, 4 and 5</italic>, and <italic>IRF8 and 9</italic>.</p><p>It is worth mentioning, that genes in the third cluster appear to require persistent STAT1 activation (<xref ref-type="bibr" rid="bib30">Hu et al., 2002</xref>; <xref ref-type="bibr" rid="bib21">Francois-Newton et al., 2012</xref>) and were the basis for the IFN signature identified in our reactome pathway analysis. Still, we were surprised about the magnitude of this 2nd gene wave. Even though IL-27 exerts a sustained pSTAT1 kinetic profile, pSTAT1 levels were down to ~10% of maximal amplitude after 3 hr of stimulation. We reasoned that additional factors could further amplify the STAT1 response for IL-27 but not for HypIL-6. Within the 1st wave of STAT1-dependent genes, we also spotted the transcription factor Interferon Response Factor 1 (<italic>IRF1</italic>), that was continuously induced throughout the kinetic series in response to IL-27 but only transiently spiking after 1 hr of HypIL-6 stimulation (<xref ref-type="fig" rid="fig5">Figure 5e</xref>). IRF1 expression was shown to prolong pSTAT1 kinetics (<xref ref-type="bibr" rid="bib103">Zenke et al., 2018</xref>) and to be required for IL-27-dependent Tr-1 differentiation and function (<xref ref-type="bibr" rid="bib39">Karwacz et al., 2017</xref>). We confirmed the kinetics of IRF1 protein expression by flow cytometry and showed higher and more sustained protein levels after IL-27 stimulation relative to HypIL-6 (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3a</xref>). Next, we tested in our RPE1 IL-27Rα cell system, whether siRNA-mediated knockdown of IRF1 would alter the gene induction profiles of certain STAT1 or STAT3-dependent marker genes. In RPE1 IL-27Rα cells, IRF1 protein levels were peaking around 6 hr after stimulation with IL-27 and transfection with IRF1-targeting siRNA knocked down expression by &gt;80% (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3b</xref>). Importantly, knockdown of IRF1 did not alter the overall kinetics of pSTAT1 and pSTAT3 activation (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3c</xref>). Induction of STAT1-dependent genes <italic>STAT1</italic>, <italic>GBP5,</italic> and <italic>OAS1</italic> as well as STAT3-dependent gene <italic>SOCS3</italic> were followed by RT qPCR (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3d</xref>). Interestingly, up to 6 hr of stimulation, the gene induction curves were identical for control- and IRF1-siRNA treated cells. Later than 6 hr – that is, when IRF1 protein levels are peaking – the gene induction was decreased between 40 and 70% in absence of IRF1. Strikingly, expression of <italic>SOCS3</italic>, a classical STAT3-dependent reporter gene was transient and independent on IRF1 levels, highlighting that IRF1 selectively amplifies STAT1-dependent gene induction. Taken together our data support a scenario whereby IL-27 by exhibiting a kinetic decoupling of STAT1 and STAT3 activation is capable of triggering independent gene expression waves, which ultimately contribute to shape its distinct biology.</p></sec><sec id="s2-7"><title>IL-27-induced STAT1 response drives global proteomic changes in Th-1 cells</title><p>Next, we aimed to uncover how the distinct gene expression programs engaged by HypIL-6 and IL-27 ultimately relate to alterations of the Th-1 cell proteome. For that, we continuously stimulated SILAC -labeled Th-1 cells for 24 hr with saturating doses of IL-27 and HypIL-6 and compared quantitative proteomic changes to unstimulated controls (<xref ref-type="fig" rid="fig6">Figure 6a</xref>). We quantified ~3600 proteins present in all three biological replicates and in all tested conditions (unstimulated/IL-27/HypIL-6). Both cytokines downregulated a similar number of proteins (IL-27: 57, HypIL-6: 52) (<xref ref-type="fig" rid="fig6">Figure 6b</xref>) with approximately half of them being shared by the two cytokines, mimicking our observations in the RNA-seq studies (<xref ref-type="fig" rid="fig6">Figure 6c</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). With 68 upregulated proteins, IL-27 was almost twice as potent as HypIL-6 (35 proteins) with very little overlap.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>IL-27-induced STAT1 response drives global proteomic changes in Th-1 cells.</title><p>(<bold>a</bold>) Workflow for quantitative SILAC proteomic analysis of Th-1 cells continuously stimulated (24 hr) with IL-27 (10 nM), HypIL-6 (20 nM) or left untreated. (<bold>b</bold>) Global proteomic changes in Th-1 cells induced by IL-27 (left) or HypIL-6 (right) represented as volcano plots. Proteins significantly up- or downregulated are highlighted in red (p value ≤ 0.05, fold change ≥+1.5 or≤−1.5). Significantly altered ISG-encoded proteins by IL-27 are highlighted in yellow. Data was obtained from three biological replicates. (<bold>c</bold>) Venn diagrams comparing unique upregulated (left) and downregulated (right) proteins by IL-27 (blue) and HypIL-6 (red) as well as shared altered proteins. ISG-encoded proteins are highlighted in yellow. (<bold>d</bold>) Heatmaps of the top 30 up- and downregulated proteins by IL-27 compared to HypIL-6. Data representation of the mean (log<sub>2</sub>) fold change of three biological replicates. (<bold>e</bold>) Heatmap representation and enrichment plot of proteins identified by GSEA reactome pathway enrichment analysis ‘Cytokine signaling and immune system’ induced by IL-27. Data representation of the mean (log<sub>2</sub>) fold change of three biological replicates. (<bold>f</bold>) Correlation of IL-27 and HypIL-6-induced RNA-seq transcript levels (≥+2 or ≤−2 fold change) with quantitative proteomic data (≥+1.5 or≤−1.5 fold change). Data representation of the mean (log<sub>2</sub>) fold change of three biological replicates.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Shared and unique proteomic changes upon IL-27 and HypIL-6 stimulation and GSEA pathway reactome analysis.</title><p>(<bold>a</bold>) Pie charts of proteomic changes (unique and shared) for upregulated (left) and downregulated (right) proteins in response to IL-27 or HypIL-6 stimulation in Th-1 cells. (<bold>b</bold>) Left: GSEA reactome pathway enrichment analysis ‘Interferon signaling’ for proteins induced by IL-27. Middle: heatmap representation pathway-associated proteins comparing IL-27 with HypIL-6 stimulation. Data represents the mean (log<sub>2</sub>) fold change of three biological replicates. Right: Localization of the identified proteins in context to the data distribution of IL-27-induced proteomic changes. Pathway-associated proteins are highlighted for IL-27 (blue) and HypIL-6 (red) as well as non-significant data distribution (gray). (<bold>c</bold>) Left: GSEA reactome pathway enrichment analysis ‘Cytokine signaling and immune system’ for proteins induced by IL-27. Middle: heatmap representation pathway-associated proteins comparing IL-27 with HypIL-6 stimulation. Data represents the mean (log<sub>2</sub>) fold change of three biological replicates. Right: Localization of the identified proteins in context to the data distribution of IL-27-induced proteomic changes. Pathway-associated proteins are highlighted for IL-27 (blue) and HypIL-6 (red) as well as non-significant data distribution (gray).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig6-figsupp1-v2.tif"/></fig></fig-group><p>Among the upregulated proteins by IL-27 but not HypIL-6, we detected several proteins with described immune-modulatory functions on T-cells. One of these proteins was Transforming Growth Factor β (TGF-β), which is a key regulator with pleiotropic functions on T-cells (<xref ref-type="bibr" rid="bib101">Yoshimura et al., 2010</xref>). TGF-β has been identified to synergistically act with IL-27 to induce IL-10 secretion from Tr-1 cells – thus accounting for one of the key anti-inflammatory functions of IL-27 (<xref ref-type="bibr" rid="bib1">Awasthi et al., 2007</xref>). On the other hand, we also found <italic>SELPLG</italic>-encoded protein RSGL-1 which is critically required for efficient migration and adhesion of Th-1 cells to inflamed intestines (<xref ref-type="bibr" rid="bib7">Brown et al., 2012</xref>; <xref ref-type="bibr" rid="bib52">Matsumoto et al., 2007</xref>). Interestingly, we found LARP7 moderately upregulated by IL-27. This negative regulator for RNA pol II was also identified in our phospho-target screening and selectively engaged by IL-27 (<xref ref-type="fig" rid="fig4">Figure 4f</xref>). IL-27 and HypIL-6 share ~60% of downregulated proteins, but without strong functional patterns. Both cytokines downregulated several proteins related to mitotic cell cycle (LIG1, CSNK2B, PSMB1) mRNA processing and splicing (NCBP2, PCBP2, NUDT21) (<xref ref-type="bibr" rid="bib80">Slenter et al., 2018</xref>).</p><p>Strikingly, a significant number (~40%) of proteins upregulated by IL-27 belong to the group of ISGs (<xref ref-type="fig" rid="fig6">Figure 6b and c</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1b</xref>). This particular set of proteins including STAT1, STAT2, MX Dynamin like GTPase 1 (MX1), Interferon Stimulated Gene 20 (ISG20) or Poly(ADP-Ribose) Polymerase Family Member 9 (PARP9) was not markedly altered by HypIL-6. Of note: the overall expression patterns of the most significantly altered proteins are congruent to the gene induction patterns observed after 6 hr and 24 hr (<xref ref-type="fig" rid="fig6">Figure 6d and e</xref>, Supp. Fig. 10b). Similar to this, GSEA reactome analysis identified again pathways associated with interferon signaling and cytokine/immune system but failed to detect any significant functional enrichment by HypIL-6 (<xref ref-type="fig" rid="fig6">Figure 6e</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1b &amp; c</xref>). Finally, we correlated RNAseq-based gene induction patterns with detected proteomic changes. To our surprise, we only found a relatively low number of shared hits. However, the identified proteins belong exclusively to a group upregulated by IL-27 (<xref ref-type="fig" rid="fig6">Figure 6f</xref>). They are all located in the ‘2nd gene wave’ cluster and all of them are regulated by ISGs (<xref ref-type="fig" rid="fig5">Figure 5e</xref>). Taken together these results provide compelling evidence that sustained pSTAT1 activation by IL-27 accounts for its gene induction and proteomic profiles, thus, giving a mechanistic explanation for the diverse biological outcomes of IL-27 and IL-6. Our observations are in good agreement with previous findings in cancer cells, showing that particularly the involvement of STAT1 activation is responsible for proteomic remodeling by IL-27 (<xref ref-type="bibr" rid="bib63">Petretto et al., 2016</xref>).</p></sec><sec id="s2-8"><title>Receptor and STAT concentrations determine the nature of the IL-6/IL-27 response</title><p>Our data suggest that STAT molecules compete for binding to a limited number of phospho-Tyr motifs in the intracellular domains of cytokine receptors. A direct consequence derived from this hypothesis is that cells can adjust and change their responses to cytokines by altering their concentrations of specific STATs or receptors molecules. To assess to what degree immune cells differ in their expression of cytokine receptors and STATs, we investigated levels of IL-6Rα, GP130, IL-27Rα, STAT1, and STAT3 protein expression across different immune cell populations making use of the Immunological Proteomic Resource (ImmPRes - <ext-link ext-link-type="uri" xlink:href="http://immpres.co.uk">http://immpres.co.uk</ext-link>) database. Strikingly, the level of expression of these proteins change dramatically across the populations studied (<xref ref-type="fig" rid="fig7">Figure 7a</xref>), suggesting that these cells could potentially produce very different responses to HypIL-6 and IL-27 stimulation.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Receptor and STAT concentrations determine the nature of the cytokine response.</title><p>(<bold>a</bold>) Copy numbers of indicated proteins determined for different T-cell subsets using mass-spectrometry-based proteomics (ImmPRes - <ext-link ext-link-type="uri" xlink:href="http://immpres.co.uk">http://immpres.co.uk</ext-link>). (<bold>b</bold>) Model predictions for varying levels of STAT1 and STAT3 (left panel) or IL-27Rα and GP130 (right panel) for phosphorylation kinetics of STAT1 and STAT3. (<bold>c</bold>) Gene expression profiles determined by RNAseq analysis comparing indicated genes of a cohort of SLE risk patients with a cohort of healthy controls. Data obtained from: <italic>Proc Natl Acad Sci U S A</italic> 115, 12565–12572. Two-tailed Student’s T-test: *p&lt;0.05, **p≤0.01,***p≤0.001; n.s., not significant. (<bold>d</bold>) Dose-dependent phosphorylation of STAT1 and STAT3 as a response to IL-27 and HypIL-6 stimulation in naive and IFNα2-primed (2 nM, 24 hr) Th-1 cells, normalized to maximal IL-27 stimulation (ctrl). Data was obtained from four biological replicates with each two technical replicates, showing mean ±std dev. (<bold>e</bold>) Phosphorylation of STAT1 (left) and STAT3 (right) as a response to IL-27 (2 nM, 15 min) and HypIL-6 (10 nM, 15 min) stimulation in healthy control (ctrl) and SLE patient CD4 +T cells. Data was obtained from five healthy control donors (<xref ref-type="bibr" rid="bib16">Diveu et al., 2009</xref>) and six SLE patients. Two-tailed Student’s T-test: *p&lt;0.05, **p≤0.01,***p≤0.001; n.s., not significant. (<bold>f</bold>) Tofacitinib titration to inhibit STAT1 and STAT3 phosphorylation by IL-27 (top, 2 nM, 15 min) HypIL-6 (bottom, 10 nM, 15 min) in Th-1 cells (left) and RPE1 IL-27Rα cells (right). Data was obtained from three donors with each two technical replicates (Th-1) and two biological experiments (RPE1 IL-27Rα cells) with each two technical replicates, showing mean ±std dev.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Validation of mathematical models for signaling kinetics of IL-27Rα receptor chimera and Y613F mutant.</title><p>(<bold>a</bold>) Pointwise median and 95% credible intervals of the WT and chimera mathematical models, using the posterior distributions for the parameters from the ABC-SMC. (<bold>b</bold>) Dose response curve in RPE1 using the posterior distributions from the ABC-SMC and varying the concentrations of HypIL-6 and IL-27 in the model. (<bold>c</bold>) Pointwise median and 95% credible intervals of the WT mathematical model and simulations of a mutant model (RPE1 IL-27Rα-Y613F)with <inline-formula><mml:math id="inf53"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula> nM<sup>−1</sup> s<sup>−1</sup> and <inline-formula><mml:math id="inf54"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula> s<sup>−1</sup>, using the posterior distributions for the parameters from the ABC-SMC for the other parameters.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig7-figsupp1-v2.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Altered total STAT levels and biased pSTAT1/pSTAT3 response in SLE.</title><p>(<bold>a</bold>) Gene expression profiles determined by RNAseq analysis comparing indicated genes of a cohort of SLE risk patients with a cohort of healthy controls. Data obtained from: <italic>Proc Natl Acad Sci U S A</italic> 115, 12565–12572. Two-tailed Student’s T-test: *p&lt;0.05, **p≤0.01,***p≤0.001; n.s., not significant. (<bold>b</bold>) Fold induction of total STAT1 and STAT3 levels in Th-1 measured by flow cytometry. Data was obtained from two biological replicates (shown). (<bold>c</bold>) Total levels of STAT1 and STAT3 measured in CD4 +by flow cytometry for healthy control (ctrl) and Lupus patients (SLE). Data was obtained from five (ctrl) and six (SLE) biological replicates. Two-tailed Student’s T-test: p-values as indicated. (<bold>d</bold>) Ratio of pSTAT1 and pSTAT3 after IL-27 (15 min, 2 nM) or HypIL-6 (15 min, 10 nM) stimulation measured in CD4 +by flow cytometry for healthy control (ctrl) and Lupus patients (SLE). Data was obtained from five (ctrl) and six (SLE) biological replicates normalized to mean ratio of healthy control samples. Two-tailed Student’s T-test: p-values as indicated.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66014-fig7-figsupp2-v2.tif"/></fig></fig-group><p>In order to quantify (and predict) how changes in expression levels of different proteins modify the kinetics of pSTAT, we made use of the two mathematical models of HypIL-6 and IL-27 stimulation and the parameters inferred with Bayesian methods. Our mathematical models could accurately reproduce the experimental results generated across our study, that is, signaling by the IL-27Rα chimeric and IL-27Rα-Y616F mutant receptors and dose/response studies (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1a–c</xref>), making use of the posterior parameter distributions generated from the Bayesian parameter calibration. Having developed mathematical models which are able to accurately explain the experimental data (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1c and d</xref>) and reproduce independent experiments (<xref ref-type="fig" rid="fig3">Figure 3b and c</xref>), we then sought to use the models to predict pSTAT signaling kinetics under different concentration regimes of receptors and STATs. To simplify the simulations, we focused our analysis in GP130 and STAT1 proteins, two of the proteins that greatly vary in the different immune populations (<xref ref-type="fig" rid="fig7">Figure 7a</xref>). As baseline values for the concentrations <inline-formula><mml:math id="inf55"><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>G</mml:mi><mml:mi>P</mml:mi><mml:mn>130</mml:mn><mml:mfenced separators="|"><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:math></inline-formula>, <inline-formula><mml:math id="inf56"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>27</mml:mn><mml:mi>R</mml:mi><mml:mi>α</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf57"><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>S</mml:mi><mml:mi>T</mml:mi><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mn>1</mml:mn><mml:mfenced separators="|"><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:math></inline-formula> and <inline-formula><mml:math id="inf58"><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>S</mml:mi><mml:mi>T</mml:mi><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mn>3</mml:mn><mml:mfenced separators="|"><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:math></inline-formula> we used approximately the median values from the posterior distributions for each parameter: <inline-formula><mml:math id="inf59"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>G</mml:mi><mml:mi>P</mml:mi><mml:mn>130</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>25</mml:mn><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf60"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>27</mml:mn><mml:mi>R</mml:mi><mml:mi>α</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>50</mml:mn><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf61"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>S</mml:mi><mml:mi>T</mml:mi><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mn>1</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>S</mml:mi><mml:mi>T</mml:mi><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mn>3</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>500</mml:mn><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>. To see the effect of varying GP130 concentrations on pSTAT signaling, we decreased the initial concentration of GP130 and simulated the model using the accepted parameters sets from the ABC-SMC to inform the other parameter values. A tenfold reduction on GP130 concentration <inline-formula><mml:math id="inf62"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>G</mml:mi><mml:mi>P</mml:mi><mml:mn>130</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>2.5</mml:mn><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> resulted in a striking loss in pSTAT1 levels induced by HypIL-6, with very little effect on pSTAT3 levels induced by this cytokine (<xref ref-type="fig" rid="fig7">Figure 7b</xref>). pSTAT1/3 kinetics induced by IL-27, however, was not affected by this decrease in GP130 concentration (<xref ref-type="fig" rid="fig7">Figure 7b</xref>). Interestingly, the HypIL-6 signaling profile predicted by our model at low GP130 concentrations strongly resemble the one induced by HypIL-6 in Th-1 cells (<xref ref-type="fig" rid="fig1">Figure 1c</xref>), where very low levels of GP130 are found, further confirming the robustness of the predictions generated by our mathematical models. When the concentration of STAT1 was increased by a factor of ten <inline-formula><mml:math id="inf63"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>S</mml:mi><mml:mi>T</mml:mi><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mn>1</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>5000</mml:mn><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>, both HypIL-6 and IL-27 induced significantly higher levels of pSTAT1 activation (<xref ref-type="fig" rid="fig7">Figure 7b</xref>). pSTAT3 levels were not affected for HypIL-6 stimulation but were decreased for IL-27 stimulation (<xref ref-type="fig" rid="fig7">Figure 7b</xref>), further indicating the competitive nature of the binding of STAT1 and STAT3 to IL-27Rα and GP130. Overall, our mathematical model predicts that changes on GP130 and STAT1 expression produce a substantial remodeling of the HypIL-6 and IL-27 signalosome, which ultimately could lead to aberrant responses.</p></sec><sec id="s2-9"><title>STAT1 protein levels in SLE patients modify HypIL-6 and IL-27 signaling responses</title><p>STAT1 is a classical IFN responsive gene and STAT1 levels are highly increased in environments rich in IFNs (<xref ref-type="bibr" rid="bib97">Wong et al., 1998</xref>). Thus, we next ask whether STAT1 levels would be increased in SLE patients, an example of disease where IFNs have been shown to correlate with a poor prognosis, making use of available gene expression datasets (<xref ref-type="bibr" rid="bib87">Tokuyama et al., 2018</xref>). We did not find differences in the expression of GP130, IL-6Rα or IL-27Rα in SLE patients (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2a</xref>). However, we detected a considerable increase in the levels of STAT1 and STAT3 transcripts in these patients when compared to healthy controls, with the increase on STAT1 expression being significantly more pronounced (<xref ref-type="fig" rid="fig7">Figure 7c</xref>). Since our mathematical model predicted that increases in STAT1 expression could significantly change cytokine-induced cellular responses by HypIL-6 and IL-27, we next experimentally tested this prediction. For that, we primed Th-1 cells with IFNα2 overnight to increase total STAT1 levels (and to a lower extent STAT3) in these cells (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2b</xref>). While both HypIL-6 and IL-27 induced comparable levels of pSTAT3 in primed and non-primed Th-1 cells, levels of pSTAT1 induced by the two cytokines were significantly upregulated in primed Th-1 cells, resulting in a bias STAT1 response and confirming our model predictions (<xref ref-type="fig" rid="fig7">Figure 7d</xref>). We next investigated whether this bias STAT1 activation by HypIL-6 and IL-27 observed in IFNα2-primed Th-1 cells was also present in SLE patients. For that we collected PBMCs from six SLE patients or five age-matched healthy controls and measured STAT1 and STAT3 expression, as well as pSTAT1 and pSTAT3 induction by HyIL-6 and IL-27 after 15 min treatments in CD4 T cells. Importantly, comparable results to those obtained with IFN-primed Th-1 cells were obtained, with signaling bias toward pSTAT1 in CD4 +T cells from SLE patients stimulated with HypIL-6 and IL-27 (<xref ref-type="fig" rid="fig7">Figure 7e</xref>, <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2c &amp; d</xref>), further supporting the fact that STAT concentrations play a critical role in defining cytokine responses in autoimmune disorders.</p><p>Our data show that STAT1 and STAT3 compete for phospho-Tyr motifs in GP130, with STAT3 having an advantage resulting from its tighter affinity to GP130. Finally, we asked whether crippling JAK activity by using sub-saturating doses of JAK inhibitors could differentially affect STAT1 and STAT3 activation by HypIL-6 and therefore rescue the altered cytokine responses found in SLE patients. To test this, RPE1 and Th-1 cells were stimulated with saturated concentrations of HypIL-6 and titrating the concentrations of Tofacitinib, a clinically approved JAK inhibitor. Strikingly, Tofacitinib inhibited HypIL-6 induced pSTAT1 more efficiently than pSTAT3 in both RPE1 IL-27Rα cells and Th-1 cells (<xref ref-type="fig" rid="fig7">Figure 7f</xref>). At 50 nM concentration, Tofacitinib inhibited pSTAT1 levels induced by HypIL-6 by 60%, while only inhibited pSTAT3 levels by 30% (<xref ref-type="fig" rid="fig7">Figure 7f</xref>) – an effect that we did not observe for IL-27 stimulation. Overall, our results show that the changes in STATs concentration found in autoimmune disorders shape cytokine signaling responses and could contribute to disease progression.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Cytokine pleiotropy is the ability of a cytokine to exert a wide range of biological responses in different cell types. This functional pleiotropy has made the study of cytokine biology extremely challenging given the strong crosstalk and shared usage of key components of their signaling pathways, leading to a high degree of signaling plasticity, yet still allowing functional selectivity (<xref ref-type="bibr" rid="bib23">Garbers et al., 2012</xref>; <xref ref-type="bibr" rid="bib38">Kang et al., 2020</xref>). Here, we aimed to identify the underlying determinants that define cytokine functional selectivity by comparing IL-27 and IL-6 at multiple scales – ranging from cell surface receptors to proteomic changes. We show that IL-27 triggers a more sustained STAT1 phosphorylation than IL-6, via a high-affinity STAT1/IL-27Rα interaction centered around Tyr613 on IL-27Rα. This in turn results in a more sustained IRF1 expression induced by IL-27, which leads to the upregulation of a second wave of gene expression unique to IL-27 and comprised of classical ISGs. We go one step further and show that this strong receptor/STAT coupling is altered in autoimmune disorders where STATs concentrations are often dysregulated. Increased expression of STAT1 in SLE patients’ biases HypIL-6 and IL-27 responses toward STAT1 activation, further contributing to the worsening of the disease. By using suboptimal doses of the JAK inhibitor Tofacitinib, we show that specific STAT proteins engaged by a given cytokine can be targeted.</p><p>The tight coupling of one receptor subunit to one particular STAT that we have identified in our study is a rather unusual phenomenon for heterodimeric cytokine receptor complexes, which has been first suggested by <xref ref-type="bibr" rid="bib62">Owaki et al., 2008</xref>. Generally, the entire signaling output driven by a cytokine-receptor complex emanates from a dominant receptor subunit, which carries several Tyr residues susceptible of being phosphorylated (<xref ref-type="bibr" rid="bib90">Umeshita-Suyama et al., 2000</xref>; <xref ref-type="bibr" rid="bib56">Nadeau et al., 1999</xref>). This in turn results in competition between different STATs for binding to shared phospho-Tyr motifs in the dominant receptor chain, leading to different kinetics of STAT phosphorylation as observed for IL-6 stimulation (<xref ref-type="bibr" rid="bib71">Rolvering et al., 2017</xref>; <xref ref-type="fig" rid="fig1">Figure 1b</xref>). Moreover, this localized signaling quantum allows phosphatases and feedback regulators – induced upon cytokine stimulation – to act in synergy to reset the system to its basal state, generating a very synchronous and coordinated signaling wave. Although very effective, this molecular paradigm presents its limitations. STAT competition for the same pool of phospho-Tyr makes the system very sensitive to changes in STAT concentration. IFNγ-primed cells, which exhibit increased STAT1 levels, trigger an IFNγ-like STAT1 response upon IL-6 stimulation (<xref ref-type="bibr" rid="bib11">Costa-Pereira et al., 2002</xref>). IL-10 anti-inflammatory properties are lost in cells with high levels of STAT1 expression, as a result of a pro-inflammatory environment rich in IFNs (<xref ref-type="bibr" rid="bib79">Sharif et al., 2004</xref>). Indeed, we show that STAT1 transcripts levels are increased in Crohn’s disease and SLE patients and they contributed to alter IL-6 responses. Strikingly, IL-27 appears to have evolved away from this general model of cytokine signaling activation. Our results show that STAT1 activation by IL-27 is tightly coupled to IL-27Rα, while STAT3 activation by this cytokine mostly depends on GP130. This decoupled STAT1 and STAT3 activation by IL-27 is possible thanks to the presence of a putative high-affinity STAT1 binding site on IL-27Rα that resembles the one present in IFNγR1 (<xref ref-type="bibr" rid="bib65">Pflanz et al., 2004</xref>). As a result of this, IL-27 can trigger sustained and independent phosphorylation of both STAT1 and STAT3. This IL-27 feature allows it to induce robust responses in dynamic immune environments. Indeed, our mathematical models of cytokine signaling, and Bayesian inference, together with the experimental observations show that changes in receptor concentration minimally affected pSTAT1/3 induced by IL-27, while they fundamentally alter IL-6 responses. Overall, our data show that cytokine responses are versatile and adapt to the continuously changing cell proteome, highlighting the need to measure cytokine receptors and STATs expression levels, in addition to cytokine levels, in disease environments to better understand and predict altered responses elicited by dysregulated cytokines.</p><p>In recent years, it has become apparent that the stability of the cytokine-receptor complex influences signaling identity by cytokines (<xref ref-type="bibr" rid="bib69">Richter et al., 2017</xref>). Short-lived complexes activate less efficiently those STAT molecules that bind with low-affinity phospho-Tyr motif in a given cytokine receptor (<xref ref-type="bibr" rid="bib51">Martinez-Fabregas et al., 2019</xref>). Our current results further support this kinetic discrimination mechanism for STAT activation. Our statistical inference identified differences in STAT recognition to the cytokine receptor phospho-Tyr motifs as one of the major determinants of STAT phosphorylation kinetics. This parameter alone was sufficient to explain transient and sustained STAT1 phosphorylation induced by IL-6 and IL-27, respectively, without the need to invoke the action of phosphatases or negative feedback regulators such as SOCSs. Indeed, our results indicate that the rate of STAT1 dephosphorylation is similar between the IL-6 and IL-27 systems, suggesting that phosphatases do not contribute to these early kinetic differences. Moreover, blocking protein translation, and therefore the upregulation of negative feedback regulators by IL-6 treatment did not result in a more sustained STAT1 phosphorylation by IL-6, again indicating that the transient kinetics of STAT1 phosphorylation by IL-6 is encoded at the receptor level and does not require further regulation. However, recent reports have found that the amplitude of STAT1 phosphorylation in response to IL-6 is regulated by levels of PTPN2 expression, suggesting that phosphatases can play additional roles in shaping IL-6 responses beyond controlling the kinetics of STAT activation (<xref ref-type="bibr" rid="bib89">Twohig et al., 2019</xref>). STAT1 phosphorylation levels by IL-27 on the other hand were significantly more sustained in the absence of protein translation, suggesting that negative feedback mechanisms are required to downmodulate signaling emanating from high-affinity STAT-receptor interactions. Overall, our results suggest that while phosphatases and negative feedback regulators play an important role in maintaining cytokine signaling homeostasis (<xref ref-type="bibr" rid="bib25">Heinrich et al., 2003</xref>), the kinetics of STAT activation appears to be already encoded at the level of receptor engagement, thus ensuring maximal efficiency and signal robustness.</p><p>Cytokine signaling plasticity can occur at the level of receptor activation. In the past years, a scenario has emerged suggesting that the absolute number of signaling active receptor complexes is a critical determinant for signal output integration. Accordingly, specific biological responses were shown to be tuned either by abundance of cell surface receptors (<xref ref-type="bibr" rid="bib48">Levin et al., 2011</xref>; <xref ref-type="bibr" rid="bib53">Moraga et al., 2009</xref>) or by the level of receptor assembly (<xref ref-type="bibr" rid="bib51">Martinez-Fabregas et al., 2019</xref>; <xref ref-type="bibr" rid="bib94">Wilmes et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Ho et al., 2017</xref>). Here, we show for the first time that IL-27-induced dimerization of IL-27Rα and GP130 at the cell surface of live cells – in good agreement with previous studies on heterodimeric cytokine receptor systems (<xref ref-type="bibr" rid="bib94">Wilmes et al., 2015</xref>; <xref ref-type="bibr" rid="bib69">Richter et al., 2017</xref>). For IL-27, the receptor subunits IL-27Rα and GP130 can be expressed at different ratios as seen for naive vs. activated T-cells (<xref ref-type="bibr" rid="bib10">Charlot-Rabiega et al., 2011</xref>) as well as intestinal cells (<xref ref-type="bibr" rid="bib15">Diegelmann et al., 2012</xref>). On T-cells, particularly after activation, IL-27Rα is expressed in strong excess over GP130, rendering GP130 as the limiting factor for receptor complex assembly (<xref ref-type="bibr" rid="bib65">Pflanz et al., 2004</xref>). Interestingly, we observe that in addition to a faster kinetic of STAT1 phosphorylation, HypIL-6 treatment induces a lower maximal amplitude in pSTAT1 activation in T cells. This is in stark contrast to our results in RPE1 cells, where high abundance of GP130 (~3000–4000 copies of cell surface GP130) is found. In these cells, both cytokines elicited similar amplitudes of STAT1 phosphorylation. Our results suggest that surface receptor density in synergy with STATs binding dynamics to phospho-Tyr motif on cytokine receptors act to define the amplitude and kinetics of STAT activation in response to cytokine stimulation.</p><p>The distinct STAT1 and STAT3 kinetic profiles induced by IL-6 and IL-27 are the prerequisite for time-correlated decoupling of genetic programs: a ‘shared GP130/STAT3-dependent wave’ and an IL-27-‘unique IL-27Rα/STAT1-dependent wave’. However, pSTAT1 levels induced by IL-27 at 3 hr were down to ~10% of maximal amplitude, suggesting that additional factors would be required to amplify the initial STAT1 response elicited by IL-27. We observed that IL-27 induces the expression of an early wave of classical STAT1-dependent genes, which is also shared by IL-6. However, while IL-27 induces the upregulation of these genes throughout the entire duration of the experiment, IL-6 only resulted in a transient spike. We reasoned that this additional factor required for IL-27 signal amplification would be among these early STAT1-dependent genes. Among this set of genes we found the transcription factor IRF1, which had been shown to act as a feedback amplificant for pSTAT1 activity (<xref ref-type="bibr" rid="bib103">Zenke et al., 2018</xref>). Importantly, IRF1 protein levels have been shown to be upregulated in response to IL-27 and IFNγ but not to IL-6 stimulation in hepatocytes (<xref ref-type="bibr" rid="bib3">Bender et al., 2009</xref>). IRF1 plays a key role in chromatin accessibility which is critically required for IL-27-induced differentiation of Tr-1 cells and subsequent IL-10 secretion (<xref ref-type="bibr" rid="bib39">Karwacz et al., 2017</xref>). Here, we could prove that the contribution of IRF1 on STAT1- but not STAT3-dependent genes is a generic feature of IL-27 signaling. This readily explains the significant transcriptomic overlap of IL-27 with type I (<xref ref-type="bibr" rid="bib34">Imamichi et al., 2012</xref>) or type II interferons (<xref ref-type="bibr" rid="bib71">Rolvering et al., 2017</xref>) after long-term stimulation with these cytokines. Along this line, it is not surprising that IL-27 – beyond its well-described effects on T-cell development – can also mount a considerable antiviral response as shown in hepatic cells and PBMCs (<xref ref-type="bibr" rid="bib17">Fakruddin et al., 2007</xref>; <xref ref-type="bibr" rid="bib22">Frank et al., 2010</xref>). Our results suggest that by modulating the kinetics of STAT phosphorylation, cytokines can modulate the expression of accessory transcription factors, such as IRF1, that act in synergy with STATs to fine-tune gene expression and provide functional diversity.</p><sec id="s3-1"><title>Data availability</title><p>Python (version 3.7) codes for the ABC-SMC model selection and parameter inference can be found in the public repository <ext-link ext-link-type="uri" xlink:href="https://github.com/PollyJeffrey/Cytokine_modelling">https://github.com/PollyJeffrey/Cytokine_modelling</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:237151dcc7f7819ee05ed2f14b2a8b50fa9a13ee;origin=https://github.com/PollyJeffrey/Cytokine_modelling;visit=swh:1:snp:1bbaf4c2b531aa6ce114c32683831b36d4ed2d68;anchor=swh:1:rev:9c3e0ddc7a96eac941baad560d1541d660b0515d">swh:1:rev:9c3e0ddc7a96eac941baad560d1541d660b0515d</ext-link>; <xref ref-type="bibr" rid="bib96">Wilmes, 2021</xref>), along with the results of the analysis. Phospho-proteomic and proteomic datasets were uploaded to the Proteome Exchange platform with accession numbers PXD024657 and PXD024188 respectively. RNA-seq dataset was uploaded in the GSE database with accession number GSE164479.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Protein expression and purification</title><p>Murine IL-27 was cloned as a linker-connected single-chain variant (p28 +EBI3) as described in <xref ref-type="bibr" rid="bib61">Oniki et al., 2006</xref>. Human HyperIL-6 (HypIL-6), and murine single-chain IL-27 were cloned into the pAcGP67-A vector (BD Biosciences) in frame with an N-terminal gp67 signal sequence and a C-terminal hexahistidine tag, and produced using the baculovirus expression system, as described in <xref ref-type="bibr" rid="bib47">LaPorte et al., 2008</xref>. Baculovirus stocks were prepared by transfection and amplification in <italic>Spodoptera frugiperda</italic> (<italic>Sf</italic>9) cells grown in SF900II media (Invitrogen) and protein expression was carried out in suspension <italic>Trichoplusiani ni</italic> (High Five) cells grown in InsectXpress media (Lonza).</p><p>Purification was performed using the method described in <xref ref-type="bibr" rid="bib81">Spangler et al., 2019</xref>. For IL-27, the cells were pelleted with centrifugation at 2000 rpm, prior to a precipitation step through addition of Tris pH 8.0, CaCl<sub>2</sub> and NiCl<sub>2</sub> to final concentrations of 200 mM, 50 mM and 1 mM, respectively. The precipitate formed was then removed through centrifugation at 6000 rpm. Nickel-NTA agarose beads (Qiagen) were added and the target proteins purified through batch binding followed by column washing in HBS-Hi buffer (HBS buffer supplemented to 500 mM NaCl and 5% glycerol, pH 7.2). Elution was performed using HBS-Hi buffer plus 200 mM imidazole. Final purification was performed by size exclusion chromatography on an ENrich SEC 650 300 column (Biorad), again equilibrated in HBS-Hi. Concentration of the purified sample was carried out using 10 kDa Millipore Amicon-Ultra spin concentrators. For HypIL-6, proteins were purified likewise, but in 10 mM HEPES (pH 7.2) containing 150 mM NaCl. Recombinant cytokines were purified to greater than 98% homogeneity.</p><p>For cell surface labeling, the anti-GFP nanobody (NB) ‘enhancer’ and ‘minimizer’ were used, which bind mEGFP with subnanomolar binding affinity (<xref ref-type="bibr" rid="bib42">Kirchhofer et al., 2010</xref>). NB was cloned into pET-21a with an additional cysteine at the C-terminus for site-specific fluorophore conjugation in a 1:1 fluorophore:nanobody stoichiometry. Furthermore, (PAS)<sub>5</sub> sequence to increase protein stability and a His-tag for purification were fused at the C-terminus. Protein expression in <italic>E. coli</italic> Rosetta (DE3) and purification by immobilized metal ion affinity chromatography was carried out by standard protocols. Purified protein was dialyzed against HEPES pH 7.5 and reacted with a twofold molar excess of DY647 maleimide (Dyomics), ATTO 643 maleimide (AT643) and ATTO Rho11 maleimide (Rho11) (ATTO-TEC GmbH), respectively. After 1 hr, a threefold molar excess (with respect to the maleimide) of cysteine was added to quench excess dye. Protein aggregates and free dye were subsequently removed by size exclusion chromatography (SEC). A labeling degree of 0.9-1:1 fluorophore:protein was achieved as determined by UV/Vis spectrophotometry.</p></sec><sec id="s4-2"><title>CD4 +T cell purification and Th-1 differentiation</title><p>Human buffy coats were obtained from the Scottish Blood Transfusion Service and peripheral blood mononuclear cells (PBMCs) of healthy donors were isolated from buffy coat samples by density gradient centrifugation according to manufacturer’s protocols (Lymphoprep, STEMCELL Technologies). From each donor, 100 × 10<sup>6</sup> PBMCs were used for isolation of CD4 +T cells. Cells were decorated with anti-CD4<sup>FITC</sup> antibodies (Biolegend, #357406) and isolated by magnetic separation according to manufacturer’s protocols (MACS Miltenyi) to a purity &gt;98% CD4+. Freshly isolated resting CD4<sup>+</sup> T cells (3 × 10<sup>7</sup> per donor) were activated under Th-1 polarizing conditions using ImmunoCult Human CD3/CD28 T Cell Activator (StemCell, Cat#10971) following manufacturer instructions for 3 days in RPMI-1640, 10% v/v FBS, 100 U/ml penicillin-streptomycin (Gibco) in the presence of the cytokines IL-2 (Novartis, #709421, 20 ng/ml), anti-IL-4 antibody (10 ng/ml, BD Biosciences, #554481), IL-12 (20 ng/ml, BioLegend, #573002). After 3 days of priming, cells were expanded for another 5 days in the presence of IL-2 (20 ng/ml).</p></sec><sec id="s4-3"><title>Human SLE patient samples</title><p>This study was authorized by the French Competent Authority dealing with Research on Human Biological Samples namely the French Ministry of Research. The Authorization number is ECH 19/04. To issue such authorization, the Ministry of Research has sought the advice of an independent ethics committee, namely the ‘Comité de Protection des Personnes,’ which voted positively, and all patients gave their written informed consent. The healthy volunteer was recruited to serve as healthy control individuals. Healthy and patients’ blood samples were collected in heparinized tubes (BD Vacutainer 368886, BD Biosciences San Jose, CA, USA) and PBMC samples were isolated using Ficoll (Pancoll, Pan Biotech #P04-60500) density gradient centrifugation. The isolated PBMCs were washed with PBS and the remaining red blood cells were lysed using RBC lysis buffer (ACK lysing buffer, Gibco #A10492-01), incubate 3 min at room temperature. Cells were washed in PBS and resuspend the cells with 1 ml of freezing medium (with DMSO, PAN Biotech, #P07-90050) and transfer the cells in a cryotube. cryotube in a Freezing container (Nalgene) and at −80°C and then transferred into liquid nitrogen container for long-term storage.</p></sec><sec id="s4-4"><title>Classification and demographic information about SLE patients and healthy controls</title><p>SLE patients were included if they fulfilled the American College of Rheumatology (ACR) Classification Criteria Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (<xref ref-type="bibr" rid="bib29">Hochberg, 1997</xref>). Exclusion criteria were current intake of 10 mg or more of prednisone or equivalent and/or use of immunosuppressants within the previous 6 months before inclusion. Use of hydroxychloroquine was not an exclusion criterion. Patients were mostly in clinical remission, half with biological remission, half with persistent anti native DNA autoantibodies. All SLE patients and healthy controls were females between 41 and 58 years old.</p></sec><sec id="s4-5"><title>(Phospho-) Proteomics</title><p>For (phospho-) proteomic experiments, Th-1 cells from each donor were split into three different conditions after initial expansion: Light SILAC media (40 mg/ml L-Lysine K0 (Sigma, #L8662) and 84 mg/ml L-Arginine R0 (Sigma, #A8094)), medium SILAC media (49 mg/ml L-Lysine U-13C6 K6 (CKGAS, #CLM-2247–0.25) and 103 mg/ml L-Arginine U-13C6 R6 (CKGAS, #CLM-2265–0.25)) and heavy SILAC media (49.7 mg/ml L-Lysine U-13C6,U-15N2 K8 (CKGAS, #CNLM-291-H-0.25) and 105.8 mg/ml L-Arginine U-13C6,U-15N2 R10 (CKGAS, #CNLM-539-H-0.25)) prepared in RPMI SILAC media (Thermo Scientific, #88365) supplemented with 10% dialyzed FBS (HyClone, #SH30079.03), 5 ml L-Glutamine (Invitrogen, #25030024), 5 ml Pen/Strep (Invitrogen, #15140122), 5 ml MEM vitamin solution (Thermo Scientific, #11120052), 5 ml Selenium-Transferrin-Insulin (Thermo Scientific, #41400045) and expanded in the presence of 20 ng/ml IL-2 and 10 ng/ml anti-IL4 for another 10 days in order to achieve complete labeling. Media was exchanged every 2 days. Incorporation of medium and heavy version of Lysine and Arginine was checked by mass spectrometry and samples with an incorporation greater than 95% were used.</p><p>After expansion, cells were starved without IL-2 for 24 hr before stimulation with 10 nM IL-27 or 20 nM HyIL-6 for 15 min (phosphoproteomics) or 24 hr (global proteomic changes). Cells were then washed three times in ice-cold PBS, mix in a 1:1:1 ratio, resuspended in SDS-containing lysis buffer (1% SDS in 100 mM Triethylammonium Bicarbonate buffer (TEAB)) and incubated on ice for 10 min to ensure cell lysis. Then, cell lysates were centrifuged at 20,000 g for 10 min at +4°C and supernatant was transferred to a clean tube. Protein concentration was determined by using BCA Protein Assay Kit (Thermo, #23227), and 10 mg of protein per experiment were reduced with 10 mM dithiothreitol (DTT, Sigma, #D0632) for 1 hr at 55°C and alkylated with 20 mM iodoacetamide (IAA, Sigma, #I6125) for 30 min at RT. Protein was then precipitated using six volumes of chilled (−20°C) acetone overnight. After precipitation, protein pellet was resuspended in 1 ml of 100 mM TEAB and digested with Trypsin (1:100 w/w, Thermo, #90058) and digested overnight at 37°C. Then, samples were cleared by centrifugation at 20000 g for 30 min at +4°C, and peptide concentration was quantified with Quantitative Colorimetric Peptide Assay (Thermo, #23275).</p><p>Phosphopeptide enrichment in the peptide fractions generated as described above was carried out using MagResyn Ti-IMAC following manufacturer instructions (2BScientific, MRTIM002).</p></sec><sec id="s4-6"><title>High pH reverse phase fractionation for phosphoproteomics</title><p>Samples were dissolved in 200 μL of 10 mM ammonium formate buffer pH 9.5 and peptides are fractionated using high pH RP chromatography. A C18 Column from Waters (XBridge peptide BEH, 130 Å, 3.5 µm 4.6 × 150 mm, Ireland) with a guard column (XBridge, C18, 3.5 µm, 4.6 × 20 mm, Waters) are used on an Ultimate 3000 HPLC (Thermo-Scientific). Buffers A and B used for fractionation consist, respectively of 10 mM ammonium formate in milliQ water (Buffer A) and 10 mM ammonium formate in 90% acetonitrile (Buffer B), both buffers were adjusted to pH 9.5 with ammonia. Fractions are collected using a WPS-3000FC autosampler (Thermo-Scientific) at 1 min intervals. Column and guard column were equilibrated with 2% buffer B for 20 min at a constant flow rate of 0.8 ml/min and a constant temperature 0 f 21°C. Samples (193 µl) are loaded onto the column at 0.8 ml/min, and separation gradient started from 2% buffer B, to 8% B in 6 min, then from 8% B to 45% B within 54 min and finally from 45% B to 100% B in 5 min. The column is washed for 15 min at 100% buffer B and equilibrated at 2% buffer B for 20 min as mentioned above. The fraction collection started 1 min after injection and stopped after 80 min (total of 80 fractions, 800 µl each). Each peptide fraction was acidified immediately after elution from the column by adding 20–30 µl 10% formic acid to each tube in the autosampler. The total number of fractions concatenated was set to 10. The content of fractions from each set was dried prior to further analysis.</p></sec><sec id="s4-7"><title>LC-MS/MS analysis</title><p>LC-MS analysis was done at the FingerPrints Proteomics Facility (University of Dundee). Analysis of peptide readout was performed on a Q Exactive plus, Mass Spectrometer (Thermo Scientific) coupled with a Dionex Ultimate 3000 RS (Thermo Scientific). LC buffers used are the following: buffer A (0.1% formic acid in Milli-Q water (v/v)) and buffer B 80% acetonitrile and 0.1% formic acid in Milli-Q water (v/v). Dried fractions were resuspended in 35 µl, 1% formic acid and aliquots of 15 μl of each fraction were loaded at 10 μl/min onto a trap column (100 μm × 2 cm, PepMap nanoViper C18 column, 5 μm, 100 Å, Thermo Scientific) equilibrated in 0.1% TFA. The trap column was washed for 5 min at the same flow rate with 0.1% TFA and then switched in-line with a Thermo Scientific, resolving C18 column (75 μm × 50 cm, PepMap RSLC C18 column, 2 μm, 100 Å). The peptides were eluted from the column at a constant flow rate of 300 nl/min with a linear gradient from 2% buffer B to 5% buffer B in 5 min then from 5% buffer B to 35% buffer B in 125 min, and finally from 35% buffer B to 98% buffer B in 2 min. The column was then washed with 98% buffer B for 20 min and re-equilibrated in 2% buffer B for 17 min. The column was kept at a constant temperature of 50°C. Q-exactive plus was operated in data dependent positive ionization mode. The source voltage was set to 2.5 Kv and the capillary temperature was 250°C.</p><p>A scan cycle comprised MS1 scan (m/z range from 350 to 1600, ion injection time of 20 ms, resolution 70,000 and automatic gain control (AGC) 1 × 10<sup>6</sup>) acquired in profile mode, followed by 15 sequential dependent MS2 scans (resolution 17500) of the most intense ions fulfilling predefined selection criteria (AGC 2 × 10<sup>5</sup>, maximum ion injection time 100 ms, isolation window of 1.4 m/z, fixed first mass of 100 m/z, spectrum data type: centroid, intensity threshold 2 × 10<sup>4</sup>, exclusion of unassigned, singly and &gt;7 charged precursors, peptide match preferred, exclude isotopes on, dynamic exclusion time 45 s). The HCD collision energy was set to 27% of the normalized collision energy. Mass accuracy is checked before the start of samples analysis.</p></sec><sec id="s4-8"><title>Mass spectrometry data analysis</title><p>Q Exactive Plus Mass Spectrometer. RAW files were analyzed, and peptides and proteins quantified using MaxQuant (<xref ref-type="bibr" rid="bib13">Cox and Mann, 2008</xref>), using the built-in search engine Andromeda (<xref ref-type="bibr" rid="bib12">Cox et al., 2011</xref>). All settings were set as default, except for the minimal peptide length of 5, and Andromeda search engine was configured for the UniProt <italic>Homo sapiens</italic> protein database (release date: 2018_09). Peptide and protein ratios only quantified in at least two out of the three replicates were considered, and the p-values were determined by Student’s t test and corrected for multiple testing using the Benjamini–Hochberg procedure (Benjamini and Hochberg, 1995).</p></sec><sec id="s4-9"><title>Plasmid constructs</title><p>For single-molecule fluorescence microscopy, monomeric non-fluorescent (Y67F) variant of eGFP was N-terminally fused to GP130. This tag (mXFP<bold>m</bold>) was engineered to specifically bind anti-GFP nanobody ‘minimizer’ (αGFP-miNB). This construct was inserted into a modified version of pSems-26 m (Covalys) using a signal peptide of Igk. The ORF was linked to a neomycin resistance cassette via an IRES site. A mXFPe-IL-27Rα construct was designed likewise but is recognized by αGFP nanobody ‘enhancer’ (mXFP<bold>e</bold>). The chimeric construct mXFP-IL-27Rα (ECD and TMD)-GP130(ICD) was a fusion construct of IL-27Rα (aa 33–540) and GP130 (aa 645–918).</p></sec><sec id="s4-10"><title>Cell lines and media</title><p>RPE1 cells were grown in DMEM/F12 containing 10% v/v FBS, penicillin-streptomycin, and L-glutamine (2 mM). RPE1 cells were stably transfected by mXFP<bold>e</bold>-IL-27Rα ( = ‘RPE1 IL-27Rα”), mutants and the chimeric construct by PEI method according to standard protocols. Using G418 selection (0.6 mg/ml) individual clones were selected, proliferated and characterized. RPE1 cells previously knocked out for endogenous GP130 (<xref ref-type="bibr" rid="bib51">Martinez-Fabregas et al., 2019</xref>) were stably transfected as above with mXFPm-GP130 ( = ‘RPE1 10x[GP130]”).</p></sec><sec id="s4-11"><title>Flow cytometry staining and antibodies</title><p>For measuring dose-response curves of STAT1/3 phosphorylation (either Th-1 cells or RPE1 clones), 96-well plated were prepared with 50 µl of cell suspensions at 2 × 10<sup>6</sup> cells/ml/well for Th-1 and 2 × 10<sup>5</sup> cells/ml/well for RPE1. The latter were detached using Accutase (Sigma). Cells were stimulated with a set of different concentrations to obtain dose-response curves. To this end, cells were stimulated for 15 min at 37°C with the respective cytokines followed by PFA fixation (2%) for 15 min at RT.</p><p>For kinetic experiments, cell suspensions were stimulated with a defined, saturating concentration of cytokines (10 nM IL-27, 20 nM HypIL-6, 100 nM wt-IL-6) in a reverse order so that all cell suspensions were PFA-fixed (2%) simultaneously. For pSTAT1/3 kinetic experiments at JAK inhibition, Tofacitinib (2 μM, Stratech, #S2789-SEL) was added after 15 min of stimulation and cells were PFA-fixed in correct order.</p><p>After fixation (15 min at RT), cells were spun down at 300 g for 6 min at 4°C. Cell pellets were resuspended and permeabilized in ice-cold methanol and kept for 30 min on ice. After permeabilization cells were fluorescently barcoded according to <xref ref-type="bibr" rid="bib46">Krutzik and Nolan, 2006</xref>. In brief: using two NHS-dyes (PacificBlue, #10163, DyLight800, #46421, Thermo Scientific), individual wells were stained with a combination of different concentrations of these dyes. After barcoding, cells are pooled and stained with anti-pSTAT1<sup>Alexa647</sup> (Cell Signaling Technologies, #8009) and anti-pSTAT3<sup>Alexa488</sup> (Biolegend, #651006) at a 1:100 dilution in PBS + 0.5% BSA for 1 hr at RT. T-cells were also stained with anti-CD8<sup>AlexaFlour700</sup> (1:120, Biolegend, #300920), anti-CD4<sup>PE</sup> (1:120, Biolegend, #357404), anti-CD3<sup>BrilliantViolet510</sup> (1:100, Biolegend, #300448). Cells were analzyed at the flow cytometer (Beckman Coulter, Cytoflex S) and individual cell populations were identified by their barcoding pattern (supp. Fig 1b). Mean fluorescence intensity (MFI) of pSTAT1<sup>647</sup>and pSTAT3<sup>488</sup> was measured for all individual cell populations.</p><p>For measuring total STAT levels, methanol-permeabilized cells were stained with anti-STAT1<sup>Alexa647</sup> (1:70, Biolegend, #558560) or anti-STAT3<sup>APC</sup> (1:50, Biolegend, #560392). Total IRF1 levels methanol-permeabilized cells were stained with anti-IRF1<sup>Alexa647</sup> (1:50, Biolegend, #14105). For measuring cell surface levels of GP130, cells were detached with Accutase (Sigma) and stained with anti-GP130<sup>APC</sup> (1:100, Biolegend, #362006) for 1 hr on ice. For measuring cell surface levels of mXFPe-IL-27Rα variants, cells were detached with Accutase (Sigma) and stained with αGFP-enNB<sup>Dy647</sup> (10 nM) for 30 min on ice.</p></sec><sec id="s4-12"><title>RNA transcriptome sequencing</title><p>Human Th-1 cells from three donors each (StemCell Technologies) were cultivated and stimulated as described in above. Cells were washed in Hank’s balanced salt solution (HBSS, Gibco) and snap frozen for storage. RNA was isolated using the RNeasy Kit (Quiagen) according to manufacturer’s protocol. All RNA 260/280 ratios were above 1.9. Of each sample, 1 μg of RNA was used. Transcriptomic analysis was done by Novogene as follows. Sequencing libraries were generated using NEBNext UltraTM RNALibrary Prep Kit for Illumina (NEB, USA) following manufacturer’s recommendations and index codes were added to attribute sequences to each sample. Briefly, mRNA was purified from total RNA using poly-T oligo-attached magnetic beads. Fragmentation was carried out using divalent cations under elevated temperature in NEBNext First StrandSynthesis Reaction Buffer (5X). First strand cDNA was synthesized using random hexamer primer and M-MuLV Reverse Transcriptase (RNase H-). Second strand cDNA synthesis was subsequently performed using DNA Polymerase I and RNase H. Remaining overhangs were converted into blunt ends via exonuclease/polymerase activities. After adenylation of 3’ ends of DNA fragments, NEBNext Adaptor with hairpin loop structure were ligated to prepare for hybridization. In order to select cDNA fragments of preferentially 150 ~ 200 bp in length, the library fragments were purified with AMPure XP system (Beckman Coulter, Beverly, USA). Then 3 μl USER Enzyme (NEB, USA) was used with size-selected, adaptor-ligated cDNA at 37°C for 15 min followed by 5 min at 95°C before PCR. Then PCR was performed with Phusion High-Fidelity DNA polymerase, Universal PCR primers and Index (X) Primer. At last, PCR products were purified (AMPure XP system) and library quality was assessed on the Agilent Bioanalyzer 2100 system.</p></sec><sec id="s4-13"><title>RNA sequencing data analysis</title><p>Primary data analysis for quality control, mapping to reference genome and quantification was conducted by Novogene as outlined below.</p><p>Quality control: Raw data (raw reads) of FASTQ format were firstly processed through in-house scripts. In this step, clean data (clean reads) were obtained by removing reads containing adapter and poly-N sequences and reads with low quality from raw data. At the same time, Q20, Q30 and GC content of the clean data were calculated. All the downstream analyses were based on the clean data with high quality.</p><p>Mapping to reference genome: Reference genome and gene model annotation files were downloaded from genome website browser (NCBI/UCSC/Ensembl) directly. Paired-end clean reads were mapped to the reference genome using HISAT2 software. HISAT2 uses a large set of small GFM indexes that collectively cover the whole genome. These small indexes (called local indexes), combined with several alignment strategies, enable rapid and accurate alignment of sequencing reads.</p><p>Quantification: HTSeq was used to count the read numbers mapped of each gene, including known and novel genes. And then RPKM of each gene was calculated based on the length of the gene and reads count mapped to this gene. RPKM, (Reads Per Kilobase of exon model per Million mapped reads), considers the effect of sequencing depth and gene length for the reads count at the same time and is currently the most commonly used method for estimating gene expression levels.</p><p>For each identified gene, the fold change was calculated by the ratio of cytokine stimulated/unstimulated expression levels within each donor and an unpaired, two-tailed t test was applied to calculate p values. Genes were considered to be significantly altered if: p value ≤ 0.05, and log<sub>2</sub> fold change ≥+1 or ≤−1. Genes with an RPKM of less than one in two or more donors were excluded from analysis so as to remove genes with abundance near detection limit. Genes without annotated function were also removed. Functional annotation of genes (KEGG pathways, GO terms) was done using DAVID Bioinformatics Resource functional annotation tool (<xref ref-type="bibr" rid="bib31">Huang et al., 2009a</xref>; <xref ref-type="bibr" rid="bib32">Huang et al., 2009b</xref>). Clustered heatmap was generated using R Studio Pheatmap package.</p></sec><sec id="s4-14"><title>siRNA-mediated knockdown of IRF1 in RPE1 cells</title><p>A set of four IRF1-siRNAs were purchased from Dharmacon and tested individually to determine levels of knockdown achieved. The siRNA providing the highest level of IRF1. knockdown (Horizon, LQ-011704-00-0005, siRNA #2: UGAACUCCCUGCCAGAUAU) were subsequently used in all the experiments. RPE1 IL-27Rα cells were plated in six-well dishes (0.4 × 10<sup>6</sup> cells per well) and transfected the next day with IRF1-siRNA or control-GAPDH siRNA (Horizon, D-001830-10-05) (Dharmacon) using DharmaFect one transfection reagent (Dharmacon) following the manufacturer’s instructions for 24 hr. At different timepoints of IL-27 (2 nM) or HypIL-6 (10 nM) stimulation, samples were collected from each one six-well. Cells were trypsinized and each sample was spun down and pellets snap-frozen in liquid nitrogen for subsequent RNA isolation (90%) or PFA-fixed for total IRF1 staining (10%) by flow cytometry.</p></sec><sec id="s4-15"><title>Real-time quantitative PCR</title><p>Cells were subject to RNA isolation using the Qiagen RNeasy kit. RNA (100 ng) was reverse transcribed to complementary DNA (cDNA) using an iScript cDNA synthesis kit (BioRad, #1708890), which was used as template for quantitative PCR. PowerTrack SYBR Green Master Mix (Takara, #A46109) was used for the reaction with the following primers:</p><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Target</th><th valign="top">For</th><th valign="top">Rev</th><th valign="top">Size</th></tr></thead><tbody><tr><td valign="top">β-actin</td><td valign="top">CATGTACGTTGCTATCCAGGC</td><td valign="top">CTCCTTAATGTCACGCACGAT</td><td valign="top">250 bp</td></tr><tr><td valign="top">STAT1</td><td valign="top">CTAGTGGAGTGGAAGCGGAG</td><td valign="top">CACCACAAACGAGCTCTGAA</td><td valign="top">252 bp</td></tr><tr><td valign="top">GBP5</td><td valign="top">TCCTCGGATTATTGCTCGGC</td><td valign="top">CCTTTGCGCTTCAGCCTTTT</td><td valign="top">309 bp</td></tr><tr><td valign="top">OAS1</td><td valign="top">GAAGGCAGCTCACGAAACC</td><td valign="top">AGGCCTCAGCCTCTTGTG</td><td valign="top">114 bp</td></tr><tr><td valign="top">SOCS3</td><td valign="top">GTCCCCCCAGAAGAGCCTATTA</td><td valign="top">TTGACGGTCTTCCGACAGAGAT</td><td valign="top">118</td></tr></tbody></table></table-wrap><p>β-actin was used as housekeeping gene for normalization. Each siRNA knockdown experiment was performed in four replicates with each sample for qPCR being done in two technical replicates.</p><sec id="s4-15-1"><title>Mathematical models</title><p>We developed two new mathematical models, making use of ordinary differential equations (ODEs), for the initial steps of cytokine-receptor binding, dimer formation and signal activation by HypIL-6 and IL-27, respectively; namely, a set of ODEs for the HypIL-6 system and a separate one for the IL-27 system (see Supplementary material 1 for the set of ODEs describing each model). These ODEs describe the rate of change of the concentration for each molecular species considered in the receptor-ligand systems (HypIL-6 and IL-27) over time. By solving these ODEs, a time-course for the concentration of total (free and bound) phosphorylated STAT1 and STAT3 can be obtained and compared to the experimental data (Supp. Fig. 5c and 5d). The HypIL-6 and IL-27 mathematical models differ due to the reactions involved in the formation of the signaling dimer for each cytokine. Under stimulation with HypIL-6, two HypIL-6 bound GP130 monomers are required to form the homodimer (Supp. Fig. 4b), <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1. Schematic model of involved reactions and parameters for IL-27 and HypIL-6 receptor activation.</xref> whereas under IL-27 stimulation, we assume that IL-27 binds to the IL-27Rα chain and not to GP130 (Supp. Fig. 4c) and hence the heterodimer is comprised of an IL-27 molecule bound to an IL-27Rα monomer and one GP130 chain. In the mathematical models, we assume that upon formation of the dimers (homo- or heterodimer), these receptor chains become immediately phosphorylated. The models do not consider JAK molecules explicitly. We are assuming that these molecules are constitutively bound to their corresponding receptor chains and that they phosphorylate immediately upon receptor phosphorylation (dimer formation). After the formation of the dimer, which we denote by <inline-formula><mml:math id="inf64"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> or <inline-formula><mml:math id="inf65"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, formed by HypIL-6 or IL-27 respectively, the biochemical reactions included in each mathematical model are similar, and are summarized as follows. <xref ref-type="table" rid="table2">Table 2</xref> provides a description of the rates for each reaction considered in each (and both) mathematical model(s). In what follows we assume mass action kinetics for all the reactions. A free cytoplasmic unphosphorylated STAT1 or STAT3 molecule can bind to either receptor chain in the dimer, provided that the intracellular tyrosine residue of the receptor in the dimer is free (Supp. Fig. 4d and 4e). The STAT1 or STAT3 molecule can subsequently dissociate from the receptor chain in the dimer or can become phosphorylated (with rate <inline-formula><mml:math id="inf66"><mml:mi>q</mml:mi></mml:math></inline-formula>) whilst bound to the dimer. We have assumed that the rate of STAT1 or STAT3 phosphorylation when bound does not depend on the STAT type (1 or 3) or on the receptor chain (Supp. Fig. 4d and 4e). Phosphorylated STAT1 (pSTAT1) and STAT3 (pSTAT3) molecules can dissociate from the dimer. Once free in the cytoplasm, they can then dephosphorylate (Supp. Fig. 4h). We have assumed that this rate of STAT dephosphorylation only depends on the concentration of the respective pSTAT type. We note that no allostery has been considered in the models and hence, phosphorylated and unphosphorylated STAT molecules dissociate from the receptor with the same rate (Supp. Fig. 4d and 4e). Finally, any molecular species containing receptor molecules can be lost from the system, due to internalization or degradation processes, via one of two hypothesized mechanisms (Supp. Fig. 4f and 4g):</p><list list-type="bullet"><list-item><p>hypothesis 1 (H<sub>1</sub>): receptors (free or bound, phosphorylated or unphosphorylated) are internalized/degraded with a rate proportional to the concentration of the species in which they are contained, or</p></list-item><list-item><p>hypothesis 2 (H<sub>2</sub>): receptors (free or bound, phosphorylated or unphosphorylated) are internalized/degraded with a rate proportional to the product of the concentration of the species in which they are contained and the sum of the concentrations of free cytoplasmic phosphorylated STAT1 and STAT3.</p></list-item></list><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Parameter mathematical notation, description, and units, where <inline-formula><mml:math id="inf67"><mml:mi>i</mml:mi><mml:mi/><mml:mo>∈</mml:mo><mml:mo>{</mml:mo><mml:mn>1,3</mml:mn><mml:mo>}</mml:mo></mml:math></inline-formula> so that STAT <inline-formula><mml:math id="inf68"><mml:mi>i</mml:mi></mml:math></inline-formula> corresponds to STAT1 or STAT3.</title></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameter</th><th>Description</th><th>Unit</th></tr></thead><tbody><tr><td><inline-formula><mml:math id="inf69"><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>1,6</mml:mn></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>1,27</mml:mn></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td>Rate of receptor-ligand binding</td><td>nM<sup>−1</sup>s<sup>−1</sup></td></tr><tr><td><inline-formula><mml:math id="inf70"><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>1,6</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>1,27</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td>Rate of receptor-ligand dissociation</td><td>s<sup>−1</sup></td></tr><tr><td><inline-formula><mml:math id="inf71"><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>2,6</mml:mn></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>2,27</mml:mn></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td>Rate of monomer-monomer binding (or dimer formation)</td><td>nM<sup>−1</sup>s<sup>−1</sup></td></tr><tr><td><inline-formula><mml:math id="inf72"><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>2,6</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>2,27</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td>Rate of dimer dissociation</td><td>s<sup>−1</sup></td></tr><tr><td><inline-formula><mml:math id="inf73"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td>Rate of STATi binding to GP130</td><td>nM<sup>−1</sup>s<sup>−1</sup></td></tr><tr><td><inline-formula><mml:math id="inf74"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td>Rate of STATi binding to IL-27Rα</td><td>nM<sup>−1</sup>s<sup>−1</sup></td></tr><tr><td><inline-formula><mml:math id="inf75"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td>Rate of STATi dissociating GP130</td><td>s<sup>−1</sup></td></tr><tr><td><inline-formula><mml:math id="inf76"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td>Rate of STATi dissociating IL-27Rα</td><td>s<sup>−1</sup></td></tr><tr><td><inline-formula><mml:math id="inf77"><mml:mi>q</mml:mi></mml:math></inline-formula></td><td>Rate of STATi phosphorylation on a dimer</td><td>s<sup>−1</sup></td></tr><tr><td><inline-formula><mml:math id="inf78"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Rate of pSTATi dephosphorylation</td><td>s<sup>−1</sup></td></tr><tr><td><inline-formula><mml:math id="inf79"><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Rate of receptor internalization/degradation under hypothesis 1</td><td>s<sup>−1</sup></td></tr><tr><td><inline-formula><mml:math id="inf80"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula></td><td>Rate of receptor internalization/degradation under hypothesis 2</td><td>nM<sup>−1</sup>s<sup>−1</sup></td></tr><tr><td><inline-formula><mml:math id="inf81"><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mfenced></mml:math></inline-formula></td><td>Initial concentration of GP130</td><td>nM</td></tr><tr><td><inline-formula><mml:math id="inf82"><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mfenced></mml:math></inline-formula></td><td>Initial concentration of IL-27Rα</td><td>nM</td></tr><tr><td><inline-formula><mml:math id="inf83"><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:math></inline-formula></td><td>Initial concentration of STATi</td><td>nM</td></tr></tbody></table></table-wrap><p>We note that hypothesis 1 assumes that receptor molecules (free or bound, phosphorylated or unphosphorylated) are being internalized/degraded as part of the natural cellular trafficking cycle. Hypothesis 2 is consistent with a potential feedback mechanism, whereby the free cytoplasmic pSTAT molecules would migrate to the nucleus and increase the translation of negative feedback proteins, such as SOCS3, which down-regulate cytokine signaling. Thus, the internalization/degradation rate of receptor molecules (free or bound, phosphorylated or unphosphorylated) under hypothesis 2 increases with the total amount of free cytoplasmic phosphorylated STAT1 and STAT3, to account for this negative feedback on surface receptor expression. A depiction of the reactions in both the HypIL-6 and IL-27 mathematical models and under each hypothesis is given in Supp. Fig. 4 where (b), (d), (f) and (h) describe the HypIL-6 model and (c), (e), (g) and (h) describe the IL-27 model. In this figure, <inline-formula><mml:math id="inf84"><mml:mi>i</mml:mi><mml:mi mathvariant="normal"/><mml:mo>∈</mml:mo><mml:mo>{</mml:mo><mml:mn>1,3</mml:mn><mml:mo>}</mml:mo></mml:math></inline-formula> so that the reactions shown can involve STAT1 or STAT3. Each reaction arrow has been shown with its rate (above or below the arrow). We note that we assume mass action kinetics for each reaction. The notation for the rate constants and initial molecular concentrations in the models, along with their descriptions and units, are given in <xref ref-type="table" rid="table2">Table 2</xref>.</p><p>The HypIL-6 mathematical model was formulated based on biochemical reactions involving the following species:</p><list list-type="bullet"><list-item><p><inline-formula><mml:math id="inf85"><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> HypIL-6,</p></list-item><list-item><p><inline-formula><mml:math id="inf86"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> GP130,</p></list-item><list-item><p><inline-formula><mml:math id="inf87"><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> GP130 - HypIL-6 monomer,</p></list-item><list-item><p><inline-formula><mml:math id="inf88"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> phosphorylated GP130 - HypIL-6 - HypIL-6 - GP130 homodimer,</p></list-item><list-item><p><inline-formula><mml:math id="inf89"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> unbound cytoplasmic unphosphorylated STAT1,</p></list-item><list-item><p><inline-formula><mml:math id="inf90"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> unbound cytoplasmic unphosphorylated STAT3,</p></list-item><list-item><p><inline-formula><mml:math id="inf91"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to STAT1,</p></list-item><list-item><p><inline-formula><mml:math id="inf92"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to STAT3,</p></list-item><list-item><p><inline-formula><mml:math id="inf93"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to pSTAT1,</p></list-item><list-item><p><inline-formula><mml:math id="inf94"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to pSTAT3,</p></list-item><list-item><p><inline-formula><mml:math id="inf95"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to two molecules of STAT1,</p></list-item><list-item><p><inline-formula><mml:math id="inf96"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to two molecules of STAT1, one of which is phosphorylated,</p></list-item><list-item><p><inline-formula><mml:math id="inf97"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to two molecules of pSTAT1,</p></list-item><list-item><p><inline-formula><mml:math id="inf98"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to two molecules of STAT3,</p></list-item><list-item><p><inline-formula><mml:math id="inf99"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to two molecules of STAT3, one of which is phosphorylated,</p></list-item><list-item><p><inline-formula><mml:math id="inf100"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to two molecules of pSTAT3,</p></list-item><list-item><p><inline-formula><mml:math id="inf101"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to one molecule of STAT1 and one of STAT3,</p></list-item><list-item><p><inline-formula><mml:math id="inf102"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to one molecule of pSTAT1 and one of STAT3,</p></list-item><list-item><p><inline-formula><mml:math id="inf103"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to one molecule of STAT1 and one of pSTAT3,</p></list-item><list-item><p><inline-formula><mml:math id="inf104"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to one molecule of pSTAT1 and one of pSTAT3,</p></list-item><list-item><p><inline-formula><mml:math id="inf105"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> unbound cytoplasmic phosphorylated STAT1,</p></list-item><list-item><p><inline-formula><mml:math id="inf106"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> unbound cytoplasmic phosphorylated STAT3.</p></list-item></list><p>The initial reactions in the HypIL-6 signaling pathway can then be described by the ODEs (1) – (22) in the supplementary text, under the law of mass action, where the terms involving the parameter <inline-formula><mml:math id="inf107"><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> apply only to the model under hypothesis 1 and the terms involving the parameter <inline-formula><mml:math id="inf108"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> apply only to the model under hypothesis 2. Square brackets around a species denote the concentration of this species with unit nM, and “.” implies a reaction bond between two molecules/species. The ODEs are valid for any time <inline-formula><mml:math id="inf109"><mml:mi>t</mml:mi></mml:math></inline-formula>, with <inline-formula><mml:math id="inf110"><mml:mi>t</mml:mi><mml:mi/><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>, but time has been omitted in the species concentration for ease of notation. We note here that, for example <inline-formula><mml:math id="inf111"><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> for all <inline-formula><mml:math id="inf112"><mml:mi>t</mml:mi><mml:mi/><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>.</p><p>Similarly, and with some species in common with the HypIL-6 model, the IL-27 model has been formulated based on biochemical reactions involving the following species:</p><list list-type="bullet"><list-item><p><inline-formula><mml:math id="inf113"><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> IL-27,</p></list-item><list-item><p><inline-formula><mml:math id="inf114"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> GP130,</p></list-item><list-item><p><inline-formula><mml:math id="inf115"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> IL-27Rα,</p></list-item><list-item><p><inline-formula><mml:math id="inf116"><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> IL-27Rα - IL-27 monomer,</p></list-item><list-item><p><inline-formula><mml:math id="inf117"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> phosphorylated IL-27Rα - IL-27 - GP130 heterodimer,</p></list-item><list-item><p><inline-formula><mml:math id="inf118"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> unbound cytoplasmic unphosphorylated STAT1,</p></list-item><list-item><p><inline-formula><mml:math id="inf119"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> unbound cytoplasmic unphosphorylated STAT3,</p></list-item><list-item><p><inline-formula><mml:math id="inf120"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to STAT1 via <inline-formula><mml:math id="inf121"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf122"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to STAT3 via <inline-formula><mml:math id="inf123"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf124"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to pSTAT1 via <inline-formula><mml:math id="inf125"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf126"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to pSTAT3 via <inline-formula><mml:math id="inf127"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf128"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to STAT1 via <inline-formula><mml:math id="inf129"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf130"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to STAT3 via <inline-formula><mml:math id="inf131"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf132"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to pSTAT1 via <inline-formula><mml:math id="inf133"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf134"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to pSTAT3 via <inline-formula><mml:math id="inf135"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf136"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to two molecules of STAT1,</p></list-item><list-item><p><inline-formula><mml:math id="inf137"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to two molecules of STAT1, phosphorylated on <inline-formula><mml:math id="inf138"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf139"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to two molecules of STAT1, phosphorylated on <inline-formula><mml:math id="inf140"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf141"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to two molecules of pSTAT1,</p></list-item><list-item><p><inline-formula><mml:math id="inf142"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to two molecules of STAT3,</p></list-item><list-item><p><inline-formula><mml:math id="inf143"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to two molecules of STAT3, phosphorylated on <inline-formula><mml:math id="inf144"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf145"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to two molecules of STAT3, phosphorylated on <inline-formula><mml:math id="inf146"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf147"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to two molecules of pSTAT3,</p></list-item><list-item><p><inline-formula><mml:math id="inf148"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to STAT1 via <inline-formula><mml:math id="inf149"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and STAT3 via <inline-formula><mml:math id="inf150"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf151"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to STAT1 via <inline-formula><mml:math id="inf152"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and STAT3 via <inline-formula><mml:math id="inf153"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf154"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to pSTAT1 via <inline-formula><mml:math id="inf155"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and STAT3 via <inline-formula><mml:math id="inf156"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf157"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to pSTAT1 via <inline-formula><mml:math id="inf158"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and STAT3 via <inline-formula><mml:math id="inf159"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf160"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to STAT1 via <inline-formula><mml:math id="inf161"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and pSTAT3 via <inline-formula><mml:math id="inf162"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf163"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound to STAT1 via <inline-formula><mml:math id="inf164"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and pSTAT3 via <inline-formula><mml:math id="inf165"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf166"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound pSTAT1 via <inline-formula><mml:math id="inf167"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and pSTAT3 via <inline-formula><mml:math id="inf168"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf169"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi/><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> dimer bound pSTAT3 via <inline-formula><mml:math id="inf170"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and pSTAT1 via <inline-formula><mml:math id="inf171"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,</p></list-item><list-item><p><inline-formula><mml:math id="inf172"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> unbound cytoplasmic phosphorylated STAT1,</p></list-item><list-item><p><inline-formula><mml:math id="inf173"><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> unbound cytoplasmic phosphorylated STAT3.</p></list-item></list><p>Again, under the law of mass action, the initial reactions in the IL-27 signaling pathway can be described by the ODEs (23) – (55) in the supplementary text. Similarly, to the HypIL-6 model, the terms in the supplementary Equations (23) - (55) involving the parameter <inline-formula><mml:math id="inf174"><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> apply only to the model under hypothesis 1 and the terms involving the parameter <inline-formula><mml:math id="inf175"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> apply only to the model under hypothesis 2.</p><p>We now describe how we have made use of the experimental data (Supp. Fig. 5c and 5d) to parameterize the mathematical models described above. Since the experimental outputs are levels of pSTAT1 and pSTAT3 as a function of time under HypIL-6 and IL-27 stimulation (Supp. Fig. 5c &amp; 5d), we consider two model outputs of interest for the HypIL-6 and IL-27 mathematical models, which are proportional to the experimental data in Supp. Fig. 5c &amp; 5d; namely, the sum of all molecular species (variables) containing phosphorylated STAT1 (free or bound) (<inline-formula><mml:math id="inf176"><mml:msup><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula>, for <inline-formula><mml:math id="inf177"><mml:mi>j</mml:mi><mml:mi/><mml:mo>∈</mml:mo><mml:mo>{</mml:mo><mml:mn>6,27</mml:mn><mml:mo>}</mml:mo></mml:math></inline-formula>) and the sum of all species (variables) containing phosphorylated STAT3 (free or bound) (<inline-formula><mml:math id="inf178"><mml:msup><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula>, for <inline-formula><mml:math id="inf179"><mml:mi>j</mml:mi><mml:mi/><mml:mo>∈</mml:mo><mml:mo>{</mml:mo><mml:mn>6,27</mml:mn><mml:mo>}</mml:mo></mml:math></inline-formula>). The total concentrations of the two model outputs of interest at any time <inline-formula><mml:math id="inf180"><mml:mi>t</mml:mi></mml:math></inline-formula> are defined by the following equations, where <inline-formula><mml:math id="inf181"><mml:mi>T</mml:mi></mml:math></inline-formula> denotes the total concentration of the given molecular species:<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="left left" columnspacing="1em" rowspacing="4pt"><mml:mtr><mml:mtd><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr></mml:mtable><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ2"><label>(2)</label><mml:math id="m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="left left" columnspacing="1em" rowspacing="4pt"><mml:mtr><mml:mtd><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr></mml:mtable><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula>for the HypIL-6 model, and by<disp-formula id="equ3"><label>(3)</label><mml:math id="m3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="left left" columnspacing="1em" rowspacing="4pt"><mml:mtr><mml:mtd><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:mn>27</mml:mn></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ4"><label>(4)</label><mml:math id="m4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="left left" columnspacing="1em" rowspacing="4pt"><mml:mtr><mml:mtd><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:mn>27</mml:mn></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow/><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mstyle></mml:math></disp-formula>for the IL-27 model.</p></sec><sec id="s4-15-2"><title>Bayesian inference</title><p>Having developed two mathematical models to describe the experimental system of HypIL-6 and IL-27 stimulation, it was then our objective to parameterize the rates of these models, making use of approximate Bayesian Computation sequential Monte Carlo (ABC-SMC) and Bayesian model selection (selecting between hypothesis 1 and 2, as described in the previous section). In this way, we can learn about which reactions and parameters in the models are regulating the differential signaling by pSTAT1 observed when stimulating with HypIL-6 and IL-27.</p><p>Model (hypothesis) selection and parameter estimation are carried out together in the Bayesian sequential Monte Carlo framework used. In the traditional ABC rejection algorithm (<xref ref-type="bibr" rid="bib85">Sunnåker et al., 2013</xref>), the parameters of a mathematical model are sampled from determined prior distributions and the mathematical model is simulated with the sampled (from those prior distributions) parameter values. If the model output is 'close' to the experimental data, as defined by a quantitative measure of distance <inline-formula><mml:math id="inf182"><mml:mi>d</mml:mi></mml:math></inline-formula>, that is, if the distance between mathematical model output and experimental data points is smaller than a fiducial threshold <inline-formula><mml:math id="inf183"><mml:mi mathvariant="normal">δ</mml:mi></mml:math></inline-formula>, that is, <inline-formula><mml:math id="inf184"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>d</mml:mi><mml:mo>&lt;</mml:mo><mml:mrow><mml:mi>δ</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, then the parameters sampled for this instance are accepted into a posterior distribution, otherwise they are rejected. This process is repeated until a posterior of size <inline-formula><mml:math id="inf185"><mml:mi>N</mml:mi></mml:math></inline-formula> is obtained. For ODE models with a small number of parameters and variables, this approach can work well. However, for larger, more complex models, such as the models considered here, this approach can be very time consuming, since one must simulate the model a large number of times in order to obtain a posterior sample of size <inline-formula><mml:math id="inf186"><mml:mi>N</mml:mi></mml:math></inline-formula>. This is due to the high dimensionality of the parameter space. For example, in the case of the HypIL-6 model, there are 16 parameters, and thus, a 16-dimensional parameter space. There is, therefore, likely to be large areas of parameter space for which, when the parameters are sampled, the distance measure, <inline-formula><mml:math id="inf187"><mml:mi>d</mml:mi></mml:math></inline-formula>, between the model and data is always greater than <inline-formula><mml:math id="inf188"><mml:mi mathvariant="normal">δ</mml:mi></mml:math></inline-formula>, and hence this procedure is not an efficient sampling strategy.</p><p>To this end, we chose to use a more accurate, iterative method, ABC-SMC. At the first iteration, the algorithm works in the same way as the rejection algorithm (described above), where “particles” (parameter sets) are accepted if they result in a distance <inline-formula><mml:math id="inf189"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>d</mml:mi><mml:mo>&lt;</mml:mo><mml:msub><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, where <inline-formula><mml:math id="inf190"><mml:msub><mml:mrow><mml:mi mathvariant="normal">δ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is reasonably large; for instance, if approximately 50% of all parameter sets sampled lead to a distance <inline-formula><mml:math id="inf191"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>d</mml:mi><mml:mo>&lt;</mml:mo><mml:msub><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>. At each successive iteration, the parameters are sampled not from the prior distributions, but from the posterior distributions which have been obtained from the previous iteration, with weights that depend on both the prior and the previous iteration distributions. The parameters are then perturbed slightly using a perturbation kernel (for more details see <xref ref-type="bibr" rid="bib88">Toni et al., 2009</xref>) and the model is simulated as above. A particle at iteration <inline-formula><mml:math id="inf192"><mml:mi>i</mml:mi></mml:math></inline-formula> is accepted if it results in a distance measure <inline-formula><mml:math id="inf193"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>d</mml:mi><mml:mo>&lt;</mml:mo><mml:msub><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, where the delta values form a decreasing sequence, <inline-formula><mml:math id="inf194"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:msub><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:msub><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mo>⋯</mml:mo><mml:mo>&gt;</mml:mo><mml:msub><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>, for <inline-formula><mml:math id="inf195"><mml:mi>M</mml:mi></mml:math></inline-formula> iterations. In this way, at each iteration the parameters are sampled from a reduced parameter space region, and hence this approach leads to a faster, more efficient, convergence to the posterior distributions.</p><p>A model (hypothesis) selection can be performed making use of the iterative method described above (see <xref ref-type="bibr" rid="bib88">Toni et al., 2009</xref>). We consider a given model (hypothesis) and its parameters are sampled from either the prior (iteration 1) or the previous iterations posterior distributions (iteration <inline-formula><mml:math id="inf196"><mml:mi>i</mml:mi></mml:math></inline-formula> such that <inline-formula><mml:math id="inf197"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>1</mml:mn><mml:mo>&lt;</mml:mo><mml:mi>i</mml:mi><mml:mo>&lt;</mml:mo><mml:mi>M</mml:mi><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> in which case the parameters are also perturbed), and again the particle is accepted if the distance between mathematical model output and experimental data points is such that <inline-formula><mml:math id="inf198"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>d</mml:mi><mml:mo>&lt;</mml:mo><mml:msub><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> for iteration <inline-formula><mml:math id="inf199"><mml:mi>i</mml:mi></mml:math></inline-formula>. This procedure continues until we obtain a posterior distribution of size <inline-formula><mml:math id="inf200"><mml:mi>N</mml:mi></mml:math></inline-formula> for each mathematical model (hypothesis) considered. The mathematical models are initially given equal weight; that is, they are considered to be equally likely. However, as the iterations of the inference algorithm proceed, if one mathematical model (hypothesis) results in parameter values that better explain the experimental data, this model (hypothesis) will have a greater number of parameter sets accepted per iteration, in the limit <inline-formula><mml:math id="inf201"><mml:mi>i</mml:mi><mml:mi/><mml:mo>→</mml:mo><mml:mi>M</mml:mi></mml:math></inline-formula>. Thus, model selection between two mathematical models (hypotheses) can be determined by the computation of the relative probability for each model (hypothesis) <inline-formula><mml:math id="inf202"><mml:mi>k</mml:mi></mml:math></inline-formula> at iteration <inline-formula><mml:math id="inf203"><mml:mi>i</mml:mi></mml:math></inline-formula>, denoted by <inline-formula><mml:math id="inf204"><mml:msubsup><mml:mrow><mml:mi mathvariant="double-struck">P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>, and defined as follows:<disp-formula id="equ5"><mml:math id="m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">i</mml:mi><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">k</mml:mi></mml:mrow><mml:mi>N</mml:mi></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula>for <inline-formula><mml:math id="inf205"><mml:mi>k</mml:mi><mml:mi/><mml:mo>∈</mml:mo><mml:mi/><mml:mo>{</mml:mo><mml:mn>1,2</mml:mn><mml:mo>}</mml:mo><mml:mo>.</mml:mo></mml:math></inline-formula> The limit <inline-formula><mml:math id="inf206"><mml:msub><mml:mrow><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>→</mml:mo><mml:mi>M</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula><inline-formula><mml:math id="inf207"><mml:msubsup><mml:mrow><mml:mi mathvariant="double-struck">P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> gives the probability <inline-formula><mml:math id="inf208"><mml:msup><mml:mrow><mml:mi mathvariant="double-struck">P</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> which yields the relative probability of mathematical model <inline-formula><mml:math id="inf209"><mml:mi>k</mml:mi></mml:math></inline-formula> in light of the experimental data.</p><p>The data sets we used to compare with the mathematical model outputs were the mean relative fluorescence intensity of total phosphorylated STAT1 and total phosphorylated STAT3 for the cytokine stimulation experiments with both RPE1 and Th-1 cells (Supp. Figure 5b and 5c). Given that the data points have units of mean fluorescence intensity and the model output has dimensions of concentration (in nM units), we normalized the data sets to obtain dimensionless values, which in turn can be compared with the normalized mathematical model outputs. To this end, and firstly, we constructed a linear model for the fluorescence intensity (background fluorescence) of antibodies of phosphorylated STAT1 and STAT3 in unstimulated cells. We then subtracted the value of this linear model at each time point from the corresponding fluorescence intensity in HypIL-6 and IL-27-stimulated cells, for each repeat of the experiment and cell type. Let us denote by <inline-formula><mml:math id="inf210"><mml:mi>f</mml:mi></mml:math></inline-formula> the experimental fluorescence intensity, <inline-formula><mml:math id="inf211"><mml:mi>f</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>r</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> corresponds to the fluorescence intensity for the <inline-formula><mml:math id="inf212"><mml:mi>r</mml:mi></mml:math></inline-formula> th repeat, <inline-formula><mml:math id="inf213"><mml:mi>r</mml:mi><mml:mi/><mml:mo>∈</mml:mo><mml:mi>R</mml:mi><mml:mi/><mml:mo>=</mml:mo><mml:mi/><mml:mo>{</mml:mo><mml:mn>1,2</mml:mn><mml:mo>,</mml:mo><mml:mn>3,4</mml:mn><mml:mo>}</mml:mo></mml:math></inline-formula> with antibody for STATi, <inline-formula><mml:math id="inf214"><mml:mi>i</mml:mi><mml:mi/><mml:mo>∈</mml:mo><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:mn>1,3</mml:mn><mml:mo>}</mml:mo></mml:math></inline-formula> at time point <inline-formula><mml:math id="inf215"><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo></mml:math></inline-formula><disp-formula id="equ6"><mml:math id="m6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>∈</mml:mo><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mspace width="thinmathspace"/><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mn>5</mml:mn><mml:mspace width="thinmathspace"/><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mn>15</mml:mn><mml:mspace width="thinmathspace"/><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mn>30</mml:mn><mml:mspace width="thinmathspace"/><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mn>60</mml:mn><mml:mspace width="thinmathspace"/><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mn>90</mml:mn><mml:mspace width="thinmathspace"/><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mn>120</mml:mn><mml:mspace width="thinmathspace"/><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mn>180</mml:mn><mml:mspace width="thinmathspace"/><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula>under stimulation by cytokine IL-j (HypIL-j when <inline-formula><mml:math id="inf216"><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>6</mml:mn></mml:math></inline-formula>), with <inline-formula><mml:math id="inf217"><mml:mi>j</mml:mi><mml:mo>∈</mml:mo><mml:mi>J</mml:mi><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:mn>6,27</mml:mn><mml:mo>}</mml:mo></mml:math></inline-formula> and in cell type <inline-formula><mml:math id="inf218"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>d</mml:mi><mml:mo>∈</mml:mo><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mtext>RPE1</mml:mtext><mml:mo>,</mml:mo><mml:mtext>Th-1</mml:mtext></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> Each data point <inline-formula><mml:math id="inf219"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>r</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> to be used in the Bayesian inference and Bayesian model selection was then obtained from <inline-formula><mml:math id="inf220"><mml:mi>f</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>r</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> with the following normalization,<disp-formula id="equ7"><label>(5)</label><mml:math id="m7"><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mo>(</mml:mo><mml:mi>r</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>f</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>r</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>f</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>r</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>30</mml:mn><mml:mo/><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mtext>27</mml:mtext><mml:mo>,</mml:mo><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:math></disp-formula></p><p>That is, our normalization has been chosen to be the time point 30 minutes with IL-27 stimulation. To compare the mathematical model output, denoted by <inline-formula><mml:math id="inf221"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> with the normalized experimental data, the mathematical output was normalized in the same way as the data, that is,<disp-formula id="equ8"><label>(6)</label><mml:math id="m8"><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:mn>27</mml:mn></mml:mrow></mml:msup><mml:mfenced separators="|"><mml:mrow><mml:mn>30</mml:mn><mml:mo/><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:math></disp-formula>where <inline-formula><mml:math id="inf222"><mml:msup><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>p</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msup><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> denotes the total, <inline-formula><mml:math id="inf223"><mml:mi>T</mml:mi></mml:math></inline-formula>, concentration of phosphorylated STATi at time <inline-formula><mml:math id="inf224"><mml:mi>t</mml:mi><mml:mi>p</mml:mi></mml:math></inline-formula> (see <xref ref-type="disp-formula" rid="equ1 equ2 equ3 equ4">Equations 1–4</xref>) when considering cell type <inline-formula><mml:math id="inf225"><mml:mi>d</mml:mi></mml:math></inline-formula> and cytokine stimulation <inline-formula><mml:math id="inf226"><mml:mi>j</mml:mi><mml:mi/><mml:mo>∈</mml:mo><mml:mi>J</mml:mi><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:mn>6,27</mml:mn><mml:mo>}</mml:mo></mml:math></inline-formula>. The data points for IL-27 stimulation at time 30 mins were chosen as normalization in <xref ref-type="disp-formula" rid="equ7">Equation (5)</xref>, since they correspond to the maximal experimental value, and thus the data, when normalized in this way, was transformed to a scale in the interval <inline-formula><mml:math id="inf227"><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mn>0,1</mml:mn></mml:mrow></mml:mfenced></mml:math></inline-formula>. Mathematical model outputs were normalized in the same way, and therefore model outputs for IL-27 will naturally go through the value 1 at time 30 mins. This choice of normalization has not influenced the results of our study. To this end, we have repeated our analysis with a different normalization time point of <inline-formula><mml:math id="inf228"><mml:mi>f</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>r</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>15</mml:mn><mml:mi/><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>27</mml:mn><mml:mo>,</mml:mo><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> (results not shown here). In particular, we found that the posterior distributions and the result of the model (hypothesis) selection were rather similar for each choice of normalization.</p><p>Once data sets and mathematical outputs have been normalized and can be compared, there is a need to quantify how close (or not) they are. To this end, we make use of a quantitative measure, called a distance and denoted by <inline-formula><mml:math id="inf229"><mml:mi>δ</mml:mi><mml:mo>(</mml:mo><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula>. In our case, we have chosen a generalization of the Euclidean distance, where<disp-formula id="equ9"><label>(7)</label><mml:math id="m9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msup><mml:mi>δ</mml:mi><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>∈</mml:mo><mml:mi>I</mml:mi></mml:mrow></mml:munder><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>∈</mml:mo><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:munder><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>∈</mml:mo><mml:mi>J</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">[</mml:mo><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msup><mml:mo stretchy="false">]</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula><inline-formula><mml:math id="inf230"><mml:mi>d</mml:mi><mml:mo>∈</mml:mo><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:mtext>RPE1</mml:mtext><mml:mo>,</mml:mo><mml:mtext>Th-1</mml:mtext><mml:mo>}</mml:mo></mml:math></inline-formula>, with <inline-formula><mml:math id="inf231"><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi></mml:mrow></mml:mfenced></mml:math></inline-formula> defined as the mean of the four experimental repeats. The mean is given by<disp-formula id="equ10"><label>(8)</label><mml:math id="m10"><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:mfrac><mml:mrow><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:munderover><mml:mrow><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mo>(</mml:mo><mml:mi>r</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>.</mml:mo></mml:math></disp-formula></p><p>With a choice of measure, we can now carry out both Bayesian (mathematical) model selection and parameter inference. Before we do so, our prior beliefs of the parameters need to be considered and defined. Each of the parameters (reaction rates in the mathematical models) and initial concentrations for the molecules in the model were sampled from a prior distribution, where the distribution was informed by independent experiments or published values, when possible. The choice of prior distributions is given in <xref ref-type="table" rid="table3">Table 3</xref>.</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Prior distribution assigned to each parameter and initial molecular concentration.</title><p>*These distributions are centered around measurements obtained from cell surface receptor quantification experiments. **These distributions were derived based on <inline-formula><mml:math id="inf232"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> values obtained from the literature (<xref ref-type="bibr" rid="bib93">Wiederkehr-Adam et al., 2003</xref>). ***These distributions are based on values derived from experimental data in which the cells were treated with Tofacitinib. † These distributions were based on values derived from experimental data in which the cells were treated with cycloheximide. ‡These distributions were based on computations involving approximate cell sizes and average numbers of molecules per cell.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameter</th><th>Prior distribution</th><th>Reference</th></tr></thead><tbody><tr><td><inline-formula><mml:math id="inf233"><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>1,6</mml:mn></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf234"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mtext>for</mml:mtext><mml:mspace width="thinmathspace"/><mml:mi>r</mml:mi><mml:mo>∼</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mn>1.5</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td>*</td></tr><tr><td><inline-formula><mml:math id="inf235"><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>1,6</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf236"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mtext>for</mml:mtext><mml:mspace width="thinmathspace"/><mml:mi>r</mml:mi><mml:mo>∼</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>3.9</mml:mn><mml:mo>,</mml:mo><mml:mn>1.96</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td>*</td></tr><tr><td><inline-formula><mml:math id="inf237"><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>1,27</mml:mn></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf238"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mtext>for</mml:mtext><mml:mspace width="thinmathspace"/><mml:mi>r</mml:mi><mml:mo>∼</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>2.34</mml:mn><mml:mo>,</mml:mo><mml:mn>1.17</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td>*</td></tr><tr><td><inline-formula><mml:math id="inf239"><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>1,27</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf240"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mtext>for</mml:mtext><mml:mspace width="thinmathspace"/><mml:mi>r</mml:mi><mml:mo>∼</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>2.82</mml:mn><mml:mo>,</mml:mo><mml:mn>1.41</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td>*</td></tr><tr><td><inline-formula><mml:math id="inf241"><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> for j∈{6,27}</td><td><inline-formula><mml:math id="inf242"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mtext>for</mml:mtext><mml:mspace width="thinmathspace"/><mml:mi>r</mml:mi><mml:mo>∼</mml:mo><mml:mi>U</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td><xref ref-type="bibr" rid="bib44">Kozer et al., 2013</xref></td></tr><tr><td><inline-formula><mml:math id="inf243"><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> for j∈{6,27}</td><td><inline-formula><mml:math id="inf244"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mtext>for</mml:mtext><mml:mspace width="thinmathspace"/><mml:mi>r</mml:mi><mml:mo>∼</mml:mo><mml:mi>U</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td><xref ref-type="bibr" rid="bib44">Kozer et al., 2013</xref></td></tr><tr><td><inline-formula><mml:math id="inf245"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula>,<inline-formula><mml:math id="inf246"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> for i∈{1,3}</td><td><inline-formula><mml:math id="inf247"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mtext>for</mml:mtext><mml:mspace width="thinmathspace"/><mml:mi>r</mml:mi><mml:mo>∼</mml:mo><mml:mi>U</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>7</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td>**</td></tr><tr><td><inline-formula><mml:math id="inf248"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula>,<inline-formula><mml:math id="inf249"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> for i∈{1,3}</td><td><inline-formula><mml:math id="inf250"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mtext>for</mml:mtext><mml:mspace width="thinmathspace"/><mml:mi>r</mml:mi><mml:mo>∼</mml:mo><mml:mi>U</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td>**</td></tr><tr><td><inline-formula><mml:math id="inf251"><mml:mi>q</mml:mi></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf252"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mtext>for</mml:mtext><mml:mspace width="thinmathspace"/><mml:mi>r</mml:mi><mml:mo>∼</mml:mo><mml:mi>U</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td>Assumed</td></tr><tr><td><inline-formula><mml:math id="inf253"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> for i∈{1,3}</td><td><inline-formula><mml:math id="inf254"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mtext>for</mml:mtext><mml:mspace width="thinmathspace"/><mml:mi>r</mml:mi><mml:mo>∼</mml:mo><mml:mi>U</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>5</mml:mn><mml:mo>,</mml:mo><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td>***</td></tr><tr><td><inline-formula><mml:math id="inf255"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> for j∈{6,27}</td><td><inline-formula><mml:math id="inf256"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mtext>for</mml:mtext><mml:mspace width="thinmathspace"/><mml:mi>r</mml:mi><mml:mo>∼</mml:mo><mml:mi>U</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>5</mml:mn><mml:mo>,</mml:mo><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td>†</td></tr><tr><td><inline-formula><mml:math id="inf257"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> for j∈{6,27}</td><td><inline-formula><mml:math id="inf258"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:mspace width="thinmathspace"/><mml:mtext>for</mml:mtext><mml:mspace width="thinmathspace"/><mml:mi>r</mml:mi><mml:mo>∼</mml:mo><mml:mi>U</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>5</mml:mn><mml:mo>,</mml:mo><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td>†</td></tr><tr><td><inline-formula><mml:math id="inf259"><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mfenced></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf260"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>12.7</mml:mn><mml:mo>,</mml:mo><mml:mn>6.35</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td>‡</td></tr><tr><td><inline-formula><mml:math id="inf261"><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mfenced></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf262"><mml:mi>N</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mn>33.8,16.9</mml:mn></mml:mrow></mml:mfenced></mml:math></inline-formula></td><td>‡</td></tr><tr><td><inline-formula><mml:math id="inf263"><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf264"><mml:mi>N</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mn>300,100</mml:mn></mml:mrow></mml:mfenced></mml:math></inline-formula></td><td><xref ref-type="bibr" rid="bib35">Itzhak et al., 2016</xref></td></tr><tr><td><inline-formula><mml:math id="inf265"><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow></mml:mfenced></mml:math></inline-formula></td><td><inline-formula><mml:math id="inf266"><mml:mi>N</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mn>400,100</mml:mn></mml:mrow></mml:mfenced></mml:math></inline-formula></td><td><xref ref-type="bibr" rid="bib35">Itzhak et al., 2016</xref></td></tr></tbody></table></table-wrap><p>We now provide additional details of the model selection and parameter estimation carried out with the normalized experimental data and mathematical models. We have experimental data for two different cell types (RPE1 and Th-1). There are a number of parameters in the HypIL-6 and IL-27 mathematical models which we have assumed to be independent of the cell type. The only parameters which we would expect to differ between cell types are the initial concentrations of the molecules ([<inline-formula><mml:math id="inf267"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> (0)], [<inline-formula><mml:math id="inf268"><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> (0)], [<inline-formula><mml:math id="inf269"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> (0)], [<inline-formula><mml:math id="inf270"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> (0)]), the rate of STAT phosphorylation (<inline-formula><mml:math id="inf271"><mml:mi>q</mml:mi></mml:math></inline-formula>), the rates of pSTAT dephosphorylation (<inline-formula><mml:math id="inf272"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf273"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>) and the rates of internalization/degradation of the receptor molecules (<inline-formula><mml:math id="inf274"><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf275"><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf276"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="inf277"><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>). Therefore, the aforementioned parameters have been estimated for each cell type, separately, and the rest of the parameters have been estimated with one cell type. We have chosen to make use of the RPE1 data to estimate these shared parameters. In particular, we ran the analysis in two stages (all our numerical codes were written in Python), in order to reduce the number of parameters to be estimated in a given ABC-SMC analysis. We first made use of the RPE1 data and secondly, the Th-1 data. We ran the model (hypothesis) selection algorithm with the RPE1 data, for a sample of size <inline-formula><mml:math id="inf278"><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula> and <inline-formula><mml:math id="inf279"><mml:mi>M</mml:mi><mml:mo>=</mml:mo><mml:mi/><mml:mn>15</mml:mn></mml:math></inline-formula> iterations, with the following sequence of delta values <inline-formula><mml:math id="inf280"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>100</mml:mn><mml:mo>,</mml:mo><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mn>5</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mn>2.5</mml:mn><mml:mo>,</mml:mo><mml:mn>2.25</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>1.75</mml:mn><mml:mo>,</mml:mo><mml:mn>1.5</mml:mn><mml:mo>,</mml:mo><mml:mn>1.25</mml:mn><mml:mo>,</mml:mo><mml:mn>1.1</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>0.9</mml:mn><mml:mo>,</mml:mo><mml:mn>0.8</mml:mn><mml:mo>,</mml:mo><mml:mn>0.7</mml:mn></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p><p>A uniform perturbation kernel (<xref ref-type="bibr" rid="bib18">Filippi et al., 2013</xref>) was used to perturb the parameters sampled at each iteration <inline-formula><mml:math id="inf281"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>1</mml:mn><mml:mo>&lt;</mml:mo><mml:mi>i</mml:mi><mml:mo>≤</mml:mo><mml:mi>M</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>. The result of the model selection clearly indicated that hypothesis 1 could explain the experimental data best.</p><p>When carrying out model (hypothesis) selection, and during the latter iterations, there were still some parameter sets accepted for hypothesis 2. Therefore, we ran the ABC-SMC parameter estimation algorithm for the RPE1 data only for hypothesis 1, in order to generate a complete posterior distribution of size <inline-formula><mml:math id="inf282"><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>. In the second stage of the inference, we then considered the Th-1 data and ran the ABC-SMC parameter estimation algorithm to infer Th-1 specific parameters (only for hypothesis 1). Those parameters that were assumed to be independent of cell type were sampled from the posterior distributions obtained during the previous RPE1 ABC-SMC inference. The same sample size, number of iterations, vector of delta values and perturbation kernel were used in the Th-1 and RPE1 analysis. We finally note that, although we used the experimental data sets in the order RPE1 followed by Th-1 here, the ordering of the cell type does not have a significant effect on the results (not shown here). Namely, our model selection results and those of the parameter inference and posterior distributions are similar to those presented here, when we reverse the order.</p></sec></sec><sec id="s4-16"><title>Mathematical model validation</title><p>Once we have carried out model selection and parameter inference as described in the previous section, we want to explore the potential of the mathematical models of cytokine early signaling to reproduce other independent experiments. We note that we make use of the posterior parameter distributions obtained from the RPE1 data ABC-SMC. Our first interest was to reproduce the dose response curve seen in Supp. Fig. 2a. To this end, we run both models using the 10<sup>4</sup> accepted parameters sets from the ABC-SMC for 18 different values of cytokine concentration, within the range [10<sup>-4</sup>-10<sup>2</sup>] log nM. The results of this analysis are seen in Supp. Fig. 13b. Our second interest was to describe the IL-27Rα-GP130 chimera experiments (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). This required us to modify the mathematical model as follows: we considered the ODEs of the IL-27 mathematical model involved in the formation of the dimer, Equations (23) – (26) (Supplementary information 1), and the ODEs of the HypIL-6 mathematical model post-dimer formation, Equations (5) – (22) (Supplementary information 1), in which <inline-formula><mml:math id="inf283"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> was replaced by <inline-formula><mml:math id="inf284"><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>. The ODE of the IL-27 induced dimer in the chimera model was modified as follows,<disp-formula id="equ11"><label>(9)</label><mml:math id="m11"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="left left" columnspacing="1em" rowspacing="4pt"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:msubsup><mml:mi>r</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>27</mml:mn></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msubsup><mml:mi>r</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>27</mml:mn></mml:mrow><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mover><mml:mrow/><mml:mo>˙</mml:mo></mml:mover></mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:mover><mml:mrow/><mml:mo>˙</mml:mo></mml:mover></mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mn>3</mml:mn><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mn>3</mml:mn><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mover><mml:mrow/><mml:mo>˙</mml:mo></mml:mover></mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>p</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mrow><mml:mover><mml:mrow/><mml:mo>˙</mml:mo></mml:mover></mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>We simulated both the original mathematical model of IL-27 and the chimera model using the accepted parameter sets from the ABC-SMC. The results can be seen in Supp. Fig. 3a.</p><p>Finally, the mathematical model was used to describe one of the mutant varieties of the IL-27Rα chain, Y613F. We sought to reproduce the results of <xref ref-type="fig" rid="fig3">Figure 3b</xref> making use of the mathematical model of IL-27 signaling. Since the Y613F mutation decreases the affinity of STAT1 to IL-27Rα, we fixed the association and dissociation rates of STAT1 to the IL 27Rα chain, <inline-formula><mml:math id="inf285"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="inf286"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula>, respectively, at values which lead to a high affinity (of the order of μM values). The specific values chosen were <inline-formula><mml:math id="inf287"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula> nM<sup>−1</sup>s<sup>−1</sup> and <inline-formula><mml:math id="inf288"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula> s<sup>−1</sup>, which yield an affinity of 10<sup>2</sup>μM. The rate <inline-formula><mml:math id="inf289"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula>, was chosen as approximately the median of the ABC-SMC posterior distribution for this parameter, and the rate <inline-formula><mml:math id="inf290"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> was then significantly decreased in order to increase the affinity. We simulated the mathematical model of IL-27 signaling using the 10<sup>4</sup> accepted ABC-SMC parameter sets, but where the rates <inline-formula><mml:math id="inf291"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="inf292"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula>, were fixed as described above. The pointwise medians and 95% credible intervals of these simulations are plotted in Supp. Fig. 13c, as well as the simulations for the WT IL-27Rα chain, without altering any of the parameter values from the posterior distributions. Altering the binding affinity of STAT1 to IL-27Rα in this way in the mathematical model allows us to generate results which qualitatively and quantitatively reproduce the experimental observations for the Y613F mutant from <xref ref-type="fig" rid="fig3">Figure 3b</xref>.</p></sec><sec id="s4-17"><title>Live-cell dual-color single-molecule imaging studies</title><p>Single-molecule imaging experiments were carried out by total internal reflection fluorescence (TIRF) microscopy with an inverted microscope (Olympus IX71) equipped with a triple-line total internal reflection (TIR) illumination condenser (Olympus) and a back-illuminated electron multiplied (EM) CCD camera (iXon DU897D, 512 × 512 pixel, Andor Technology) as recently described (<xref ref-type="bibr" rid="bib94">Wilmes et al., 2015</xref>; <xref ref-type="bibr" rid="bib95">Wilmes et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Moraga et al., 2015b</xref>). A ×150 magnification objective with a numerical aperture of 1.45 (UAPO 150 3/1.45 TIRFM, Olympus) was used for TIR illumination. All experiments were carried out at room temperature in medium without phenol red supplemented with an oxygen scavenger and a redox-active photoprotectant to minimize photobleaching (<xref ref-type="bibr" rid="bib92">Vogelsang et al., 2008</xref>). For Heterodimerization experiments of IL-27Rα and GP130 cell surface labeling of RPE1 GP130 KO, co-transfected with mXFPe-IL-27Rα and mXFPm-GP130, was achieved by adding αGFP-enNB<sup>RHO11</sup> and αGFP-miNB<sup>DY647</sup> to the medium at equal concentrations (5 nM) and incubated for at least 5 min prior to stimulation with IL-27 (20 nM) or HypIL-6 (20 nM). For homodimerization experiments with mXFPm-GP130, αGFP-miNB<sup>DY647</sup> and αGFP-miNB<sup>RHO11</sup> (<xref ref-type="bibr" rid="bib42">Kirchhofer et al., 2010</xref>) were used for cell surface receptor labeling as described above. The nanobodies were kept in the bulk solution during the whole experiment in order to ensure high equilibrium binding to mXFP-GP130. For simultaneous dual-color acquisition, αGFP-NB<sup>RHO11</sup> was excited by a 561 nm diode-pumped solid-state laser at 0.95 mW (~32 W/cm<sup>2</sup>) and αGFP-NB<sup>DY647</sup> by a 642 nm laser diode at 0.65 mW (~22 W/cm<sup>2</sup>). Fluorescence was detected using a spectral image splitter (DualView, Optical Insight) with a 640 DCXR dichroic beam splitter (Chroma) in combination with the bandpass filter 585/40 (Semrock) for detection of RHO11 and 690/70 (Chroma) for detection of DY647 dividing each emission channel into 512 × 256 pixel. Image stacks of 150 frames were recorded at 32 ms/frame.</p><p>Single-molecule localization and single-molecule tracking were carried out using the multiple-target tracing (MTT) algorithm (<xref ref-type="bibr" rid="bib78">Sergé et al., 2008</xref>) as described previously (<xref ref-type="bibr" rid="bib102">You et al., 2016</xref>). Step-length histograms were obtained from single-molecule trajectories and fitted by two fraction mixture model of Brownian diffusion. Average diffusion constants were determined from the slope (2–10 steps) of the mean square displacement versus time lapse diagrams. Immobile molecules were identified by the density-based spatial clustering of applications with noise (DBSCAN) algorithm as described recently (<xref ref-type="bibr" rid="bib70">Röder et al., 2014</xref>). For comparing diffusion properties and for co-tracking analysis, immobile particles were excluded from the data set. Prior to co-localization analysis, imaging channels were aligned with sub-pixel precision by using a spatial transformation. To this end, a transformation matrix was calculated based on a calibration measurement with multicolor fluorescent beads (TetraSpeck microspheres 0.1 mm, Invitrogen) visible in both spectral channels (cp2tform of type ‘affine’, The MathWorks MATLAB 2009a).</p><p>Individual molecules detected in the both spectral channels were regarded as co-localized, if a particle was detected in both channels of a single frame within a distance threshold of 100 nm radius. For single-molecule co-tracking analysis, the MTT algorithm was applied to this dataset of co-localized molecules to reconstruct co-locomotion trajectories (co-trajectories) from the identified population of co-localizations. For the co-tracking analysis, only trajectories with a minimum of 10 steps (~320 ms) were considered in order to robustly remove random receptor co-localizations (<xref ref-type="bibr" rid="bib95">Wilmes et al., 2020</xref>). For heterodimerization experiments of mXFPe-IL-27Rα and mXFPm-GP130, the relative fraction of dimerized receptors was calculated from the number of co-trajectories relative to the number of IL-27Rα trajectories. GP130 was expressed in moderate excess (~1.5–2 fold), so that maximal receptor assembly was not limited by abundance of the low-affinity subunit GP130.</p><p>For homodimerization experiments with GP130, the relative fraction of co-tracked molecules was determined with respect to the absolute number of trajectories and corrected for GP130 stochastically double-labeled with the same fluorophore species as follows:<disp-formula id="equ12"><mml:math id="m12"><mml:msup><mml:mrow><mml:mi>A</mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>*</mml:mi></mml:mrow></mml:msup><mml:mi/><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>A</mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>×</mml:mo><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>B</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced><mml:mo>×</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>B</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mi/><mml:mi/><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mo>.</mml:mo><mml:mi/><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mo>-</mml:mo><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mi/><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mi>A</mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>*</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mi>B</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:math></disp-formula>where A, B, AB, and AB* are the numbers of trajectories observed for Rho11, DY647, co-trajectories and corrected co-trajectories, respectively.</p><p>The two-dimensional equilibrium dissociation constants (<inline-formula><mml:math id="inf293"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>D</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>) were calculated according to the law of mass action for a monomer-dimer equilibrium:</p><p>Heterodimerization (IL-27Rα + GP130):<disp-formula id="equ13"><mml:math id="m13"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>D</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>G</mml:mi><mml:mi>P</mml:mi><mml:mn>130</mml:mn><mml:mo stretchy="false">]</mml:mo><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>α</mml:mi><mml:mo>×</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>27</mml:mn><mml:mi>R</mml:mi><mml:mi>a</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>×</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>27</mml:mn><mml:mi>R</mml:mi><mml:mi>a</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>α</mml:mi><mml:mo>×</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>27</mml:mn><mml:mi>R</mml:mi><mml:mi>a</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>α</mml:mi><mml:mo>×</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>27</mml:mn><mml:mi>R</mml:mi><mml:mi>a</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula>or<disp-formula id="equ14"><mml:math id="m14"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>D</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>G</mml:mi><mml:mi>P</mml:mi><mml:mn>130</mml:mn></mml:mrow></mml:mfenced><mml:mo>×</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>α</mml:mi></mml:mrow></mml:mfrac><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>27</mml:mn><mml:mi>R</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:mfenced><mml:mo>×</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mi>α</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:math></disp-formula>with:<disp-formula id="equ15"><mml:math id="m15"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:mi>f</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>27</mml:mn><mml:mspace width="thinmathspace"/><mml:mi>b</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>27</mml:mn><mml:mspace width="thinmathspace"/><mml:mi>R</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>w</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>G</mml:mi><mml:mi>P</mml:mi><mml:mn>130</mml:mn></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>Homodimerization (GP130 + GP130):<disp-formula id="equ16"><mml:math id="m16"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>D</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:math></disp-formula><disp-formula id="equ17"><mml:math id="m17"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>D</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>G</mml:mi><mml:mi>P</mml:mi><mml:mn>130</mml:mn></mml:mrow></mml:mfenced><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:mo>×</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mi>α</mml:mi><mml:mo>×</mml:mo><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>G</mml:mi><mml:mi>P</mml:mi><mml:mn>130</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>×</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mi>α</mml:mi><mml:mo>×</mml:mo><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>G</mml:mi><mml:mi>P</mml:mi><mml:mn>130</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:math></disp-formula>with:<disp-formula id="equ18"><mml:math id="m18"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:mi>f</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>G</mml:mi><mml:mi>P</mml:mi><mml:mn>130</mml:mn><mml:mspace width="thinmathspace"/><mml:mi>h</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>s</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>G</mml:mi><mml:mi>P</mml:mi><mml:mn>130</mml:mn></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mstyle></mml:math></disp-formula>where [<italic>M</italic>] and [<italic>D</italic>] are the concentrations of the monomer and the dimer, respectively, and [<italic>M</italic>]<sub>0</sub> is the total receptor concentration.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank members of the Moraga, Molina-París, Piehler and Mitra laboratories for helpful advice and discussion. We thank G Hikade and H Kenneweg for technical support, C P Richter for providing software for single-molecule image analysis, R Kurre (Integrated Bioimaging Facility Osnabrück) for support with fluorescence microscopy and the FingerPrints Proteomics facility (Dundee) for support with the mass spectrometry data. Graphic material was provided by smart servier medical art. This work was supported by the Wellcome-Trust-202323/Z/16/Z (IM EP), ERC-206-STG grant (IM JMF EP PKF), EMBO (SW 454–2017), DFG (SFB 944, P8/Z, JP), National Heart, Lung and Blood Institute (K22HL125593, MK) and Contrat de Plan Etat Région Hauts de France and Institut pour la Recherche sur le Cancer de Lille (SM SG). CMP and GL were supported by H2020 (ITN QuanTII, grant agreement number 764698). PJ is supported by the EPSRC, AstraZeneca and the Smith Institute (Smith Institute CASE studentship, award reference 1969354). Numerical work was undertaken on ARC3, which is part of the High-Performance Computing facilities at the University of Leeds, UK.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Formal analysis</p></fn><fn fn-type="con" id="con11"><p>Methodology</p></fn><fn fn-type="con" id="con12"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Supervision, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Data curation, Supervision, Funding acquisition, Investigation, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Human subjects: This study was authorized by the French Competent Authority dealing with Research on Human Biological Samples namely the French Ministry of Research. The Authorization number is ECH 19/04. all patients gave their written informed consent.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Ordinary differential equations for mathematical modeling of IL-27 and HypIL-6 signaling.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-66014-supp1-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-66014-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Python (version 3.7) codes for the ABC-SMC model selection and parameter inference can be found in the public repository '<ext-link ext-link-type="uri" xlink:href="https://github.com/PollyJeffrey/Cytokine_modelling'">https://github.com/PollyJeffrey/Cytokine_modelling'</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:rev:9c3e0ddc7a96eac941baad560d1541d660b0515d">https://archive.softwareheritage.org/swh:1:rev:9c3e0ddc7a96eac941baad560d1541d660b0515d</ext-link>), along with the results of the analysis. Phospho-proteomic and proteomic datasets were uploaded to the Proteome Exchange platform with accession numbers PXD024657 and PXD024188 respectively. RNA-seq dataset was uploaded in the GSE database with accession number GSE164479.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Wilmes</surname><given-names>S</given-names></name><name><surname>Jeffrey</surname><given-names>P</given-names></name><name><surname>Martinez-Fabregas</surname><given-names>J</given-names></name><name><surname>Hafer</surname><given-names>M</given-names></name><name><surname>Fyfe</surname><given-names>P</given-names></name><name><surname>Pohler</surname><given-names>E</given-names></name><name><surname>Gaggero</surname><given-names>S</given-names></name><name><surname>López-García</surname><given-names>M</given-names></name><name><surname>Lythe</surname><given-names>G</given-names></name><name><surname>Guerrier</surname><given-names>T</given-names></name><name><surname>Launay</surname><given-names>D</given-names></name><name><surname>Suman</surname><given-names>M</given-names></name><name><surname>Piehler</surname><given-names>J</given-names></name><name><surname>Molina-París</surname><given-names>C</given-names></name><name><surname>Moraga</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses in autoimmune disorders</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE164479">GSE164479</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Wilmes</surname><given-names>S</given-names></name><name><surname>Jeffrey</surname><given-names>P</given-names></name><name><surname>Martinez-Fabregas</surname><given-names>J</given-names></name><name><surname>Hafer</surname><given-names>M</given-names></name><name><surname>Fyfe</surname><given-names>P</given-names></name><name><surname>Pohler</surname><given-names>E</given-names></name><name><surname>Gaggero</surname><given-names>S</given-names></name><name><surname>López-García</surname><given-names>M</given-names></name><name><surname>Lythe</surname><given-names>G</given-names></name><name><surname>Guerrier</surname><given-names>T</given-names></name><name><surname>Launay</surname><given-names>D</given-names></name><name><surname>Suman</surname><given-names>M</given-names></name><name><surname>Piehler</surname><given-names>J</given-names></name><name><surname>Molina-París</surname><given-names>C</given-names></name><name><surname>Moraga</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses in autoimmune disorders</data-title><source>PRIDE</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD024188">PXD024188</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Wilmes</surname><given-names>S</given-names></name><name><surname>Jeffrey</surname><given-names>P</given-names></name><name><surname>Martinez-Fabregas</surname><given-names>J</given-names></name><name><surname>Hafer</surname><given-names>M</given-names></name><name><surname>Fyfe</surname><given-names>P</given-names></name><name><surname>Pohler</surname><given-names>E</given-names></name><name><surname>Gaggero</surname><given-names>S</given-names></name><name><surname>López-García</surname><given-names>M</given-names></name><name><surname>Lythe</surname><given-names>G</given-names></name><name><surname>Guerrier</surname><given-names>T</given-names></name><name><surname>Launay</surname><given-names>D</given-names></name><name><surname>Suman</surname><given-names>M</given-names></name><name><surname>Piehler</surname><given-names>J</given-names></name><name><surname>Molina-París</surname><given-names>C</given-names></name><name><surname>Moraga</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses in autoimmune disorders</data-title><source>PRIDE</source><pub-id assigning-authority="EBI" pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD024657">PXD024657</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awasthi</surname> <given-names>A</given-names></name><name><surname>Carrier</surname> <given-names>Y</given-names></name><name><surname>Peron</surname> <given-names>JP</given-names></name><name><surname>Bettelli</surname> <given-names>E</given-names></name><name><surname>Kamanaka</surname> <given-names>M</given-names></name><name><surname>Flavell</surname> <given-names>RA</given-names></name><name><surname>Kuchroo</surname> <given-names>VK</given-names></name><name><surname>Oukka</surname> <given-names>M</given-names></name><name><surname>Weiner</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells</article-title><source>Nature Immunology</source><volume>8</volume><fpage>1380</fpage><lpage>1389</lpage><pub-id pub-id-type="doi">10.1038/ni1541</pub-id><pub-id pub-id-type="pmid">17994022</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bancerek</surname> <given-names>J</given-names></name><name><surname>Poss</surname> <given-names>ZC</given-names></name><name><surname>Steinparzer</surname> <given-names>I</given-names></name><name><surname>Sedlyarov</surname> <given-names>V</given-names></name><name><surname>Pfaffenwimmer</surname> <given-names>T</given-names></name><name><surname>Mikulic</surname> <given-names>I</given-names></name><name><surname>Dölken</surname> <given-names>L</given-names></name><name><surname>Strobl</surname> <given-names>B</given-names></name><name><surname>Müller</surname> <given-names>M</given-names></name><name><surname>Taatjes</surname> <given-names>DJ</given-names></name><name><surname>Kovarik</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response</article-title><source>Immunity</source><volume>38</volume><fpage>250</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.10.017</pub-id><pub-id pub-id-type="pmid">23352233</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bender</surname> <given-names>H</given-names></name><name><surname>Wiesinger</surname> <given-names>MY</given-names></name><name><surname>Nordhoff</surname> <given-names>C</given-names></name><name><surname>Schoenherr</surname> <given-names>C</given-names></name><name><surname>Haan</surname> <given-names>C</given-names></name><name><surname>Ludwig</surname> <given-names>S</given-names></name><name><surname>Weiskirchen</surname> <given-names>R</given-names></name><name><surname>Kato</surname> <given-names>N</given-names></name><name><surname>Heinrich</surname> <given-names>PC</given-names></name><name><surname>Haan</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Interleukin-27 displays interferon-gamma-like functions in human hepatoma cells and hepatocytes</article-title><source>Hepatology</source><volume>50</volume><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1002/hep.22988</pub-id><pub-id pub-id-type="pmid">19582813</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betz</surname> <given-names>UA</given-names></name><name><surname>Müller</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Regulated expression of gp130 and IL-6 receptor alpha chain in T cell maturation and activation</article-title><source>International Immunology</source><volume>10</volume><fpage>1175</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1093/intimm/10.8.1175</pub-id><pub-id pub-id-type="pmid">9723704</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulanger</surname> <given-names>MJ</given-names></name><name><surname>Chow</surname> <given-names>DC</given-names></name><name><surname>Brevnova</surname> <given-names>EE</given-names></name><name><surname>Garcia</surname> <given-names>KC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex</article-title><source>Science</source><volume>300</volume><fpage>2101</fpage><lpage>2104</lpage><pub-id pub-id-type="doi">10.1126/science.1083901</pub-id><pub-id pub-id-type="pmid">12829785</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brender</surname> <given-names>C</given-names></name><name><surname>Tannahill</surname> <given-names>GM</given-names></name><name><surname>Jenkins</surname> <given-names>BJ</given-names></name><name><surname>Fletcher</surname> <given-names>J</given-names></name><name><surname>Columbus</surname> <given-names>R</given-names></name><name><surname>Saris</surname> <given-names>CJ</given-names></name><name><surname>Ernst</surname> <given-names>M</given-names></name><name><surname>Nicola</surname> <given-names>NA</given-names></name><name><surname>Hilton</surname> <given-names>DJ</given-names></name><name><surname>Alexander</surname> <given-names>WS</given-names></name><name><surname>Starr</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Suppressor of cytokine signaling 3 regulates CD8 T-cell proliferation by inhibition of interleukins 6 and 27</article-title><source>Blood</source><volume>110</volume><fpage>2528</fpage><lpage>2536</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-08-041541</pub-id><pub-id pub-id-type="pmid">17609432</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname> <given-names>JB</given-names></name><name><surname>Cheresh</surname> <given-names>P</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Ryu</surname> <given-names>H</given-names></name><name><surname>Managlia</surname> <given-names>E</given-names></name><name><surname>Barrett</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>P-selectin glycoprotein ligand-1 is needed for sequential recruitment of T-helper 1 (Th1) and local generation of Th17 T cells in dextran sodium sulfate (DSS) colitis</article-title><source>Inflammatory Bowel Diseases</source><volume>18</volume><fpage>323</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1002/ibd.21779</pub-id><pub-id pub-id-type="pmid">22009715</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camporeale</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?</article-title><source>Frontiers in Bioscience</source><volume>17</volume><fpage>2306</fpage><lpage>2326</lpage><pub-id pub-id-type="doi">10.2741/4054</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro</surname> <given-names>M</given-names></name><name><surname>de Boer</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Testing structural identifiability by a simple scaling method</article-title><source>PLOS Computational Biology</source><volume>16</volume><elocation-id>e1008248</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1008248</pub-id><pub-id pub-id-type="pmid">33141821</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charlot-Rabiega</surname> <given-names>P</given-names></name><name><surname>Bardel</surname> <given-names>E</given-names></name><name><surname>Dietrich</surname> <given-names>C</given-names></name><name><surname>Kastelein</surname> <given-names>R</given-names></name><name><surname>Devergne</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Signaling events involved in interleukin 27 (IL-27)-induced proliferation of human naive CD4+ T cells and B cells</article-title><source>Journal of Biological Chemistry</source><volume>286</volume><fpage>27350</fpage><lpage>27362</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.221010</pub-id><pub-id pub-id-type="pmid">21669870</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa-Pereira</surname> <given-names>AP</given-names></name><name><surname>Tininini</surname> <given-names>S</given-names></name><name><surname>Strobl</surname> <given-names>B</given-names></name><name><surname>Alonzi</surname> <given-names>T</given-names></name><name><surname>Schlaak</surname> <given-names>JF</given-names></name><name><surname>Is'harc</surname> <given-names>H</given-names></name><name><surname>Gesualdo</surname> <given-names>I</given-names></name><name><surname>Newman</surname> <given-names>SJ</given-names></name><name><surname>Kerr</surname> <given-names>IM</given-names></name><name><surname>Poli</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Mutational switch of an IL-6 response to an interferon- -like response</article-title><source>PNAS</source><volume>99</volume><fpage>8043</fpage><lpage>8047</lpage><pub-id pub-id-type="doi">10.1073/pnas.122236099</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname> <given-names>J</given-names></name><name><surname>Neuhauser</surname> <given-names>N</given-names></name><name><surname>Michalski</surname> <given-names>A</given-names></name><name><surname>Scheltema</surname> <given-names>RA</given-names></name><name><surname>Olsen</surname> <given-names>JV</given-names></name><name><surname>Mann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Andromeda: a peptide search engine integrated into the MaxQuant environment</article-title><source>Journal of Proteome Research</source><volume>10</volume><fpage>1794</fpage><lpage>1805</lpage><pub-id pub-id-type="doi">10.1021/pr101065j</pub-id><pub-id pub-id-type="pmid">21254760</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname> <given-names>J</given-names></name><name><surname>Mann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification</article-title><source>Nature Biotechnology</source><volume>26</volume><fpage>1367</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1038/nbt.1511</pub-id><pub-id pub-id-type="pmid">19029910</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croker</surname> <given-names>BA</given-names></name><name><surname>Krebs</surname> <given-names>DL</given-names></name><name><surname>Zhang</surname> <given-names>JG</given-names></name><name><surname>Wormald</surname> <given-names>S</given-names></name><name><surname>Willson</surname> <given-names>TA</given-names></name><name><surname>Stanley</surname> <given-names>EG</given-names></name><name><surname>Robb</surname> <given-names>L</given-names></name><name><surname>Greenhalgh</surname> <given-names>CJ</given-names></name><name><surname>Förster</surname> <given-names>I</given-names></name><name><surname>Clausen</surname> <given-names>BE</given-names></name><name><surname>Nicola</surname> <given-names>NA</given-names></name><name><surname>Metcalf</surname> <given-names>D</given-names></name><name><surname>Hilton</surname> <given-names>DJ</given-names></name><name><surname>Roberts</surname> <given-names>AW</given-names></name><name><surname>Alexander</surname> <given-names>WS</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>SOCS3 negatively regulates IL-6 signaling in vivo</article-title><source>Nature Immunology</source><volume>4</volume><fpage>540</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1038/ni931</pub-id><pub-id pub-id-type="pmid">12754505</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diegelmann</surname> <given-names>J</given-names></name><name><surname>Olszak</surname> <given-names>T</given-names></name><name><surname>Göke</surname> <given-names>B</given-names></name><name><surname>Blumberg</surname> <given-names>RS</given-names></name><name><surname>Brand</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins</article-title><source>Journal of Biological Chemistry</source><volume>287</volume><fpage>286</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.294355</pub-id><pub-id pub-id-type="pmid">22069308</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diveu</surname> <given-names>C</given-names></name><name><surname>McGeachy</surname> <given-names>MJ</given-names></name><name><surname>Boniface</surname> <given-names>K</given-names></name><name><surname>Stumhofer</surname> <given-names>JS</given-names></name><name><surname>Sathe</surname> <given-names>M</given-names></name><name><surname>Joyce-Shaikh</surname> <given-names>B</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Tato</surname> <given-names>CM</given-names></name><name><surname>McClanahan</surname> <given-names>TK</given-names></name><name><surname>de Waal Malefyt</surname> <given-names>R</given-names></name><name><surname>Hunter</surname> <given-names>CA</given-names></name><name><surname>Cua</surname> <given-names>DJ</given-names></name><name><surname>Kastelein</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells</article-title><source>The Journal of Immunology</source><volume>182</volume><fpage>5748</fpage><lpage>5756</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0801162</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fakruddin</surname> <given-names>JM</given-names></name><name><surname>Lempicki</surname> <given-names>RA</given-names></name><name><surname>Gorelick</surname> <given-names>RJ</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Adelsberger</surname> <given-names>JW</given-names></name><name><surname>Garcia-Pineres</surname> <given-names>AJ</given-names></name><name><surname>Pinto</surname> <given-names>LA</given-names></name><name><surname>Lane</surname> <given-names>HC</given-names></name><name><surname>Imamichi</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27</article-title><source>Blood</source><volume>109</volume><fpage>1841</fpage><lpage>1849</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-02-001578</pub-id><pub-id pub-id-type="pmid">17068156</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filippi</surname> <given-names>S</given-names></name><name><surname>Barnes</surname> <given-names>CP</given-names></name><name><surname>Cornebise</surname> <given-names>J</given-names></name><name><surname>Stumpf</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>On optimality of kernels for approximate bayesian computation using sequential monte carlo</article-title><source>Statistical Applications in Genetics and Molecular Biology</source><volume>12</volume><fpage>87</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1515/sagmb-2012-0069</pub-id><pub-id pub-id-type="pmid">23502346</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname> <given-names>M</given-names></name><name><surname>Goldschmitt</surname> <given-names>J</given-names></name><name><surname>Peschel</surname> <given-names>C</given-names></name><name><surname>Brakenhoff</surname> <given-names>JP</given-names></name><name><surname>Kallen</surname> <given-names>KJ</given-names></name><name><surname>Wollmer</surname> <given-names>A</given-names></name><name><surname>Grötzinger</surname> <given-names>J</given-names></name><name><surname>Rose-John</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion</article-title><source>Nature Biotechnology</source><volume>15</volume><fpage>142</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1038/nbt0297-142</pub-id><pub-id pub-id-type="pmid">9035138</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname> <given-names>DC</given-names></name><name><surname>Zhang</surname> <given-names>GX</given-names></name><name><surname>El-Behi</surname> <given-names>M</given-names></name><name><surname>Fonseca-Kelly</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Yu</surname> <given-names>S</given-names></name><name><surname>Saris</surname> <given-names>CJ</given-names></name><name><surname>Gran</surname> <given-names>B</given-names></name><name><surname>Ciric</surname> <given-names>B</given-names></name><name><surname>Rostami</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells</article-title><source>Nature Immunology</source><volume>8</volume><fpage>1372</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.1038/ni1540</pub-id><pub-id pub-id-type="pmid">17994023</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francois-Newton</surname> <given-names>V</given-names></name><name><surname>Livingstone</surname> <given-names>M</given-names></name><name><surname>Payelle-Brogard</surname> <given-names>B</given-names></name><name><surname>Uzé</surname> <given-names>G</given-names></name><name><surname>Pellegrini</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>USP18 establishes the transcriptional and anti-proliferative interferon α/β differential</article-title><source>Biochemical Journal</source><volume>446</volume><fpage>509</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1042/BJ20120541</pub-id><pub-id pub-id-type="pmid">22731491</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname> <given-names>AC</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Katsounas</surname> <given-names>A</given-names></name><name><surname>Bharucha</surname> <given-names>JP</given-names></name><name><surname>Kottilil</surname> <given-names>S</given-names></name><name><surname>Imamichi</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Interleukin-27, an anti-HIV-1 cytokine, inhibits replication of hepatitis C virus</article-title><source>Journal of Interferon &amp; Cytokine Research</source><volume>30</volume><fpage>427</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1089/jir.2009.0093</pub-id><pub-id pub-id-type="pmid">20235668</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garbers</surname> <given-names>C</given-names></name><name><surname>Hermanns</surname> <given-names>HM</given-names></name><name><surname>Schaper</surname> <given-names>F</given-names></name><name><surname>Müller-Newen</surname> <given-names>G</given-names></name><name><surname>Grötzinger</surname> <given-names>J</given-names></name><name><surname>Rose-John</surname> <given-names>S</given-names></name><name><surname>Scheller</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Plasticity and cross-talk of interleukin 6-type cytokines</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>23</volume><fpage>85</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2012.04.001</pub-id><pub-id pub-id-type="pmid">22595692</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorby</surname> <given-names>C</given-names></name><name><surname>Sotolongo Bellón</surname> <given-names>J</given-names></name><name><surname>Wilmes</surname> <given-names>S</given-names></name><name><surname>Warda</surname> <given-names>W</given-names></name><name><surname>Pohler</surname> <given-names>E</given-names></name><name><surname>Fyfe</surname> <given-names>PK</given-names></name><name><surname>Cozzani</surname> <given-names>A</given-names></name><name><surname>Ferrand</surname> <given-names>C</given-names></name><name><surname>Walter</surname> <given-names>MR</given-names></name><name><surname>Mitra</surname> <given-names>S</given-names></name><name><surname>Piehler</surname> <given-names>J</given-names></name><name><surname>Moraga</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses</article-title><source>Science Signaling</source><volume>13</volume><elocation-id>eabc0653</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.abc0653</pub-id><pub-id pub-id-type="pmid">32934073</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinrich</surname> <given-names>PC</given-names></name><name><surname>Behrmann</surname> <given-names>I</given-names></name><name><surname>Haan</surname> <given-names>S</given-names></name><name><surname>Hermanns</surname> <given-names>HM</given-names></name><name><surname>Müller-Newen</surname> <given-names>G</given-names></name><name><surname>Schaper</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Principles of interleukin (IL)-6-type cytokine signalling and its regulation</article-title><source>Biochemical Journal</source><volume>374</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1042/bj20030407</pub-id><pub-id pub-id-type="pmid">12773095</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirahara</surname> <given-names>K</given-names></name><name><surname>Ghoreschi</surname> <given-names>K</given-names></name><name><surname>Yang</surname> <given-names>XP</given-names></name><name><surname>Takahashi</surname> <given-names>H</given-names></name><name><surname>Laurence</surname> <given-names>A</given-names></name><name><surname>Vahedi</surname> <given-names>G</given-names></name><name><surname>Sciumè</surname> <given-names>G</given-names></name><name><surname>Hall</surname> <given-names>AO</given-names></name><name><surname>Dupont</surname> <given-names>CD</given-names></name><name><surname>Francisco</surname> <given-names>LM</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Tanaka</surname> <given-names>M</given-names></name><name><surname>Kanno</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>HW</given-names></name><name><surname>Sharpe</surname> <given-names>AH</given-names></name><name><surname>Hunter</surname> <given-names>CA</given-names></name><name><surname>O'Shea</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1</article-title><source>Immunity</source><volume>36</volume><fpage>1017</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.03.024</pub-id><pub-id pub-id-type="pmid">22726954</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirahara</surname> <given-names>K</given-names></name><name><surname>Onodera</surname> <given-names>A</given-names></name><name><surname>Villarino</surname> <given-names>AV</given-names></name><name><surname>Bonelli</surname> <given-names>M</given-names></name><name><surname>Sciumè</surname> <given-names>G</given-names></name><name><surname>Laurence</surname> <given-names>A</given-names></name><name><surname>Sun</surname> <given-names>HW</given-names></name><name><surname>Brooks</surname> <given-names>SR</given-names></name><name><surname>Vahedi</surname> <given-names>G</given-names></name><name><surname>Shih</surname> <given-names>HY</given-names></name><name><surname>Gutierrez-Cruz</surname> <given-names>G</given-names></name><name><surname>Iwata</surname> <given-names>S</given-names></name><name><surname>Suzuki</surname> <given-names>R</given-names></name><name><surname>Mikami</surname> <given-names>Y</given-names></name><name><surname>Okamoto</surname> <given-names>Y</given-names></name><name><surname>Nakayama</surname> <given-names>T</given-names></name><name><surname>Holland</surname> <given-names>SM</given-names></name><name><surname>Hunter</surname> <given-names>CA</given-names></name><name><surname>Kanno</surname> <given-names>Y</given-names></name><name><surname>O'Shea</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Asymmetric action of STAT transcription factors drives transcriptional outputs and cytokine specificity</article-title><source>Immunity</source><volume>42</volume><fpage>877</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.04.014</pub-id><pub-id pub-id-type="pmid">25992861</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname> <given-names>CCM</given-names></name><name><surname>Chhabra</surname> <given-names>A</given-names></name><name><surname>Starkl</surname> <given-names>P</given-names></name><name><surname>Schnorr</surname> <given-names>PJ</given-names></name><name><surname>Wilmes</surname> <given-names>S</given-names></name><name><surname>Moraga</surname> <given-names>I</given-names></name><name><surname>Kwon</surname> <given-names>HS</given-names></name><name><surname>Gaudenzio</surname> <given-names>N</given-names></name><name><surname>Sibilano</surname> <given-names>R</given-names></name><name><surname>Wehrman</surname> <given-names>TS</given-names></name><name><surname>Gakovic</surname> <given-names>M</given-names></name><name><surname>Sockolosky</surname> <given-names>JT</given-names></name><name><surname>Tiffany</surname> <given-names>MR</given-names></name><name><surname>Ring</surname> <given-names>AM</given-names></name><name><surname>Piehler</surname> <given-names>J</given-names></name><name><surname>Weissman</surname> <given-names>IL</given-names></name><name><surname>Galli</surname> <given-names>SJ</given-names></name><name><surname>Shizuru</surname> <given-names>JA</given-names></name><name><surname>Garcia</surname> <given-names>KC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Decoupling the functional pleiotropy of stem cell factor by tuning c-Kit signaling</article-title><source>Cell</source><volume>168</volume><fpage>1041</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.02.011</pub-id><pub-id pub-id-type="pmid">28283060</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title><source>Arthritis &amp; Rheumatism</source><volume>40</volume><elocation-id>1725</elocation-id><pub-id pub-id-type="doi">10.1002/art.1780400928</pub-id><pub-id pub-id-type="pmid">9324032</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>X</given-names></name><name><surname>Herrero</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>WP</given-names></name><name><surname>Antoniv</surname> <given-names>TT</given-names></name><name><surname>Falck-Pedersen</surname> <given-names>E</given-names></name><name><surname>Koch</surname> <given-names>AE</given-names></name><name><surname>Woods</surname> <given-names>JM</given-names></name><name><surname>Haines</surname> <given-names>GK</given-names></name><name><surname>Ivashkiv</surname> <given-names>LB</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Sensitization of IFN-gamma Jak-STAT signaling during macrophage activation</article-title><source>Nature Immunology</source><volume>3</volume><fpage>859</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1038/ni828</pub-id><pub-id pub-id-type="pmid">12172544</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>daW</given-names></name><name><surname>Sherman</surname> <given-names>BT</given-names></name><name><surname>Lempicki</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2009">2009a</year><article-title>Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists</article-title><source>Nucleic Acids Research</source><volume>37</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1093/nar/gkn923</pub-id><pub-id pub-id-type="pmid">19033363</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>daW</given-names></name><name><surname>Sherman</surname> <given-names>BT</given-names></name><name><surname>Lempicki</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2009">2009b</year><article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title><source>Nature Protocols</source><volume>4</volume><fpage>44</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id><pub-id pub-id-type="pmid">19131956</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname> <given-names>CA</given-names></name><name><surname>Jones</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>IL-6 as a keystone cytokine in health and disease</article-title><source>Nature Immunology</source><volume>16</volume><fpage>448</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1038/ni.3153</pub-id><pub-id pub-id-type="pmid">25898198</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imamichi</surname> <given-names>T</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Huang</surname> <given-names>daW</given-names></name><name><surname>Sherman</surname> <given-names>B</given-names></name><name><surname>Lempicki</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Interleukin-27 induces interferon-inducible genes: analysis of gene expression profiles using affymetrix microarray and DAVID</article-title><source>Methods in Molecular Biology</source><volume>820</volume><fpage>25</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1007/978-1-61779-439-1_3</pub-id><pub-id pub-id-type="pmid">22131024</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itzhak</surname> <given-names>DN</given-names></name><name><surname>Tyanova</surname> <given-names>S</given-names></name><name><surname>Cox</surname> <given-names>J</given-names></name><name><surname>Borner</surname> <given-names>GH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Global, quantitative and dynamic mapping of protein subcellular localization</article-title><source>eLife</source><volume>5</volume><elocation-id>e16950</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.16950</pub-id><pub-id pub-id-type="pmid">27278775</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>GW</given-names></name><name><surname>McLoughlin</surname> <given-names>RM</given-names></name><name><surname>Hammond</surname> <given-names>VJ</given-names></name><name><surname>Parker</surname> <given-names>CR</given-names></name><name><surname>Williams</surname> <given-names>JD</given-names></name><name><surname>Malhotra</surname> <given-names>R</given-names></name><name><surname>Scheller</surname> <given-names>J</given-names></name><name><surname>Williams</surname> <given-names>AS</given-names></name><name><surname>Rose-John</surname> <given-names>S</given-names></name><name><surname>Topley</surname> <given-names>N</given-names></name><name><surname>Jones</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells</article-title><source>Journal of Immunology</source><volume>184</volume><fpage>2130</fpage><lpage>2139</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0901528</pub-id><pub-id pub-id-type="pmid">20083667</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamiya</surname> <given-names>S</given-names></name><name><surname>Owaki</surname> <given-names>T</given-names></name><name><surname>Morishima</surname> <given-names>N</given-names></name><name><surname>Fukai</surname> <given-names>F</given-names></name><name><surname>Mizuguchi</surname> <given-names>J</given-names></name><name><surname>Yoshimoto</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells</article-title><source>The Journal of Immunology</source><volume>173</volume><fpage>3871</fpage><lpage>3877</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.173.6.3871</pub-id><pub-id pub-id-type="pmid">15356135</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname> <given-names>S</given-names></name><name><surname>Narazaki</surname> <given-names>M</given-names></name><name><surname>Metwally</surname> <given-names>H</given-names></name><name><surname>Kishimoto</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Historical overview of the interleukin-6 family cytokine</article-title><source>Journal of Experimental Medicine</source><volume>217</volume><elocation-id>0347</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20190347</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karwacz</surname> <given-names>K</given-names></name><name><surname>Miraldi</surname> <given-names>ER</given-names></name><name><surname>Pokrovskii</surname> <given-names>M</given-names></name><name><surname>Madi</surname> <given-names>A</given-names></name><name><surname>Yosef</surname> <given-names>N</given-names></name><name><surname>Wortman</surname> <given-names>I</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Watters</surname> <given-names>A</given-names></name><name><surname>Carriero</surname> <given-names>N</given-names></name><name><surname>Awasthi</surname> <given-names>A</given-names></name><name><surname>Regev</surname> <given-names>A</given-names></name><name><surname>Bonneau</surname> <given-names>R</given-names></name><name><surname>Littman</surname> <given-names>D</given-names></name><name><surname>Kuchroo</surname> <given-names>VK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Critical role of IRF1 and BATF in forming chromatin landscape during type 1 regulatory cell differentiation</article-title><source>Nature Immunology</source><volume>18</volume><fpage>412</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/ni.3683</pub-id><pub-id pub-id-type="pmid">28166218</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>H</given-names></name><name><surname>Hawley</surname> <given-names>TS</given-names></name><name><surname>Hawley</surname> <given-names>RG</given-names></name><name><surname>Baumann</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Protein tyrosine phosphatase 2 (SHP-2) moderates signaling by gp130 but is not required for the induction of acute-phase plasma protein genes in hepatic cells</article-title><source>Molecular and Cellular Biology</source><volume>18</volume><fpage>1525</fpage><lpage>1533</lpage><pub-id pub-id-type="doi">10.1128/MCB.18.3.1525</pub-id><pub-id pub-id-type="pmid">9488469</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname> <given-names>A</given-names></name><name><surname>Kishimoto</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>IL-6: regulator of treg/Th17 balance</article-title><source>European Journal of Immunology</source><volume>40</volume><fpage>1830</fpage><lpage>1835</lpage><pub-id pub-id-type="doi">10.1002/eji.201040391</pub-id><pub-id pub-id-type="pmid">20583029</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchhofer</surname> <given-names>A</given-names></name><name><surname>Helma</surname> <given-names>J</given-names></name><name><surname>Schmidthals</surname> <given-names>K</given-names></name><name><surname>Frauer</surname> <given-names>C</given-names></name><name><surname>Cui</surname> <given-names>S</given-names></name><name><surname>Karcher</surname> <given-names>A</given-names></name><name><surname>Pellis</surname> <given-names>M</given-names></name><name><surname>Muyldermans</surname> <given-names>S</given-names></name><name><surname>Casas-Delucchi</surname> <given-names>CS</given-names></name><name><surname>Cardoso</surname> <given-names>MC</given-names></name><name><surname>Leonhardt</surname> <given-names>H</given-names></name><name><surname>Hopfner</surname> <given-names>KP</given-names></name><name><surname>Rothbauer</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Modulation of protein properties in living cells using nanobodies</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>17</volume><fpage>133</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1727</pub-id><pub-id pub-id-type="pmid">20010839</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korn</surname> <given-names>T</given-names></name><name><surname>Mitsdoerffer</surname> <given-names>M</given-names></name><name><surname>Croxford</surname> <given-names>AL</given-names></name><name><surname>Awasthi</surname> <given-names>A</given-names></name><name><surname>Dardalhon</surname> <given-names>VA</given-names></name><name><surname>Galileos</surname> <given-names>G</given-names></name><name><surname>Vollmar</surname> <given-names>P</given-names></name><name><surname>Stritesky</surname> <given-names>GL</given-names></name><name><surname>Kaplan</surname> <given-names>MH</given-names></name><name><surname>Waisman</surname> <given-names>A</given-names></name><name><surname>Kuchroo</surname> <given-names>VK</given-names></name><name><surname>Oukka</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells</article-title><source>PNAS</source><volume>105</volume><fpage>18460</fpage><lpage>18465</lpage><pub-id pub-id-type="doi">10.1073/pnas.0809850105</pub-id><pub-id pub-id-type="pmid">19015529</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozer</surname> <given-names>N</given-names></name><name><surname>Barua</surname> <given-names>D</given-names></name><name><surname>Orchard</surname> <given-names>S</given-names></name><name><surname>Nice</surname> <given-names>EC</given-names></name><name><surname>Burgess</surname> <given-names>AW</given-names></name><name><surname>Hlavacek</surname> <given-names>WS</given-names></name><name><surname>Clayton</surname> <given-names>AH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Exploring higher-order EGFR oligomerisation and phosphorylation--a combined experimental and theoretical approach</article-title><source>Molecular BioSystems</source><volume>9</volume><fpage>1849</fpage><lpage>1863</lpage><pub-id pub-id-type="doi">10.1039/c3mb70073a</pub-id><pub-id pub-id-type="pmid">23629589</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krutzik</surname> <given-names>PO</given-names></name><name><surname>Clutter</surname> <given-names>MR</given-names></name><name><surname>Trejo</surname> <given-names>A</given-names></name><name><surname>Nolan</surname> <given-names>GP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Fluorescent cell barcoding for multiplex flow cytometry</article-title><source>Current Protocols in Cytometry</source><volume>Chapter 6</volume><elocation-id>Unit 31</elocation-id><pub-id pub-id-type="doi">10.1002/0471142956.cy0631s55</pub-id><pub-id pub-id-type="pmid">21207359</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krutzik</surname> <given-names>PO</given-names></name><name><surname>Nolan</surname> <given-names>GP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling</article-title><source>Nature Methods</source><volume>3</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1038/nmeth872</pub-id><pub-id pub-id-type="pmid">16628206</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaPorte</surname> <given-names>SL</given-names></name><name><surname>Juo</surname> <given-names>ZS</given-names></name><name><surname>Vaclavikova</surname> <given-names>J</given-names></name><name><surname>Colf</surname> <given-names>LA</given-names></name><name><surname>Qi</surname> <given-names>X</given-names></name><name><surname>Heller</surname> <given-names>NM</given-names></name><name><surname>Keegan</surname> <given-names>AD</given-names></name><name><surname>Garcia</surname> <given-names>KC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system</article-title><source>Cell</source><volume>132</volume><fpage>259</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.12.030</pub-id><pub-id pub-id-type="pmid">18243101</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname> <given-names>D</given-names></name><name><surname>Harari</surname> <given-names>D</given-names></name><name><surname>Schreiber</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Stochastic receptor expression determines cell fate upon interferon treatment</article-title><source>Molecular and Cellular Biology</source><volume>31</volume><fpage>3252</fpage><lpage>3266</lpage><pub-id pub-id-type="doi">10.1128/MCB.05251-11</pub-id><pub-id pub-id-type="pmid">21690295</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Jaehnig</surname> <given-names>EJ</given-names></name><name><surname>Shi</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W199</fpage><lpage>W205</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz401</pub-id><pub-id pub-id-type="pmid">31114916</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname> <given-names>S</given-names></name><name><surname>Ghilardi</surname> <given-names>N</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>de Sauvage</surname> <given-names>FJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms</article-title><source>PNAS</source><volume>100</volume><fpage>15047</fpage><lpage>15052</lpage><pub-id pub-id-type="doi">10.1073/pnas.2536517100</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Fabregas</surname> <given-names>J</given-names></name><name><surname>Wilmes</surname> <given-names>S</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Hafer</surname> <given-names>M</given-names></name><name><surname>Pohler</surname> <given-names>E</given-names></name><name><surname>Lokau</surname> <given-names>J</given-names></name><name><surname>Garbers</surname> <given-names>C</given-names></name><name><surname>Cozzani</surname> <given-names>A</given-names></name><name><surname>Fyfe</surname> <given-names>PK</given-names></name><name><surname>Piehler</surname> <given-names>J</given-names></name><name><surname>Kazemian</surname> <given-names>M</given-names></name><name><surname>Mitra</surname> <given-names>S</given-names></name><name><surname>Moraga</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Kinetics of cytokine receptor trafficking determine signaling and functional selectivity</article-title><source>eLife</source><volume>8</volume><elocation-id>e49314</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.49314</pub-id><pub-id pub-id-type="pmid">31774398</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname> <given-names>M</given-names></name><name><surname>Shigeta</surname> <given-names>A</given-names></name><name><surname>Furukawa</surname> <given-names>Y</given-names></name><name><surname>Tanaka</surname> <given-names>T</given-names></name><name><surname>Miyasaka</surname> <given-names>M</given-names></name><name><surname>Hirata</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>CD43 collaborates with P-Selectin glycoprotein Ligand-1 to mediate E-Selectin-Dependent T cell migration into inflamed skin</article-title><source>The Journal of Immunology</source><volume>178</volume><fpage>2499</fpage><lpage>2506</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.4.2499</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moraga</surname> <given-names>I</given-names></name><name><surname>Harari</surname> <given-names>D</given-names></name><name><surname>Schreiber</surname> <given-names>G</given-names></name><name><surname>Uzé</surname> <given-names>G</given-names></name><name><surname>Pellegrini</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Receptor density is key to the alpha2/beta interferon differential activities</article-title><source>Molecular and Cellular Biology</source><volume>29</volume><fpage>4778</fpage><lpage>4787</lpage><pub-id pub-id-type="doi">10.1128/MCB.01808-08</pub-id><pub-id pub-id-type="pmid">19564411</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moraga</surname> <given-names>I</given-names></name><name><surname>Richter</surname> <given-names>D</given-names></name><name><surname>Wilmes</surname> <given-names>S</given-names></name><name><surname>Winkelmann</surname> <given-names>H</given-names></name><name><surname>Jude</surname> <given-names>K</given-names></name><name><surname>Thomas</surname> <given-names>C</given-names></name><name><surname>Suhoski</surname> <given-names>MM</given-names></name><name><surname>Engleman</surname> <given-names>EG</given-names></name><name><surname>Piehler</surname> <given-names>J</given-names></name><name><surname>Garcia</surname> <given-names>KC</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>Instructive roles for cytokine-receptor binding parameters in determining signaling and functional potency</article-title><source>Science Signaling</source><volume>8</volume><elocation-id>ra114</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aab2677</pub-id><pub-id pub-id-type="pmid">26554818</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moraga</surname> <given-names>I</given-names></name><name><surname>Wernig</surname> <given-names>G</given-names></name><name><surname>Wilmes</surname> <given-names>S</given-names></name><name><surname>Gryshkova</surname> <given-names>V</given-names></name><name><surname>Richter</surname> <given-names>CP</given-names></name><name><surname>Hong</surname> <given-names>WJ</given-names></name><name><surname>Sinha</surname> <given-names>R</given-names></name><name><surname>Guo</surname> <given-names>F</given-names></name><name><surname>Fabionar</surname> <given-names>H</given-names></name><name><surname>Wehrman</surname> <given-names>TS</given-names></name><name><surname>Krutzik</surname> <given-names>P</given-names></name><name><surname>Demharter</surname> <given-names>S</given-names></name><name><surname>Plo</surname> <given-names>I</given-names></name><name><surname>Weissman</surname> <given-names>IL</given-names></name><name><surname>Minary</surname> <given-names>P</given-names></name><name><surname>Majeti</surname> <given-names>R</given-names></name><name><surname>Constantinescu</surname> <given-names>SN</given-names></name><name><surname>Piehler</surname> <given-names>J</given-names></name><name><surname>Garcia</surname> <given-names>KC</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands</article-title><source>Cell</source><volume>160</volume><fpage>1196</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.02.011</pub-id><pub-id pub-id-type="pmid">25728669</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadeau</surname> <given-names>OW</given-names></name><name><surname>Domanski</surname> <given-names>P</given-names></name><name><surname>Usacheva</surname> <given-names>A</given-names></name><name><surname>Uddin</surname> <given-names>S</given-names></name><name><surname>Platanias</surname> <given-names>LC</given-names></name><name><surname>Pitha</surname> <given-names>P</given-names></name><name><surname>Raz</surname> <given-names>R</given-names></name><name><surname>Levy</surname> <given-names>D</given-names></name><name><surname>Majchrzak</surname> <given-names>B</given-names></name><name><surname>Fish</surname> <given-names>E</given-names></name><name><surname>Colamonici</surname> <given-names>OR</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The proximal tyrosines of the cytoplasmic domain of the beta chain of the type I interferon receptor are essential for signal transducer and activator of transcription (Stat) 2 activation evidence that two Stat2 sites are required to reach a threshold of interferon alpha-induced Stat2 tyrosine phosphorylation that allows normal formation of interferon-stimulated gene factor 3</article-title><source>The Journal of Biological Chemistry</source><volume>274</volume><fpage>4045</fpage><lpage>4052</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.7.4045</pub-id><pub-id pub-id-type="pmid">9933596</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neufert</surname> <given-names>C</given-names></name><name><surname>Becker</surname> <given-names>C</given-names></name><name><surname>Wirtz</surname> <given-names>S</given-names></name><name><surname>Fantini</surname> <given-names>MC</given-names></name><name><surname>Weigmann</surname> <given-names>B</given-names></name><name><surname>Galle</surname> <given-names>PR</given-names></name><name><surname>Neurath</surname> <given-names>MF</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1</article-title><source>European Journal of Immunology</source><volume>37</volume><fpage>1809</fpage><lpage>1816</lpage><pub-id pub-id-type="doi">10.1002/eji.200636896</pub-id><pub-id pub-id-type="pmid">17549733</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Hagan</surname> <given-names>KL</given-names></name><name><surname>Miller</surname> <given-names>SD</given-names></name><name><surname>Phee</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Pak2 is essential for the function of Foxp3+ regulatory T cells through maintaining a suppressive treg phenotype</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>17097</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-17078-7</pub-id><pub-id pub-id-type="pmid">29213081</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Shea</surname> <given-names>JJ</given-names></name><name><surname>Plenge</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>JAK and STAT signaling molecules in Immunoregulation and immune-mediated disease</article-title><source>Immunity</source><volume>36</volume><fpage>542</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.03.014</pub-id><pub-id pub-id-type="pmid">22520847</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oberg</surname> <given-names>HH</given-names></name><name><surname>Wesch</surname> <given-names>D</given-names></name><name><surname>Grüssel</surname> <given-names>S</given-names></name><name><surname>Rose-John</surname> <given-names>S</given-names></name><name><surname>Kabelitz</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+CD25- and CD25high regulatory T cells</article-title><source>International Immunology</source><volume>18</volume><fpage>555</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxh396</pub-id><pub-id pub-id-type="pmid">16540526</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oniki</surname> <given-names>S</given-names></name><name><surname>Nagai</surname> <given-names>H</given-names></name><name><surname>Horikawa</surname> <given-names>T</given-names></name><name><surname>Furukawa</surname> <given-names>J</given-names></name><name><surname>Belladonna</surname> <given-names>ML</given-names></name><name><surname>Yoshimoto</surname> <given-names>T</given-names></name><name><surname>Hara</surname> <given-names>I</given-names></name><name><surname>Nishigori</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma</article-title><source>Cancer Research</source><volume>66</volume><fpage>6395</fpage><lpage>6404</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4087</pub-id><pub-id pub-id-type="pmid">16778218</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owaki</surname> <given-names>T</given-names></name><name><surname>Asakawa</surname> <given-names>M</given-names></name><name><surname>Morishima</surname> <given-names>N</given-names></name><name><surname>Mizoguchi</surname> <given-names>I</given-names></name><name><surname>Fukai</surname> <given-names>F</given-names></name><name><surname>Takeda</surname> <given-names>K</given-names></name><name><surname>Mizuguchi</surname> <given-names>J</given-names></name><name><surname>Yoshimoto</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>STAT3 is indispensable to IL-27-mediated cell proliferation but not to IL-27-induced Th1 differentiation and suppression of proinflammatory cytokine production</article-title><source>The Journal of Immunology</source><volume>180</volume><fpage>2903</fpage><lpage>2911</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.5.2903</pub-id><pub-id pub-id-type="pmid">18292512</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petretto</surname> <given-names>A</given-names></name><name><surname>Carbotti</surname> <given-names>G</given-names></name><name><surname>Inglese</surname> <given-names>E</given-names></name><name><surname>Lavarello</surname> <given-names>C</given-names></name><name><surname>Pistillo</surname> <given-names>MP</given-names></name><name><surname>Rigo</surname> <given-names>V</given-names></name><name><surname>Croce</surname> <given-names>M</given-names></name><name><surname>Longo</surname> <given-names>L</given-names></name><name><surname>Martini</surname> <given-names>S</given-names></name><name><surname>Vacca</surname> <given-names>P</given-names></name><name><surname>Ferrini</surname> <given-names>S</given-names></name><name><surname>Fabbi</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Proteomic analysis uncovers common effects of IFN-γ and IL-27 on the HLA class I antigen presentation machinery in human Cancer cells</article-title><source>Oncotarget</source><volume>7</volume><fpage>72518</fpage><lpage>72536</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.12235</pub-id><pub-id pub-id-type="pmid">27683036</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pflanz</surname> <given-names>S</given-names></name><name><surname>Timans</surname> <given-names>JC</given-names></name><name><surname>Cheung</surname> <given-names>J</given-names></name><name><surname>Rosales</surname> <given-names>R</given-names></name><name><surname>Kanzler</surname> <given-names>H</given-names></name><name><surname>Gilbert</surname> <given-names>J</given-names></name><name><surname>Hibbert</surname> <given-names>L</given-names></name><name><surname>Churakova</surname> <given-names>T</given-names></name><name><surname>Travis</surname> <given-names>M</given-names></name><name><surname>Vaisberg</surname> <given-names>E</given-names></name><name><surname>Blumenschein</surname> <given-names>WM</given-names></name><name><surname>Mattson</surname> <given-names>JD</given-names></name><name><surname>Wagner</surname> <given-names>JL</given-names></name><name><surname>To</surname> <given-names>W</given-names></name><name><surname>Zurawski</surname> <given-names>S</given-names></name><name><surname>McClanahan</surname> <given-names>TK</given-names></name><name><surname>Gorman</surname> <given-names>DM</given-names></name><name><surname>Bazan</surname> <given-names>JF</given-names></name><name><surname>de Waal Malefyt</surname> <given-names>R</given-names></name><name><surname>Rennick</surname> <given-names>D</given-names></name><name><surname>Kastelein</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells</article-title><source>Immunity</source><volume>16</volume><fpage>779</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(02)00324-2</pub-id><pub-id pub-id-type="pmid">12121660</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pflanz</surname> <given-names>S</given-names></name><name><surname>Hibbert</surname> <given-names>L</given-names></name><name><surname>Mattson</surname> <given-names>J</given-names></name><name><surname>Rosales</surname> <given-names>R</given-names></name><name><surname>Vaisberg</surname> <given-names>E</given-names></name><name><surname>Bazan</surname> <given-names>JF</given-names></name><name><surname>Phillips</surname> <given-names>JH</given-names></name><name><surname>McClanahan</surname> <given-names>TK</given-names></name><name><surname>de Waal Malefyt</surname> <given-names>R</given-names></name><name><surname>Kastelein</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>WSX-1 and glycoprotein 130 constitute a Signal-Transducing receptor for IL-27</article-title><source>The Journal of Immunology</source><volume>172</volume><fpage>2225</fpage><lpage>2231</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.4.2225</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pot</surname> <given-names>C</given-names></name><name><surname>Apetoh</surname> <given-names>L</given-names></name><name><surname>Awasthi</surname> <given-names>A</given-names></name><name><surname>Kuchroo</surname> <given-names>VK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27</article-title><source>Seminars in Immunology</source><volume>23</volume><fpage>438</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2011.08.003</pub-id><pub-id pub-id-type="pmid">21893418</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pradhan</surname> <given-names>A</given-names></name><name><surname>Lambert</surname> <given-names>QT</given-names></name><name><surname>Griner</surname> <given-names>LN</given-names></name><name><surname>Reuther</surname> <given-names>GW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Activation of JAK2-V617F by components of heterodimeric cytokine receptors</article-title><source>Journal of Biological Chemistry</source><volume>285</volume><fpage>16651</fpage><lpage>16663</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.071191</pub-id><pub-id pub-id-type="pmid">20363735</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regis</surname> <given-names>G</given-names></name><name><surname>Pensa</surname> <given-names>S</given-names></name><name><surname>Boselli</surname> <given-names>D</given-names></name><name><surname>Novelli</surname> <given-names>F</given-names></name><name><surname>Poli</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Ups and downs: the STAT1:stat3 seesaw of interferon and gp130 receptor signalling</article-title><source>Seminars in Cell &amp; Developmental Biology</source><volume>19</volume><fpage>351</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2008.06.004</pub-id><pub-id pub-id-type="pmid">18620071</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richter</surname> <given-names>D</given-names></name><name><surname>Moraga</surname> <given-names>I</given-names></name><name><surname>Winkelmann</surname> <given-names>H</given-names></name><name><surname>Birkholz</surname> <given-names>O</given-names></name><name><surname>Wilmes</surname> <given-names>S</given-names></name><name><surname>Schulte</surname> <given-names>M</given-names></name><name><surname>Kraich</surname> <given-names>M</given-names></name><name><surname>Kenneweg</surname> <given-names>H</given-names></name><name><surname>Beutel</surname> <given-names>O</given-names></name><name><surname>Selenschik</surname> <given-names>P</given-names></name><name><surname>Paterok</surname> <given-names>D</given-names></name><name><surname>Gavutis</surname> <given-names>M</given-names></name><name><surname>Schmidt</surname> <given-names>T</given-names></name><name><surname>Garcia</surname> <given-names>KC</given-names></name><name><surname>Müller</surname> <given-names>TD</given-names></name><name><surname>Piehler</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ligand-induced type II interleukin-4 receptor dimers are sustained by rapid re-association within plasma membrane microcompartments</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>15976</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms15976</pub-id><pub-id pub-id-type="pmid">28706306</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Röder</surname> <given-names>F</given-names></name><name><surname>Lubk</surname> <given-names>A</given-names></name><name><surname>Wolf</surname> <given-names>D</given-names></name><name><surname>Niermann</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Noise estimation for off-axis electron holography</article-title><source>Ultramicroscopy</source><volume>144</volume><fpage>32</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.ultramic.2014.04.002</pub-id><pub-id pub-id-type="pmid">24821224</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolvering</surname> <given-names>C</given-names></name><name><surname>Zimmer</surname> <given-names>AD</given-names></name><name><surname>Kozar</surname> <given-names>I</given-names></name><name><surname>Hermanns</surname> <given-names>HM</given-names></name><name><surname>Letellier</surname> <given-names>E</given-names></name><name><surname>Vallar</surname> <given-names>L</given-names></name><name><surname>Nazarov</surname> <given-names>PV</given-names></name><name><surname>Nicot</surname> <given-names>N</given-names></name><name><surname>Ginolhac</surname> <given-names>A</given-names></name><name><surname>Haan</surname> <given-names>S</given-names></name><name><surname>Behrmann</surname> <given-names>I</given-names></name><name><surname>Haan</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Crosstalk between different family members: il27 recapitulates ifnγ responses in HCC cells, but is inhibited by IL6-type cytokines</article-title><source>Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research</source><volume>1864</volume><fpage>516</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2016.12.006</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose-John</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Interleukin-6 family cytokines</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>10</volume><elocation-id>a028415</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a028415</pub-id><pub-id pub-id-type="pmid">28620096</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ruprecht</surname> <given-names>V</given-names></name><name><surname>Weghuber</surname> <given-names>J</given-names></name><name><surname>Wieser</surname> <given-names>S</given-names></name><name><surname>Schütz</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><source>Advances in Planar Lipid Bilayers and Liposomes</source><publisher-loc>Amsterdam, Netherlands</publisher-loc><publisher-name>Elsevier</publisher-name></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rusinova</surname> <given-names>I</given-names></name><name><surname>Forster</surname> <given-names>S</given-names></name><name><surname>Yu</surname> <given-names>S</given-names></name><name><surname>Kannan</surname> <given-names>A</given-names></name><name><surname>Masse</surname> <given-names>M</given-names></name><name><surname>Cumming</surname> <given-names>H</given-names></name><name><surname>Chapman</surname> <given-names>R</given-names></name><name><surname>Hertzog</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Interferome v2.0: an updated database of annotated interferon-regulated genes</article-title><source>Nucleic Acids Research</source><volume>41</volume><fpage>D1040</fpage><lpage>D1046</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1215</pub-id><pub-id pub-id-type="pmid">23203888</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutz</surname> <given-names>S</given-names></name><name><surname>Kayagaki</surname> <given-names>N</given-names></name><name><surname>Phung</surname> <given-names>QT</given-names></name><name><surname>Eidenschenk</surname> <given-names>C</given-names></name><name><surname>Noubade</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Lesch</surname> <given-names>J</given-names></name><name><surname>Lu</surname> <given-names>R</given-names></name><name><surname>Newton</surname> <given-names>K</given-names></name><name><surname>Huang</surname> <given-names>OW</given-names></name><name><surname>Cochran</surname> <given-names>AG</given-names></name><name><surname>Vasser</surname> <given-names>M</given-names></name><name><surname>Fauber</surname> <given-names>BP</given-names></name><name><surname>DeVoss</surname> <given-names>J</given-names></name><name><surname>Webster</surname> <given-names>J</given-names></name><name><surname>Diehl</surname> <given-names>L</given-names></name><name><surname>Modrusan</surname> <given-names>Z</given-names></name><name><surname>Kirkpatrick</surname> <given-names>DS</given-names></name><name><surname>Lill</surname> <given-names>JR</given-names></name><name><surname>Ouyang</surname> <given-names>W</given-names></name><name><surname>Dixit</surname> <given-names>VM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Deubiquitinase DUBA is a post-translational Brake on interleukin-17 production in T cells</article-title><source>Nature</source><volume>518</volume><fpage>417</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/nature13979</pub-id><pub-id pub-id-type="pmid">25470037</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname> <given-names>J</given-names></name><name><surname>Tabunoki</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A comprehensive profile of ChIP-Seq-Based STAT1 target genes suggests the complexity of STAT1-Mediated gene regulatory mechanisms</article-title><source>Gene Regulation and Systems Biology</source><volume>7</volume><fpage>GRSB.S11433</fpage><lpage>.11456</lpage><pub-id pub-id-type="doi">10.4137/GRSB.S11433</pub-id><pub-id pub-id-type="pmid">23645984</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname> <given-names>J</given-names></name><name><surname>Weissenbach</surname> <given-names>M</given-names></name><name><surname>Haan</surname> <given-names>S</given-names></name><name><surname>Heinrich</surname> <given-names>PC</given-names></name><name><surname>Schaper</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130</article-title><source>Journal of Biological Chemistry</source><volume>275</volume><fpage>12848</fpage><lpage>12856</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.17.12848</pub-id><pub-id pub-id-type="pmid">10777583</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sergé</surname> <given-names>A</given-names></name><name><surname>Bertaux</surname> <given-names>N</given-names></name><name><surname>Rigneault</surname> <given-names>H</given-names></name><name><surname>Marguet</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Dynamic multiple-target tracing to probe spatiotemporal cartography of cell membranes</article-title><source>Nature Methods</source><volume>5</volume><fpage>687</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1233</pub-id><pub-id pub-id-type="pmid">18604216</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharif</surname> <given-names>MN</given-names></name><name><surname>Tassiulas</surname> <given-names>I</given-names></name><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Mecklenbräuker</surname> <given-names>I</given-names></name><name><surname>Tarakhovsky</surname> <given-names>A</given-names></name><name><surname>Ivashkiv</surname> <given-names>LB</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis</article-title><source>The Journal of Immunology</source><volume>172</volume><fpage>6476</fpage><lpage>6481</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.10.6476</pub-id><pub-id pub-id-type="pmid">15128840</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slenter</surname> <given-names>DN</given-names></name><name><surname>Kutmon</surname> <given-names>M</given-names></name><name><surname>Hanspers</surname> <given-names>K</given-names></name><name><surname>Riutta</surname> <given-names>A</given-names></name><name><surname>Windsor</surname> <given-names>J</given-names></name><name><surname>Nunes</surname> <given-names>N</given-names></name><name><surname>Mélius</surname> <given-names>J</given-names></name><name><surname>Cirillo</surname> <given-names>E</given-names></name><name><surname>Coort</surname> <given-names>SL</given-names></name><name><surname>Digles</surname> <given-names>D</given-names></name><name><surname>Ehrhart</surname> <given-names>F</given-names></name><name><surname>Giesbertz</surname> <given-names>P</given-names></name><name><surname>Kalafati</surname> <given-names>M</given-names></name><name><surname>Martens</surname> <given-names>M</given-names></name><name><surname>Miller</surname> <given-names>R</given-names></name><name><surname>Nishida</surname> <given-names>K</given-names></name><name><surname>Rieswijk</surname> <given-names>L</given-names></name><name><surname>Waagmeester</surname> <given-names>A</given-names></name><name><surname>Eijssen</surname> <given-names>LMT</given-names></name><name><surname>Evelo</surname> <given-names>CT</given-names></name><name><surname>Pico</surname> <given-names>AR</given-names></name><name><surname>Willighagen</surname> <given-names>EL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>D661</fpage><lpage>D667</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1064</pub-id><pub-id pub-id-type="pmid">29136241</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spangler</surname> <given-names>JB</given-names></name><name><surname>Moraga</surname> <given-names>I</given-names></name><name><surname>Jude</surname> <given-names>KM</given-names></name><name><surname>Savvides</surname> <given-names>CS</given-names></name><name><surname>Garcia</surname> <given-names>KC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A strategy for the selection of monovalent antibodies that span protein dimer interfaces</article-title><source>Journal of Biological Chemistry</source><volume>294</volume><fpage>13876</fpage><lpage>13886</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.009213</pub-id><pub-id pub-id-type="pmid">31387945</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stumhofer</surname> <given-names>JS</given-names></name><name><surname>Laurence</surname> <given-names>A</given-names></name><name><surname>Wilson</surname> <given-names>EH</given-names></name><name><surname>Huang</surname> <given-names>E</given-names></name><name><surname>Tato</surname> <given-names>CM</given-names></name><name><surname>Johnson</surname> <given-names>LM</given-names></name><name><surname>Villarino</surname> <given-names>AV</given-names></name><name><surname>Huang</surname> <given-names>Q</given-names></name><name><surname>Yoshimura</surname> <given-names>A</given-names></name><name><surname>Sehy</surname> <given-names>D</given-names></name><name><surname>Saris</surname> <given-names>CJ</given-names></name><name><surname>O'Shea</surname> <given-names>JJ</given-names></name><name><surname>Hennighausen</surname> <given-names>L</given-names></name><name><surname>Ernst</surname> <given-names>M</given-names></name><name><surname>Hunter</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system</article-title><source>Nature Immunology</source><volume>7</volume><fpage>937</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1038/ni1376</pub-id><pub-id pub-id-type="pmid">16906166</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stumhofer</surname> <given-names>JS</given-names></name><name><surname>Silver</surname> <given-names>JS</given-names></name><name><surname>Laurence</surname> <given-names>A</given-names></name><name><surname>Porrett</surname> <given-names>PM</given-names></name><name><surname>Harris</surname> <given-names>TH</given-names></name><name><surname>Turka</surname> <given-names>LA</given-names></name><name><surname>Ernst</surname> <given-names>M</given-names></name><name><surname>Saris</surname> <given-names>CJ</given-names></name><name><surname>O'Shea</surname> <given-names>JJ</given-names></name><name><surname>Hunter</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10</article-title><source>Nature Immunology</source><volume>8</volume><fpage>1363</fpage><lpage>1371</lpage><pub-id pub-id-type="doi">10.1038/ni1537</pub-id><pub-id pub-id-type="pmid">17994025</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suh</surname> <given-names>HN</given-names></name><name><surname>Lee</surname> <given-names>SH</given-names></name><name><surname>Lee</surname> <given-names>MY</given-names></name><name><surname>Lee</surname> <given-names>YJ</given-names></name><name><surname>Lee</surname> <given-names>JH</given-names></name><name><surname>Han</surname> <given-names>HJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Role of interleukin-6 in the control of DNA synthesis of hepatocytes: involvement of PKC, p44/42 MAPKs, and PPARdelta</article-title><source>Cellular Physiology and Biochemistry</source><volume>22</volume><fpage>673</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1159/000185551</pub-id><pub-id pub-id-type="pmid">19088449</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunnåker</surname> <given-names>M</given-names></name><name><surname>Busetto</surname> <given-names>AG</given-names></name><name><surname>Numminen</surname> <given-names>E</given-names></name><name><surname>Corander</surname> <given-names>J</given-names></name><name><surname>Foll</surname> <given-names>M</given-names></name><name><surname>Dessimoz</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Approximate bayesian computation</article-title><source>PLOS Computational Biology</source><volume>9</volume><elocation-id>e1002803</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1002803</pub-id><pub-id pub-id-type="pmid">23341757</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname> <given-names>A</given-names></name><name><surname>Hamano</surname> <given-names>S</given-names></name><name><surname>Yamanaka</surname> <given-names>A</given-names></name><name><surname>Hanada</surname> <given-names>T</given-names></name><name><surname>Ishibashi</surname> <given-names>T</given-names></name><name><surname>Mak</surname> <given-names>TW</given-names></name><name><surname>Yoshimura</surname> <given-names>A</given-names></name><name><surname>Yoshida</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment</article-title><source>The Journal of Immunology</source><volume>170</volume><fpage>4886</fpage><lpage>4890</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.170.10.4886</pub-id><pub-id pub-id-type="pmid">12734330</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokuyama</surname> <given-names>M</given-names></name><name><surname>Kong</surname> <given-names>Y</given-names></name><name><surname>Song</surname> <given-names>E</given-names></name><name><surname>Jayewickreme</surname> <given-names>T</given-names></name><name><surname>Kang</surname> <given-names>I</given-names></name><name><surname>Iwasaki</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ERVmap analysis reveals genome-wide transcription of human endogenous retroviruses</article-title><source>PNAS</source><volume>115</volume><fpage>12565</fpage><lpage>12572</lpage><pub-id pub-id-type="doi">10.1073/pnas.1814589115</pub-id><pub-id pub-id-type="pmid">30455304</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toni</surname> <given-names>T</given-names></name><name><surname>Welch</surname> <given-names>D</given-names></name><name><surname>Strelkowa</surname> <given-names>N</given-names></name><name><surname>Ipsen</surname> <given-names>A</given-names></name><name><surname>Stumpf</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Approximate bayesian computation scheme for parameter inference and model selection in dynamical systems</article-title><source>Journal of the Royal Society Interface</source><volume>6</volume><fpage>187</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1098/rsif.2008.0172</pub-id><pub-id pub-id-type="pmid">19205079</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twohig</surname> <given-names>JP</given-names></name><name><surname>Cardus Figueras</surname> <given-names>A</given-names></name><name><surname>Andrews</surname> <given-names>R</given-names></name><name><surname>Wiede</surname> <given-names>F</given-names></name><name><surname>Cossins</surname> <given-names>BC</given-names></name><name><surname>Derrac Soria</surname> <given-names>A</given-names></name><name><surname>Lewis</surname> <given-names>MJ</given-names></name><name><surname>Townsend</surname> <given-names>MJ</given-names></name><name><surname>Millrine</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Hill</surname> <given-names>DG</given-names></name><name><surname>Uceda Fernandez</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Szomolay</surname> <given-names>B</given-names></name><name><surname>Pepper</surname> <given-names>CJ</given-names></name><name><surname>Taylor</surname> <given-names>PR</given-names></name><name><surname>Pitzalis</surname> <given-names>C</given-names></name><name><surname>Tiganis</surname> <given-names>T</given-names></name><name><surname>Williams</surname> <given-names>NM</given-names></name><name><surname>Jones</surname> <given-names>GW</given-names></name><name><surname>Jones</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Activation of naïve CD4<sup>+</sup> T cells re-tunes STAT1 signaling to deliver unique cytokine responses in memory CD4<sup>+</sup> T cells</article-title><source>Nature Immunology</source><volume>20</volume><fpage>458</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0350-0</pub-id><pub-id pub-id-type="pmid">30890796</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umeshita-Suyama</surname> <given-names>R</given-names></name><name><surname>Sugimoto</surname> <given-names>R</given-names></name><name><surname>Akaiwa</surname> <given-names>M</given-names></name><name><surname>Arima</surname> <given-names>K</given-names></name><name><surname>Yu</surname> <given-names>B</given-names></name><name><surname>Wada</surname> <given-names>M</given-names></name><name><surname>Kuwano</surname> <given-names>M</given-names></name><name><surname>Nakajima</surname> <given-names>K</given-names></name><name><surname>Hamasaki</surname> <given-names>N</given-names></name><name><surname>Izuhara</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Characterization of IL-4 and IL-13 signals dependent on the human IL-13 receptor alpha chain 1: redundancy of requirement of tyrosine residue for STAT3 activation</article-title><source>International Immunology</source><volume>12</volume><fpage>1499</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.1093/intimm/12.11.1499</pub-id><pub-id pub-id-type="pmid">11058569</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villarino</surname> <given-names>AV</given-names></name><name><surname>Stumhofer</surname> <given-names>JS</given-names></name><name><surname>Saris</surname> <given-names>CJM</given-names></name><name><surname>Kastelein</surname> <given-names>RA</given-names></name><name><surname>de Sauvage</surname> <given-names>FJ</given-names></name><name><surname>Hunter</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>IL-27 limits IL-2 production during Th1 differentiation</article-title><source>The Journal of Immunology</source><volume>176</volume><fpage>237</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.1.237</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelsang</surname> <given-names>J</given-names></name><name><surname>Kasper</surname> <given-names>R</given-names></name><name><surname>Steinhauer</surname> <given-names>C</given-names></name><name><surname>Person</surname> <given-names>B</given-names></name><name><surname>Heilemann</surname> <given-names>M</given-names></name><name><surname>Sauer</surname> <given-names>M</given-names></name><name><surname>Tinnefeld</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A reducing and oxidizing system minimizes photobleaching and blinking of fluorescent dyes</article-title><source>Angewandte Chemie International Edition</source><volume>47</volume><fpage>5465</fpage><lpage>5469</lpage><pub-id pub-id-type="doi">10.1002/anie.200801518</pub-id><pub-id pub-id-type="pmid">18601270</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiederkehr-Adam</surname> <given-names>M</given-names></name><name><surname>Ernst</surname> <given-names>P</given-names></name><name><surname>Müller</surname> <given-names>K</given-names></name><name><surname>Bieck</surname> <given-names>E</given-names></name><name><surname>Gombert</surname> <given-names>FO</given-names></name><name><surname>Ottl</surname> <given-names>J</given-names></name><name><surname>Graff</surname> <given-names>P</given-names></name><name><surname>Grossmüller</surname> <given-names>F</given-names></name><name><surname>Heim</surname> <given-names>MH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Characterization of phosphopeptide motifs specific for the src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3</article-title><source>Journal of Biological Chemistry</source><volume>278</volume><fpage>16117</fpage><lpage>16128</lpage><pub-id pub-id-type="doi">10.1074/jbc.M300261200</pub-id><pub-id pub-id-type="pmid">12591923</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilmes</surname> <given-names>S</given-names></name><name><surname>Beutel</surname> <given-names>O</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Francois-Newton</surname> <given-names>V</given-names></name><name><surname>Richter</surname> <given-names>CP</given-names></name><name><surname>Janning</surname> <given-names>D</given-names></name><name><surname>Kroll</surname> <given-names>C</given-names></name><name><surname>Hanhart</surname> <given-names>P</given-names></name><name><surname>Hötte</surname> <given-names>K</given-names></name><name><surname>You</surname> <given-names>C</given-names></name><name><surname>Uzé</surname> <given-names>G</given-names></name><name><surname>Pellegrini</surname> <given-names>S</given-names></name><name><surname>Piehler</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling</article-title><source>Journal of Cell Biology</source><volume>209</volume><fpage>579</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1083/jcb.201412049</pub-id><pub-id pub-id-type="pmid">26008745</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilmes</surname> <given-names>S</given-names></name><name><surname>Hafer</surname> <given-names>M</given-names></name><name><surname>Vuorio</surname> <given-names>J</given-names></name><name><surname>Tucker</surname> <given-names>JA</given-names></name><name><surname>Winkelmann</surname> <given-names>H</given-names></name><name><surname>Löchte</surname> <given-names>S</given-names></name><name><surname>Stanly</surname> <given-names>TA</given-names></name><name><surname>Pulgar Prieto</surname> <given-names>KD</given-names></name><name><surname>Poojari</surname> <given-names>C</given-names></name><name><surname>Sharma</surname> <given-names>V</given-names></name><name><surname>Richter</surname> <given-names>CP</given-names></name><name><surname>Kurre</surname> <given-names>R</given-names></name><name><surname>Hubbard</surname> <given-names>SR</given-names></name><name><surname>Garcia</surname> <given-names>KC</given-names></name><name><surname>Moraga</surname> <given-names>I</given-names></name><name><surname>Vattulainen</surname> <given-names>I</given-names></name><name><surname>Hitchcock</surname> <given-names>IS</given-names></name><name><surname>Piehler</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations</article-title><source>Science</source><volume>367</volume><fpage>643</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1126/science.aaw3242</pub-id><pub-id pub-id-type="pmid">32029621</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Wilmes</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Cytokine_modelling</data-title><source>Software Heritage</source><version designator="swh:1:rev:9c3e0ddc7a96eac941baad560d1541d660b0515d">swh:1:rev:9c3e0ddc7a96eac941baad560d1541d660b0515d</version><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:rev:9c3e0ddc7a96eac941baad560d1541d660b0515d">https://archive.softwareheritage.org/swh:1:rev:9c3e0ddc7a96eac941baad560d1541d660b0515d</ext-link></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname> <given-names>LH</given-names></name><name><surname>Hatzinisiriou</surname> <given-names>I</given-names></name><name><surname>Devenish</surname> <given-names>RJ</given-names></name><name><surname>Ralph</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>IFN-gamma priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs</article-title><source>Journal of Immunology</source><volume>160</volume><fpage>5475</fpage><lpage>5484</lpage><pub-id pub-id-type="pmid">9605150</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasukawa</surname> <given-names>H</given-names></name><name><surname>Ohishi</surname> <given-names>M</given-names></name><name><surname>Mori</surname> <given-names>H</given-names></name><name><surname>Murakami</surname> <given-names>M</given-names></name><name><surname>Chinen</surname> <given-names>T</given-names></name><name><surname>Aki</surname> <given-names>D</given-names></name><name><surname>Hanada</surname> <given-names>T</given-names></name><name><surname>Takeda</surname> <given-names>K</given-names></name><name><surname>Akira</surname> <given-names>S</given-names></name><name><surname>Hoshijima</surname> <given-names>M</given-names></name><name><surname>Hirano</surname> <given-names>T</given-names></name><name><surname>Chien</surname> <given-names>KR</given-names></name><name><surname>Yoshimura</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages</article-title><source>Nature Immunology</source><volume>4</volume><fpage>551</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1038/ni938</pub-id><pub-id pub-id-type="pmid">12754507</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>DZ</given-names></name><name><surname>Field</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>PAK signaling in cancer</article-title><source>Cellular Logistics</source><volume>2</volume><fpage>105</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.4161/cl.21882</pub-id><pub-id pub-id-type="pmid">23162742</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname> <given-names>H</given-names></name><name><surname>Hunter</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The immunobiology of interleukin-27</article-title><source>Annual Review of Immunology</source><volume>33</volume><fpage>417</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032414-112134</pub-id><pub-id pub-id-type="pmid">25861977</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshimura</surname> <given-names>A</given-names></name><name><surname>Wakabayashi</surname> <given-names>Y</given-names></name><name><surname>Mori</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cellular and molecular basis for the regulation of inflammation by TGF-beta</article-title><source>Journal of Biochemistry</source><volume>147</volume><fpage>781</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1093/jb/mvq043</pub-id><pub-id pub-id-type="pmid">20410014</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname> <given-names>C</given-names></name><name><surname>Marquez-Lago</surname> <given-names>TT</given-names></name><name><surname>Richter</surname> <given-names>CP</given-names></name><name><surname>Wilmes</surname> <given-names>S</given-names></name><name><surname>Moraga</surname> <given-names>I</given-names></name><name><surname>Garcia</surname> <given-names>KC</given-names></name><name><surname>Leier</surname> <given-names>A</given-names></name><name><surname>Piehler</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Receptor dimer stabilization by hierarchical plasma membrane microcompartments regulates cytokine signaling</article-title><source>Science Advances</source><volume>2</volume><elocation-id>e1600452</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.1600452</pub-id><pub-id pub-id-type="pmid">27957535</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zenke</surname> <given-names>K</given-names></name><name><surname>Muroi</surname> <given-names>M</given-names></name><name><surname>Tanamoto</surname> <given-names>KI</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>IRF1 supports DNA binding of STAT1 by promoting its phosphorylation</article-title><source>Immunology and Cell Biology</source><volume>96</volume><fpage>1095</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1111/imcb.12185</pub-id><pub-id pub-id-type="pmid">29893425</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.66014.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Graw</surname><given-names>Frederik</given-names></name><role>Reviewing Editor</role><aff><institution>Heidelberg University</institution><country>Germany</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Thurley</surname><given-names>Kevin</given-names> </name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/10.1101/2021.01.08.425379">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.01.08.425379v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This study is a great example of an elaborated combination of experimental and mathematical analyses to examine an intriguing, pleiotropic immunological signaling pathway. While a good number of individual aspects of this signaling pathway have been studied and reported before, the presented work puzzles together many pieces and succeeds to present a conclusive and comprehensive model of this particular cytokine system. The main conclusions are well supported by the presented data and the manuscript will be of interest and relevance for the study of many other cytokine signaling pathways, being of broad relevance for immunologists and cell biologists.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses in autoimmunity&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Jos van der Meer as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Kevin Thurley (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential Revisions:</p><p>All reviewers appreciated the elaborated and thorough analyses presented in this paper. Given this exhaustive amount of work leading to this comprehensive analyses, all reviewers also noticed that the paper is very complex and extensive. To help the reader focus, they recommend to re-think if some material and text could not be shortened or shifted to the discussion or supplement.</p><p>The detailed comments below address some specific points that the reviewers noted. In particular this addresses the following main points:</p><p>1. Please reconsider the title of the manuscript, as focusing on autoimmunity does not seem to fully capture your work</p><p>2. Some aspects regarding the statistical analyses and the mathematical modeling (e.g. hypotheses considerations) need to be explained in more detail and clarified.</p><p>3. Please consider to show a full characterization of the RPE1-cells that were used (see comment Reviewer 3)</p><p><italic>Reviewer #1 (Recommendations for authors):</italic></p><p>– Combining the mathematical model with the experimental data, a Bayesian Model selection and parameter inference approach is used to select between two model hypothesis and, later on, perform parameter estimation. It is not totally clear to me how an upfront Bayesian model selection can be done without addressing the issue of parameter inference. Therefore, shouldn't the comparison of the two model hypotheses not also been applied to the Th1-cell dataset, and not only the RPE1?</p><p>– (Figure 2c): The measurement of IL-27 at 30 minutes for REP1 and Th1 does not seem to contain any statistical variation. This also seems to force the model to match this data point for any parameter combination. What is the reason that there is no variation within this data point? As this also seems to be a critical point for differences between the dynamics caused by the two cytokines, would model predictions change if e.g. random variation is added to this data point?</p><p>– It is indicated in the text that the parameter inference by approximate Bayesian computation revealed statistically significant differences between the binding rates of certain receptors/molecular (p.7 top). Could you comment on the statistical tests used to compare the posterior distributions of the respective parameters to make this claim? The posterior distributions nicely show a deviation of the parameter estimates from the uniform prior distributions. However, especially in case of multi-parametric and high-dimensional models as here, there can still be the problem of correlating individual parameter estimates inhibiting parameter identifiability. To which extent are individual parameter estimates correlated within the accepted parameter combinations? In addition, more details on the ABC-approach should be given algorithm/software used, required number of particles accepted, possible number of runs (i.e., updating prior distribution by found posterior).</p><p><italic>Reviewer #3 (Recommendations for authors):</italic>I commend the authors for an exhaustive amount of work on this exciting signaling pathway. I would like to focus on a few points now that I have a slightly more critical view on.1. Most individual findings have been reported before (or at least there have been indications). Understandably, this makes defining a clear punch line difficult, but honestly, focussing on &quot;autoimmune diseases&quot; already in the title to me appears a bit farfetched. The SLE aspect is only touched upon in the manuscript, and it is neither very informative nor central to the story. It is good to have it in, just to illustrate natural conditions in which altered STAT levels shapes cytokine responses, but it clearly should not be the selling point.</p><p>2. An aspect that I furthermore miss in the introduction and discussion part is the fact, that basically all cytokine receptor systems appear to have a rather strong preference for certain STATs. It appears rather trivial that different receptors / receptor chains will have different affinities for the different STATs and this has been addressed in a few studies previously (e.g. STAT1, STAT3 in ref. 42), or STAT2 in IFNAR1 in PMID:8605876. The present manuscript arrived at the conclusion of differing affinities of STAT1 and STAT3 for GP130 and IL-27Ra by rather intricate modeling approaches and confirms this biochemically. This is OK, but I find it a bit disconcerting that this is sold as a fascinating new finding, while I would say it is the most expected explanation. I dint want to diminish this achievement, just strongly suggest toning this down a bit and, most importantly, add a few words on the known and suspected differential affinities of the various STATs to cytokine receptors in general.</p><p>3. In Figure 1d, GP130 was over expressed in RPE1 cells and the authors' conclusion was that GP130 levels do not contribute to sustained pSTAT1. In fact, Figure 1d does look as if pSTAT1 <italic>is</italic> sustained; particularly when you compared to the normalized plot of Th1 cells in Suppl Figure 1c, where the authors mark this difference even in red with δ signs. It would be very interesting to know if 10xGP130 cells stimulated with (Typ)IL-6 would now also show enhanced expression of IRF1 and a second wave of transcription?</p><p>4. I would recommend the authors to show a full characterization of the RPE1 cells they use (e.g. for model parameterization and most further experiments) analogously to Th1 cells in Figure 1b and c (i.e. in terms of IL-27 vs IL-6 signaling) in one comprehensive supplementary figure. Suppl. Figure 4 goes in that direction, but it would be good to have this in the beginning (before the modeling) and in an identical fashion to the Th1 experiment. Please further make sure to identify more clearly (in text and/or legends or even figure labels) which cells were used in which experiment (e.g. &quot;RPE1-IL-27Ra&quot; or &quot;RPE1-IL-27-Ra/GP130&quot;).</p><p>5. In the modeling figure, Figure 2c, I assume the Y-axes labels were swapped? If not, this needs to be explained!</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.66014.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential Revisions:</p><p>All reviewers appreciated the elaborated and thorough analyses presented in this paper. Given this exhaustive amount of work leading to this comprehensive analyses, all reviewers also noticed that the paper is very complex and extensive. To help the reader focus, they recommend to re-think if some material and text could not be shortened or shifted to the discussion or supplement.</p><p>The detailed comments below address some specific points that the reviewers noted. In particular this addresses the following main points:</p><p>1. Please reconsider the title of the manuscript, as focusing on autoimmunity does not seem to fully capture your work</p><p>2. Some aspects regarding the statistical analyses and the mathematical modeling (e.g. hypotheses considerations) need to be explained in more detail and clarified.</p><p>3. Please consider to show a full characterization of the RPE1-cells that were used (see comment Reviewer 3)</p></disp-quote><p>We thank the reviewers for their very positive comments. Following their advice, we have modified the title of the manuscript, provided a more detailed description of the mathematical model and consolidated all data characterizing RPE1 cells to the same Supplementary Figure 2. Additionally, we have moved Figure 6 to Supp. Figure 11 to streamline the text and simplify the manuscript. Please find below our answers to the specific comments raised by the reviewers.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for authors):</p><p>– Combining the mathematical model with the experimental data, a Bayesian Model selection and parameter inference approach is used to select between two model hypothesis and, later on, perform parameter estimation. It is not totally clear to me how an upfront Bayesian model selection can be done without addressing the issue of parameter inference. Therefore, shouldn't the comparison of the two model hypotheses not also been applied to the Th1-cell dataset, and not only the RPE1?</p></disp-quote><p>As the reviewer implies, mathematical model selection and parameter estimation are carried out in parallel. We have clarified this issue and the details of the analysis in the Materials and methods, Bayesian inference section. We chose to carry out the Bayesian inference sequentially, i.e., in RPE1 cells followed by Th-1 cells in order to reduce the total number of parameters to be inferred during any one analysis (since a subset of the parameters were shared between cell types). The model selection was therefore carried out in the RPE1 cells first, and the result of this inference was carried on to the Th-1 cell analysis. Hence the decision only to carry out parameter estimation for hypothesis 1 in the Th-1 cells. The ordering of the cell types in the analysis was chosen since we had better initial estimates of receptor and STAT concentrations in RPE1 cells. We have however carried out the analysis in the opposite order as well, Th-1 followed by RPE1, and the result of the model selection and parameter inference does not change.</p><disp-quote content-type="editor-comment"><p>– (Figure 2c): The measurement of IL-27 at 30 minutes for REP1 and Th1 does not seem to contain any statistical variation. This also seems to force the model to match this data point for any parameter combination. What is the reason that there is no variation within this data point? As this also seems to be a critical point for differences between the dynamics caused by the two cytokines, would model predictions change if e.g. random variation is added to this data point?</p></disp-quote><p>The reviewer is correct that there is no variation at this point. This is due to the normalisation of the experimental data, as in Equation 5. The mathematical model output was normalised in the same way (Equation 6) so that the model naturally passed through this point. The normalisation was required since the dimensions of the data and model output were not the same. The normalisation point of IL-27 at time 30 minutes was chosen since it is the maximum value in the data set, and hence after normalisation the data was transformed to a range of [0; 1]. This normalisation has been clarified in the Materials and methods, Bayesian inference section. In order to check that the choice of normalisation point did not have a dramatic effect on the results of the analysis, we carried out the model selection and parameter estimation using a different normalisation point (IL-27 at time 15 minutes), and the results were rather similar.</p><disp-quote content-type="editor-comment"><p>– It is indicated in the text that the parameter inference by approximate Bayesian computation revealed statistically significant differences between the binding rates of certain receptors/molecular (p.7 top). Could you comment on the statistical tests used to compare the posterior distributions of the respective parameters to make this claim? The posterior distributions nicely show a deviation of the parameter estimates from the uniform prior distributions. However, especially in case of multi-parametric and high-dimensional models as here, there can still be the problem of correlating individual parameter estimates inhibiting parameter identifiability. To which extent are individual parameter estimates correlated within the accepted parameter combinations? In addition, more details on the ABC-approach should be given algorithm/software used, required number of particles accepted, possible number of runs (i.e., updating prior distribution by found posterior).</p></disp-quote><p>We have carried out a structural identifiability analysis for both mathematical models, and the result of this analysis indicated that all parameters were individually structurally identifiable. We have added a comment about this analysis in the main text. Whilst it is true that there are some strong correlations between individual pairs of parameters in their posterior distributions, the particular parameters that are discussed in the main text (i.e., the pairs of STAT/receptor interaction parameters on the second row of Figure 2d) are not strongly correlated and thus, we can be confident that the posterior distributions are representative of the rates we wished to infer. We have added a table of summary statistics for the posterior distributions of these parameters, to further elucidate the differences found. We also carried out two-sample paired t-tests for the means of the distributions for each pair of STAT/receptor parameters, after thinning of the distributions (taking every 100th value from each posterior distribution, resulting in thinned distributions with size 10<sup>2</sup>). The thinning was necessary since the sample size was so large (N = 10<sup>4</sup>) that the t-test would reveal a significant difference between any pair of parameters considered in Figure 2d. We found when using a thinned sample of size 10<sup>2</sup>, that there were significant differences between the means of the STAT/receptor parameter pairs at the 5% level, as expected. To clarify that these significant differences were not still due to the relatively large sample size (10<sup>2</sup>), we carried out t-tests using the same method for the parameter pairs on the top row of Figure 2d (ligand binding and dimerisation parameters) and found that the means of these pairs of distributions were not significantly different at the 5% level. We have not included the t-test analysis in the manuscript. Finally, we have added to the Materials and methods, Bayesian inference section, more details about the ABC approach used as suggested by the reviewer. We have also provided a link to a GitHub repository which contains the Python codes of the main analyses carried out here (Bayesian model selection and parameter inference). The results of these analyses are also included in the GitHub repository.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for authors):</p><p>I commend the authors for an exhaustive amount of work on this exciting signaling pathway. I would like to focus on a few points now that I have a slightly more critical view on.</p><p>1. Most individual findings have been reported before (or at least there have been indications). Understandably, this makes defining a clear punch line difficult, but honestly, focussing on &quot;autoimmune diseases&quot; already in the title to me appears a bit far fetched. The SLE aspect is only touched upon in the manuscript, and it is neither very informative nor central to the story. It is good to have it in, just to illustrate natural conditions in which altered STAT levels shapes cytokine responses, but it clearly should not be the selling point.</p></disp-quote><p>We thank the reviewer for his comment. We agree with the reviewer that this part is not the most integral part of the study and therefore we have changed the title of our manuscript to reflect this.</p><disp-quote content-type="editor-comment"><p>2. An aspect that I furthermore miss in the introduction and discussion part is the fact, that basically all cytokine receptor systems appear to have a rather strong preference for certain STATs. It appears rather trivial that different receptors / receptor chains will have different affinities for the different STATs and this has been addressed in a few studies previously (e.g. STAT1, STAT3 in ref. 42), or STAT2 in IFNAR1 in PMID:8605876. The present manuscript arrived at the conclusion of differing affinities of STAT1 and STAT3 for GP130 and IL-27Ra by rather intricate modeling approaches and confirms this biochemically. This is OK, but I find it a bit disconcerting that this is sold as a fascinating new finding, while I would say it is the most expected explanation. I dint want to diminish this achievement, just strongly suggest toning this down a bit and, most importantly, add a few words on the known and suspected differential affinities of the various STATs to cytokine receptors in general.</p></disp-quote><p>We agree with the reviewer in that the observation that cytokine receptors all have a certain preference for STAT activation has been well described in literature. However, in recent years the cytokine field has started to realize that cytokine signalling signatures are very plastic and cytokine responses can change dramatically depending on the environment where the responsive cells is localized. This ultimately contributes to the large functional pleiotropy exhibited by cytokines. Our work now provides molecular bases to support these initial observations. We show that the STAT-receptor preference is not as strong as initially believed and that small alterations in STAT and receptor concentration, as those found in pro-inflammatory environments (e.g. SLE) can dramatically change the response of a cell to a given cytokine. In addition, we show that IL-27 has evolved away from this general mechanism of cytokine signalling. By decoupling the binding of STAT1 and STAT3 to IL-27Ra and GP130 respectively, the IL-27 system shows unique properties that allows it to cope with the changing environments. To follow the reviewer suggestions, we have added a paragraph to the introduction giving some background on different STAT affinities to the receptor phospho-Tyrosine motifs and how this would lead to a STAT competition model.</p><disp-quote content-type="editor-comment"><p>3. In Figure 1d, GP130 was over expressed in RPE1 cells and the authors' conclusion was that GP130 levels do not contribute to sustained pSTAT1. In fact, Figure 1d does look as if pSTAT1 is sustained; particularly when you compared to the normalized plot of Th1 cells in Suppl Figure 1c, where the authors mark this difference even in red with δ signs. It would be very interesting to know if 10xGP130 cells stimulated with (Typ)IL-6 would now also show enhanced expression of IRF1 and a second wave of transcription?</p></disp-quote><p>We thank the reviewer for this suggestion. We have performed additional experiments comparing “RPE1 IL27Ra” and “RPE1 10x[GP130]” in their ability to induce IRF1 protein in response to IL-27 or HypIL-6 stimulation (Author response image 1). Interestingly, we found that IRF1 levels are equally low in the course of HypIL-6 stimulation regardless how much GP130 was present. Due to the large volume of data that the manuscript already has, we have decided to not include this data.</p><disp-quote content-type="editor-comment"><p>4. I would recommend the authors to show a full characterization of the RPE1 cells they use (e.g. for model parameterization and most further experiments) analogously to Th1 cells in Figure 1b and c (i.e. in terms of IL-27 vs IL-6 signaling) in one comprehensive supplementary figure. Suppl. Figure 4 goes in that direction, but it would be good to have this in the beginning (before the modeling) and in an identical fashion to the Th1 experiment. Please further make sure to identify more clearly (in text and/or legends or even figure labels) which cells were used in which experiment (e.g. &quot;RPE1-IL-27Ra&quot; or &quot;RPE1-IL-27-Ra/GP130&quot;).</p></disp-quote><p>We agree that having a full characterization of the “RPE1 IL-27Ra” model system prior to the modelling part will clearly help to understand the outcome of the modelling approach. Therefore, we have rearranged the supp. figures and now provide a characterization of that model system in Supp. Figure 2. Further, we have added labels indicating which cell system was used in certain experiments (i.e. in supp. Figure 11).</p><disp-quote content-type="editor-comment"><p>5. In the modeling figure, Figure 2c, I assume the Y-axes labels were swapped? If not, this needs to be explained!</p></disp-quote><p>We have corrected this error.</p></body></sub-article></article>